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Abstract 
Immunologic self-tolerance is maintained by both central and peripheral 
mechanisms.  Furthermore, regulation of mature lymphocyte responses is governed by 
inhibitory as well as stimulatory signals.  TCR recognition of cognate peptide bound to 
MHC molecules provides the initial stimulus leading to T lymphocyte activation and 
determines the antigen specificity of any subsequent response.  However, lymphocytes 
must discriminate between foreign and self antigens presented by self-MHC molecules to 
maintain self tolerance and avoid pathological autoimmunity.  Consequently, TCR 
ligation alone is reported to result in abortive activation, T cell anergy, apoptosis, and 
tolerance.  Under normal physiological conditions, costimulatory signals modify 
lymphocyte responsiveness to TCR ligation to prevent autoimmunity while enabling 
robust responses to foreign antigen.  Members of the CD28/B7 superfamily provide the 
critical secondary signals essential for normal immune cell function.   
CD28 is an essential positive costimulatory molecule with critical functions in 
thymic development, lineage commitment, and regulation of peripheral lymphocyte 
responses to antigenic stimuli.  CD28 ligation by APC-expressed B7 molecules alters 
proximal signaling events subsequent to MHC/TCR interactions, and initiates unique 
signaling pathways that alter mRNA stability and gene transcription.   Furthermore, 
CD28 signaling is required for regulatory T cell development and function.   Thus, CD28 
has a central role in both potentiating lymphocyte activation mediated by TCR 
engagement and regulating peripheral tolerance.  In contrast, Ctla-4 mediates an 
inhibitory signal upon binding B7 molecules on an antigen-presenting cell.  Its 
importance in governing lymphocyte responses is manifested in the fatal 
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lymphoproliferative disorder seen in Ctla-4-/- mice. The lymphocyte proliferation is 
polyclonal, antigen and CD28 dependent, and arises from defects in peripheral CD4+ T 
cell regulation.  The high percentage of peripheral T lymphocytes expressing activation 
markers is accompanied by lymphocyte infiltration into numerous non-lymphoid tissues 
and results in death by 3-4 weeks.  While still controversial, Ctla-4 signaling has been 
reported to be essential for induction of peripheral T lymphocyte tolerance in vivo and in 
some model systems is proposed to regulate both T lymphocyte anergy induction and the 
immune suppressive effects of some regulatory T cells in the prevention of 
autoimmunity.   
Signaling pathways activated by TCR ligation and CD28 costimulation have been 
extensively characterized.  In contrast, the mechanisms mediating Ctla-4 maintenance of 
tolerance remain largely unknown.  Ctla-4 gene expression is tightly controlled during T 
cell development and activation, and its intracellular localization and expression on the 
cell surface is regulated by numerous pathways and intermediates.  While a tailless Ctla-4 
mutant is capable of inhibiting T cell activation, recent studies have shown that a ligand 
independent form of Ctla-4 is also capable of providing an inhibitory signal to T 
lymphocytes.  In conjunction with the strictly controlled expression kinetics and the 
perfect amino acid homology between the intracellular domains of mouse and human 
Ctla-4, this data suggests that Ctla-4 may participate in the modulation or initiation of 
intracellular signaling pathways. 
Positive and negative costimulatory receptors on the T cell modify lymphocyte 
responses by altering both quantitative and qualitative aspects of the lymphocyte 
response including threshold of activation, cytokine secretion, and memory responses.  
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Positive costimulation augments T cell responses, in part, by downregulating the 
expression of genes that actively maintain the quiescent phenotype.  This study was 
initiated to determine the role of Ctla-4 ligation in modifying the global gene expression 
profile of stimulated T cells and to determine if the Ctla-4 mediated maintenance of T 
cell tolerance was achieved, in part, by altering the transcription of quiescence genes 
necessary for the prevention of T cell activation subsequent to TCR and CD28 
stimulation.   
Previous studies investigating the influence of Ctla-4 ligation on transcriptional 
profiles of activated lymphocytes detected only quantitative alterations in the 
transcriptional regulation initiated by CD28 signaling.  In contrast, our data suggests that 
quantitative effects of Ctla-4 ligation that differentially influence pathways acting 
downstream of stimulatory receptors results in a stable and qualitatively unique 
phenotype detectable at the level of the transcriptome.  Thus, the cumulative effect of 
Ctla-4 signaling is unique and not constrained to reversing alterations in expression 
initiated by CD28.  In addition, Ctla-4 ligation can be shown to influence T lymphocyte 
responsiveness and the resulting global expression profile within 4 hours after stimulation 
and prior to detectable Ctla-4 surface expression.  In a subpopulation of T cells, TCR 
stimulation activates pathways that result in commitment to activation with 2-6 hours.  In 
contrast, CD28 signaling must be maintained for 12-16 hours to ensure maximal 
responses at the population level.  The period of sensitivity to Ctla-4 inhibition of 
activation is more constrained and does not extend beyond 12 hours.  Together, these data 
support a potential role for Ctla-4 in modification of the early transcriptional response 
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and may explain various alterations in phenotype resulting from Ctla-4 ligation that have 
been reported in secondary responses. 
Identification of genes involved in lymphocyte activation, maintenance of self-
tolerance, and attenuation of immune responses opens the door to therapeutic 
manipulation of the pathways implicated.  CD28 costimulation results in general 
amplification of TCR-initiated transcriptional responses, and specifically alters the 
expression profile of a subset of genes.  In contrast, Ctla-4 ligation directly and 
specifically alters the expression of a select group of genes when ligated, and results in 
minimal suppression of the global CD28-mediated costimulatory transcriptional 
response.  Ctla-4 regulated genes comprise a heterogeneous family, but include known 
quiescence factors, transcriptional regulators, and various determinants of cell cycle 
progression and senescence.  The role of Ctla-4 in maintaining self-tolerance indicates 
that targeted manipulation of these gene products presents a novel therapeutic 
opportunity, and suggests that the mechanisms involved in Ctla-4-mediated maintenance 
of peripheral T cell tolerance and regulation of immune responsiveness is more nuanced 
than previously thought.  In addition, this study provides the most comprehensive 
description of global gene expression during primary lymphocyte activation yet available.  
The integration of statistical and bioinfomatics analyses with large scale data mining 
tools identifies genes not previously characterized in lymphocytes and can direct future 
work by predicting potentially interacting gene products and pathways.   
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INTRODUCTION 
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Introduction: 
Central and peripheral mechanisms of tolerance in the immune system 
 Broad specificity within the adaptive immune system enables potent 
immunological defenses against a wide range of foreign pathogens.  The repertoire of the 
peripheral T lymphocyte compartment encompasses an estimated 25x106 T-cell receptors 
(TCRs) enabling recognition of both foreign and self-antigens(1).  While the diversity of 
the TCR repertoire is necessary for effective immune surveillance against a range of 
potential pathogens, the processes that generate diverse TCR specificities also result in 
the generation of antigen receptors specific for self-peptides.  Mechanisms of central 
tolerance serve to eliminate potently self-reactive lymphocytes during thymic maturation 
by induction of apoptosis in thymocytes that recognize self-peptide bound to Major 
Histocompatibility Complex (MHC) with high affinity, in a process termed “negative 
selection”.  Deletion of overtly autoreactive thymocytes is dependent on intra-thymic 
presentation of diverse peripheral tissue antigens to developing lymphocytes.  Impaired 
self-peptide presentation results from defects in the regulation of transcription of 
peripheral antigens in the thymus and leads to autoimmune pathology with broad 
specificity for peripheral tissues(2, 3).  Negative selection potently suppresses the 
generation of autoreactive lymphocytes, but mature peripheral lymphocytes with TCRs 
specific for self-antigen are nonetheless detectable in healthy individuals(4, 5). 
Mechanisms of peripheral tolerance serve to prevent or attenuate pathological activation 
of autoreactive lymphocytes that avoid thymic deletion.  Nonetheless, positive selection 
of thymocytes ensures that all peripheral lymphocytes express TCRs with low inherent 
affinity for self-peptide/MHC complexes.  Consequently, avoidance of inadvertent 
 3
lymphocyte activation in the periphery is dependent on additional receptor-ligand 
interactions that regulate lymphocyte responsiveness to TCR engagement, coordinate 
numerous cellular responses, and modulate the scope of any resulting immune activation. 
  
 
T Lymphocytes and the Immune Response: 
 
 The Two Signal Model of T Cell Activation 
Peripheral T cell responses to a given antigen involve the clonal expansion of a 
small subset of T cells that possess unique TCRs but have common antigen specificity.  
As a result, the overall response to antigen encounter is a direct consequence of factors 
influencing the activation, expansion, and regulation of individual T cells.  TCR 
engagement of peptide/MHC (pMHC) ligands on professional antigen presenting cells 
(APCs) is critical for the initiation of T cell mediated immune responses(6). TCR 
recognition of cognate pMHC, referred to as signal one, is required for T cell activation 
and determines the antigen specificity of T cells involved in normal immune responses. 
In addition, the TCR is differentially responsive to subtle changes in its ligand and can 
mediate signals that result in diverse biological responses(7, 8). 
TCRs possess inherent affinity for self-pMHC as a result of positive selection 
during thymic development.  Central tolerance mechanisms restrict the affinity of 
interactions between TCRs and self-pMHC that are involved in peripheral immune 
homeostasis, and serve to prevent unwarranted lymphocyte activation.  In the absence of 
additional signals, TCR engagement by a MHC-antigen complex is reported to result in 
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anergy, apoptosis, or inefficient T cell activation(9).  The requirement for an additional 
signal to optimize T cell activation has proven critical for the maintenance of peripheral 
self-tolerance and the initiation of productive immune responses.   
The two-signal model of lymphocyte activation states that optimal lymphocyte 
responses require an initial signal resulting from TCR interaction with APC-expressed 
pMHC complexes, coupled with a secondary antigen-independent signal termed 
costimulation(10)(Figure 1.1).  CD28 is the archetypal costimulatory molecule and is 
constitutively expressed by >90% of human CD4+ T cells, and >50% of human CD8+ T 
cells. CD28 interaction with B7 molecules on APCs provides signal two and results in 
enhanced activation, accelerated cell cycle progression, T cell survival, and clonal 
expansion(11, 12).  The hallmark of CD28 costimulation is enhanced interleukin-2 (IL-2) 
production and bcl-xL upregulation, which promote T cell expansion and support the 
development of an effective immune response(13).  CD28 enhances T cell activation by 
diverse mechanisms that serve to enable TCR signaling and promote prolonged T cell-
APC interaction. 
  CD28 engagement amplifies membrane-proximal signaling initiated by the TCR, 
but also transduces a unique signal reportedly necessary for the stabilization of some 
RNA transcripts and efficient upregulation of numerous genes including IL-2 and bcl-
XL(11, 14-18). In addition, CD28 signaling potentiates the macromolecular 
reorganization of the cell membrane initiated by TCR ligation, resulting in aggregation of 
numerous multimolecular signaling complexes at the site of T cell/APC contact(19-21).  
In fact, recent work suggests that CD28:B7 interactions in the absence of TCR triggering 
are sufficient for cell polarization and lipid raft aggregation.(22)  The resulting structure,  
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Figure 1.1: The two signal model of T cell Activation  
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Figure 1.1:  The two-signal model of T cell activation.  In addition to antigen receptor 
triggering, T cells require second antigen-independent signals via CD28:B7 interaction in 
order to respond efficiently.  CD28 ligation enhances TCR-induced signals, and also 
transmits a unique signal that results in increased survival, facilitates cell-cycle entry, and 
leads to efficient cytokine production.  Ctla-4 ligation interferes with proximal TCR 
signaling and suppresses distal effects of CD28 costimulation.  The relative balance of 
CD28 and Ctla-4 signaling may dictate the outcome of antigen-receptor engagement in a 
manner dependent on B7 ligand availability.
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termed the immunological synapse (IS), stabilizes the intercellular contact for as much as 
24 hours, and is reportedly necessary for full commitment to activation(23). However, the 
temporal parameters governing CD28 costimulation have not been well defined. 
While CD28 functions primarily to enhance lymphocyte activation, it also plays a 
prominent role in the maintenance of peripheral tolerance.  CD28 signaling is obligatory 
for the development and maintenance of regulatory T cells(24), up-regulates immune 
attenuators including Ctla-4, and skews T cell responses towards an autoimmune 
protective Th2 phenotype(24, 25).  CD28-mediated effects on TCR signaling pathways 
have been well characterized, but the molecular and biochemical mechanisms mediating 
qualitative effects of CD28 costimulation are poorly understood and the distal effectors of 
CD28 signaling have not been fully elucidated.   
 
 
The B7/CD28 family of immomodulatory receptors: 
 
 Members of the B7/CD28 family of receptors regulate diverse aspects of 
the adaptive immune system and are key determinants of T cell responsiveness and 
effector function (Table 1.1).  Signaling pathways initiated by B7/CD28 family members 
are essential components of mechanisms that simultaneously promote and sustain T cell 
responses to pathogens and serve to maintain tolerance to self-antigen by inhibition or 
attenuation of T cell responses.  CD28 and Ctla-4 are the critical costimulatory receptors 
regulating antigen responsiveness of mature peripheral T cells, and provide positive and 
negative second signals to T cells,  
 8
Table 1.1: The B7/CD28 family of immunomodulatory receptors 
 
A:  Comparison of CD28 family members. 
 
 
 
Comparison of CD28 family of receptors 
  CD28 CTLA-4 ICOS PD-1 BTLA 
% identity 100% 30% 27% 23% 23% 
Chromosome           
  Human 2q33 2q33 2q33 2q37 3q13.2 
  Mouse 1C1, 30.1 cM 1C2, 30.1 cM 1C2, 32 cM 1D, 55 cM 16A1 
Structure           
  Ligand binding motif MYPPPY MYPPPY FDPPPF ? ? 
  Cytoplasmic domain PI3K motif, PP2A PI3K motif, PP2A, SHP2 PI3K ITIM motif, SHP2ITSM motif, SHP1 Two ITIM motifs 
Expression           
  Cell type T T T, NK T, B, M T, B  
 
 
 
 
 
 
 
 
9Comparison of B7 family of costimulatory molecules 
  B7-1 (B7.1) B7-2 (B7.2) ICOSL (B7h, B7-H2; B7RP-1) PD-L1 (B7-H1) 
PD-L2 (B7-
DC) B7-H3 
B7-H4 
(B7x; 
B7S1) 
% identity of 
extracellular 
domain 
100% 27% 27% 25% 23% 29% 21% 
Chromosome               
  Human 3q13 3q21 21q22 9p24 9p24 15q24 1p13.1 
  Mouse 16B, 32.8 16B, 
26.9 
10C1 19B 19B 9A 3F2.2 
Expressiona               
  Lymphoidb B, M, DC, T B, M, 
DC, T 
B, M, DC, T B, M, DC, T DC, M B, T, M, 
DC, NK 
T, B, M, 
DC 
  Non-lymphoid Rare; 
including 
podocyte 
Rare FibroblastEndothelialEpithelial Endothelial, Tissues (including 
placenta);Tumors (including many T cell 
lymphomas, carcinomas, melanomas, 
glioblastoma 
Some B cell 
lymphomas 
Bone 
Marrow 
Lung and 
ovarian 
tumors 
Receptor CD28 
CTLA-4 
CD28 
CTLA-4 
ICOS PD-1 PD-1 ? ? 
aProtein, but not mRNA expression is summarized; see text for regulation of expression. 
bB=B cell; M=macrophage; DC=dendritic cell; T=T cell; NK=natural killer cell. 
B: 
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Table 1.1:  Comparison of CD28 (Panel A) and B7 (Panel B) family members.   
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respectively.  CD28 transmits signals important for T cell survival and proliferation, 
while Ctla-4 inhibits T cell responses and regulates peripheral tolerance.  Ctla-4 and B7 
share B7 ligands, B7.1 and B7.2.  Regulation of Ctla-4 and CD28 signaling is effected by 
precise control of surface expression, availability of ligands, differential ligand-binding 
characteristics, and unique signaling properties.  Additional members of the CD28 family 
include ICOS, PD-1, and BTLA.  While the ligand for the inhibitory receptor BTLA 
remains undiscovered, both ICOS and PD-1 are known to bind B7 family members. 
ICOS and PD-1 result in positive and negative regulation of T cell responses respectively.  
However, CD28 and Ctla-4 are unique in their ability to regulate primary T cell responses 
and provide dominant signals controlling T cell activation in naïve lymphocytes. 
 
 
Biology of CD28 Costimulation: 
 
 CD28 costimulation is essential for normal immune function.  CD28-deficient 
mice or mice treated with antagonists of CD28:B7 interaction manifest profoundly 
defective responses to allograft antigens(11), infectious pathogens(26-29), GVHD(30), 
and induction of contact hypersensitivity(31).  Similarly, absence of CD28 costimulation 
reduces T cell proliferation in vitro and in vivo in response to  TCR stimulation(32-34).  
More globally, CD28 deficiency results in diminished germinal centre formation and 
defective isotype class switching in B cells, and diminished CD4-dependent CD8+ T cell 
responses(35-37).   
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CD28 is uniquely capable of synergizing with TCR-mediated signals to activate 
transcription factors controlling proliferation, differentiation, and cell death including 
NFκB(18), NFAT(15, 38), and AP-1(39).  While receptor-ligand interactions mediating 
costimulatory signals are diverse, CD28 is unique in its ability to integrate signals with 
the TCR and to centrally determine the outcome of antigen receptor engagement in naïve 
T cells(40, 41).  Moreover, CD28 is unique in its ability to provide signals required for 
cellular activation, cell cycle entry, and efficient cytokine production in lymphocytes, and 
results in greater enhancement of immune responses than other costimulatory receptor 
interactions(42, 43).  An essential component of CD28 costimulation is regulation of 
distal determinants of cell death, proliferation, and differentiation including cytokines 
interleukin 2 (IL-2), interferon gamma (ifn-γ), and interleukin 4 (IL-4)(44); chemokines 
Mip-1alpha/CCL3(45); cytokine receptors CD25, IL-12R, and CXCR5(26, 46, 47); and 
APC counter-receptors Ctla-4/CD152, CD154/CD40L, ICOS, CD134/OX40, and 4-
1BB(47, 48).  Thus, CD28 orchestrates the regulation of genes that shape the phenotype 
of responding cells in ways that determine not only their immediate response, but also 
their ability to respond to and provide intercellular signals in subsequent days. 
 
CD28 regulates key signaling intermediates that control the initiation and character of 
an immune response 
 CD28-ligand interactions determine proximal regulation of signaling thresholds as 
well as subsequent events leading to gain of effector function.  Quantitatively, CD28 
costimulation functions primarily to potentiate signals initiated by TCR engagement.  
CD28 costimulation directly alters intrinsic properties of TCR signaling by facilitating 
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TCR/pMHC interaction and enhancing ZAP70 phosphorylation(49-51).  In addition, 
CD28 enhances TCR-induced glycolipid-enriched membrane microdomain (GEM) 
aggregation following TCR triggering and amplifies early TCR-signaling events 
mediated by PLC-γ(21, 51-53).  Distally, CD28 alters the global expression profile of 
antigen receptor activated lymphocytes by amplifying gene regulations that result from 
TCR stimulation(15, 54).  At the single-cell level, altered expression of CD28 target 
genes define cellular differentiation, burst size(55), and long-term cytokine 
production(34).  Thus, CD28-mediated signals modulate the evolving character of an 
immune response via mechanisms distinct from its membrane-proximal enhancement of 
TCR signaling.   
CD28 signaling modifies the activity of proteins involved in the determination of 
cellular commitment to proliferation prior to significant changes in transcription.  The 
hallmark of CD28 function is the upregulation of Il-2 production and CD25 expression 
subsequent to antigen receptor engagement(26, 33, 44, 55).  In vivo, however, common 
γ-chain cytokines, including IL-2 are not essential for antigen-driven cellular 
proliferation(56, 57) and CD28 enhancement of cell cycle entry and progression is at 
least partially independent of IL-2 production(58).   
CD28 directly modulates cell cycle regulators prior to IL-2 production.  
Repression of E2f regulated genes is central to the ability of inactive pRB to maintain 
cells in the G0 stage of the cell cycle(59).  CDK4/CDK6 mediated phosphorylation of 
pRB allows entry into the cell cycle, and progression through late G1 and S phases is 
dependent on cyclin-E/CDK2 phosphorylation of pRB as well(59).  CD28 signaling 
upregulates D cyclin expression (60, 61) and leads to the activation of CDK4/CDK6 and 
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the consequent phosphorylation of pRB within 3-4 hours of activation, and prior to IL-2 
production(62).  Inhibition of CDK protein activity by CDK-interaction protein (CIP), 
and INK and cyclin-dependent Kinase inhibitors(KIP) protein families prevents entry into 
G1(63).  CD28 signaling results in degradation of KIP1 via the PI3K-AKT pathway, but 
KIP1-deficient mice maintain normal proliferative responses to activation signals 
initiated by CD3/CD28 probably as a result of redundant inhibition of cell cycle entry by 
INK4C, which is also antagonized by CD28 signaling(61).  
Entry into the cell cycle is accompanied by increases in cellular metabolism, 
increased expression of genes involved in synthetic pathways, and increases in cell 
size(64)  in a process enhanced by CD28(15, 65).  The CD28 signaling pathways leading 
to enhancement of cellular metabolism and macromolecular synthesis implicates MTOR, 
(66) acting downstream of PI3K in a pathway commonly dysregulated in cancer(67, 68).  
Similarly, the pleiotropic transcription factor c-myc regulates genes controlling 
transcription initiation factors, ribosomal RNA synthesis, and determinants of cellular 
division (E2Fs and CDC25(64)), making it a potential downstream target of CD28(69). 
 
CD28 regulates mechanism influencing peripheral self-tolerance 
TCR-triggering without concomitant CD28 ligation is reported to result in the 
induction of anergy or apoptosis.  TCR engagement in the absence of costimulation may 
enhance apoptosis induction by failing to sufficiently upregulate anti-apoptosis factors or 
via inhibition of cell cycle progression(70-72).  CD28 signaling specifically induces 
expression of the anti-apoptotic factor bcl-xL (73) in a NF-kB dependent manner while 
simultaneously repressing pro-apoptotic factors including p73(74).  Thus, CD28 
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signaling may critically determine the clonal diversity of an immune response by 
enhancing survival of antigen-receptor-stimulated T lymphocytes in a cell-specific 
manner.   
CD28 signaling may also control peripheral tolerance by regulating anergy 
induction.  Anergy is an acquired, antigen-specific state of hyporesponsiveness in which 
lymphocytes fail to respond to appropriate antigenic stimulation(Reviewed in (75)). 
Anergy induction in T cells is a tolerance mechanism that results in the persistence of 
lymphocytes that are functionally inactivated by antigen encounter and remain 
hyporesponsive to subsequent antigen receptor triggering even in the context of sufficient 
CD28 costimulation.(76) Therapeutic anergy induction has potential in treating 
autoimmune disease and has been used to prolong allograft survival in animal 
models(77).  Two general forms of anergy have been described that represent distinct 
biological states resulting from distinguishable signaling events.(78)  Clonal anergy is 
principally a state of growth arrest resulting from incomplete T cell activation and is most 
often seen in previously activated cells.  Clonal anergy is reversible by addition of 
exogenous IL-2 or anti-Ox40 treatment, results from a defect in the Ras/MAP kinase 
pathway that may involve Egr-2(79), and generally does not result in suppressed effector 
function.  In contrast, adaptive anergy generally develops in vivo following submitogenic 
antigen-receptor triggering on naïve CD4+ lymphocytes in the absence of CD28 
mediated costimulation or the presence of significant coinhibitory signals(80).  Adaptive 
tolerance induction occurs subsequent to an initial proliferative response and requires 
antigen persistence. Concomitant CD28 ligation prevents antigen-receptor-mediated 
induction of T cell anergy(81) through mechanisms dependent on CD28 enhancement of 
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cell cycle progression(80).  The state of adaptive anergy results from an early block in 
tyrosine kinase activation with consequent inhibition of calcium mobilization and 
impaired signaling through the IL-2 receptor(82), and proximal signaling defects in 
anergic cells may be related to defective LAT activation(83).  However, it has also been 
demonstrated that anergy avoidance subsequent to CD28 ligation utilizes PKC-theta-
dependent pathways distinct from those that augment proliferation(84) supporting the 
notion that CD28 determines qualitative aspects of immune responsiveness.    
Numerous genes identified as potential mediators of anergy induction have 
recognized roles in T cell activation and costimulatory pathways.  In particular, Cbl-b is 
one of several E3 ubiquitin ligases involved in the induction and maintenance of an 
anergic phenotype((85), Reviewed in (86)) that has a key role in the integration of 
costimulatory signals originating with CD28 and Ctla-4(87).  Identification of pathways 
and signaling determinants involved in anergy induction will necessitate a detailed 
understanding of T cell costimulatory pathways and may enable therapeutic manipulation 
of this endogenous mechanism of self-tolerance. 
 
CD28 alters qualitative aspects of T cell differentiation 
Cellular division in CD4+ lymphocytes is accompanied by irreversible acquisition 
of specific phenotypes defined by cytokine profile.  Following activation, 
undifferentiated naïve CD4+ Th0 cells respond to costimulatory signals that direct 
development toward the Th1 and Th2 effector cell lineages that coordinate cell-mediated 
immunity and humoral responses respectively (Reviewed in (88)).  Th1 effector cells 
secrete interferon-gamma, and regulate CD8+ T cell responses in response to intracellular 
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pathogens.  In contrast, Th2 cells produce IL-4, promote allergic responses, and are 
critical for effective immunity against helminthes.  Polarizing influences result in the 
expression of distinct transcription factors in Th1 and Th2 cells necessary for cellular 
differentiation, particularly T-bet and GATA3 respectively(89), and are partially 
influenced by cellular division(89-91).  CD28 preferentially skews T lymphocyte 
differentiation towards a Th2 phenotype via NF-kB induction of GATA3(92-94).  
Concomitant Ctla-4 engagement counteracts CD28 mediated changes in gene 
transcription via direct inhibition of GATA3 but not T-bet mRNA expression(54, 95) and 
encourages Th1 differentiation of activated naïve T cells.(96)  Moreover, Ctla-4 
deficiency increases the efficiency of CD28 signaling and results in enhanced NF-kB 
activation, GATA3 expression, and Th2 skewing(97).  Thus, integration of costimulatory 
signals is critical to lineage fate determination in naïve cells with resulting long-term 
consequences and differential susceptibility to infection and autoimmunity.  While the 
critical determinants of lineage fate decisions have been identified, a precise 
understanding of the upstream regulatory mechanisms involved in costimulatory signal 
integration that precede lineage commitment will enhance our ability to design 
knowledge-based therapeutic intervention strategies. 
 
Epigenetic regulation of gene expression by CD28 
In Eukaryotic cells, the physical structure of genes influences their expression.  
DNA methylation and chromatin remodeling are critical determinants of gene 
accessibility for transcriptional machinery.  CD28 signaling results in chromatin 
modification and epigenetic regulation of gene expression.(90, 98-105)  Mechanisms of 
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CD28-mediated epigenetic regulation of gene expression involve posttranslational 
regulation of constitutively expressed proteins, as evidenced by the fact that cytosine 
demethylation at the IL-2 locus occurs within 20 minutes of TCR/CD28 ligation.(104)  
Similarly, modification of chromatin accessibility at gene loci involved in cellular 
differentiation (IL-4 and IFN-γ) have been detected within one hour of TCR/CD28 
ligation, and reinforce the notion that proximal signal integration of the TCR and CD28 
pathways is definitive soon after activation(89).  CD28-mediated signals reinforce re-
positioning of the SW1/SNF-related chromatin remodeling BAF complex within minutes 
of TCR/CD28 engagement in naïve T cells in a process that is critically dependent on 
both PKC/RAS pathways and calcium flux.(98)  CD28 engagement results in robust 
expression of c-REL(102) through a CsA sensitive pathway(15), and results in chromatin 
modification of the IL-2 gene locus via interaction with the CD28-responsive regulatory 
element.(18, 102)  Critically, recent observations suggest that stable chromatin 
remodeling may alter subsequent cellular responses to activating stimuli.  Antibody 
ligation of CD3 and CD28 results in increased IL-2 expression following active 
demethylation of a specific CpG site, recruitment of Oct-1, and histone 
modification.(106)  Oct-1 remains bound to the IL-2 enhancer following termination of 
stimulatory signaling resulting in accelerated and magnified gene transcription upon 
reactivation.  Moreover, fully-activated CD4+ effector cells possessed stable histone 
acetylation and loss of cytosine methylation at the IL-2 promoter enhancer with 
concomitant chromatin remodeling.  In contrast, CD4+ T cells rendered anergic by TCR 
ligation in the absence of costimulation showed no histone acetylation or cytosine 
demethylation in the IL-2 promoter/enhancer region, and an absence of chromatin 
 19
remodeling(107).  CD28 signal-specific epigenetic modification of the IL-5 gene locus 
has also been implicated in Th2 lineage differentiation and appears dependent on NFκB 
activation and GATA 3 upregulation(108).  Stable epigenetic modification of target genes 
as a consequence of costimulation may provide a historical record of prior signaling 
events that have the potential to influence future responses. 
 
 
CD28- and TCR-signaling utilize unique and overlapping pathways: 
 
The TCR and CD28 signal independently and display unique biophysical and 
biochemical properties.  Relative to TCR interactions with peptide/MHC complexes on 
the APC, CD28 displays significantly higher on and off rates in its interactions with B7 
ligands(42, 50).  Moreover, APCs express many more B7 molecules than TCR ligands, 
suggesting that CD28 engagement by B7 ligands is more numerous, dynamic, and fluid 
than TCR-pMHC interactions.  Unlike the TCR, which signals through ten 
immunoreceptor tyrosine-based activation motifs (ITAMs) located on CD3-ζ 
chains(109), CD28 signaling is dependent on non-ITAM tyrosine phosphorylation events 
and a proline rich region(110).  While the mechanism by which TCR-pMHC interaction 
initiates signaling, a process termed receptor triggering, remains controversial, it may 
depend on the inherent biophysical properties of the receptor ligand pairs that results in 
size-based segregation of the relevant cell-surface molecules based on the dimension of 
their ectodomains(42, 111-113).  CD28 ligation activates discrete signaling cascades that 
differentially depend on its association with the TCR and localization to the 
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immunological synapse(15-17).  CD28 aggregation in the immunological synapse is 
driven by APC-expressed B7(114) in a process dependent on the B7 cytoplasmic 
tail(115) that may regulate the micrometer-scale colocalization of the TCR and CD28 that 
is necessary for efficient costimulation(116).  Both CD28 and the TCR relocalize to 
glycolipid enriched membrane microdomains (GEMs) containing active LCK protein 
tyrosine kinase upon interaction with their cognate ligands(112, 117).  Association with 
the PTKs LCK or FYN results in phosphorylation of tyrosine residues in the cytoplasmic 
domains of CD28 and the TCR(118).  In contrast to their shared dependence on PTK 
activity, the TCR, but not CD28, ligation results in activation of ζ-chain associated 
ZAP70 and phosphorylation of the LAT-SLP76 (linker for activation of T cells-SH2 
domain containing protein of 76 kDa) complex(51).  LAT-SLP76 phosphorylation and 
recruitment provides the structural framework upon which various adaptors and enzymes 
aggregate to activate all of the main pathways responsible for T cell activation(109).  The 
resultant signaling complex results in rapid activation of PLC-γ, cleavage of membrane 
lipids to produce PIP2, PIP3, and DAG, increased intracellular calcium, and activation of 
RAS (via GRP, a DAG-binding guanine exchange factor(GEF)) and most PKCs(119).  
Simultaneously, RAS-GRP and VAV1 activity produces activated RAS-GTP and RHO 
family GTPases,  and PI3K modified lipid byproducts are generated, with the resultant 
effect of reorganizing the plasma membrane and cytoskeleton, and orientation of the 
MTOC towards the site of APC contact(120, 121).  Secondary changes in chromatin 
accessibility at specific loci, accelerated intracellular vesicular trafficking, and nuclear 
translocation of constitutively expressed transcription factors are detectable within hours. 
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Under conditions of supraphysiological TCR ligation, as may occur with antibody 
binding, stable TCR aggregation in the absence of costimulation can result in activation 
of all the main signaling pathways implicated in T cell activation, cell cycle entry, and 
widespread gene regulation.  In contrast, isolated CD28 ligation does not lead to cellular 
activation, results in limited transient gene regulations, and has no known biological 
effect(15, 17, 54).  However, the gene regulations that occur subsequent to CD28 
engagement in the absence of TCR ligation specify some of the pathways involved in 
CD28 costimulation of TCR signals.  In particular, binding of the p85 regulatory subunit 
of PI3K by the phosphorylated tail of CD28 initiates a PtdIns-dependent kinase(PDK)- 
and AKT-dependent phosphorylation of glycogen synthase kinases 3α and 3β(15, 122, 
123).  Ablation of PI3K interactions with CD28 by mutation of the relevant tyrosine 
residue results in defective AKT activation(124), diminished IL-2 production(125), 
reduced bcl-xL expression(126, 127), and a general reduction in antigen-driven T cell 
responses in vivo(128).  Activated AKT is a critical downstream mediator of CD28 
signaling as AKT amplifies TCR mediated gene regulations by cooperative influences on 
NF-kB activity with TCR-induced PKC-θ, and GSK3 inhibits NFAT export(15, 129-
131).   
The ability of CD28 signaling to directly regulate the activity and nuclear 
localization transcription factors underlies its ability to influence cell cycle progression 
and metabolism in activated T cells.  AKT in particular is hypothesized to regulate 
numerous transcription factors downstream of CD28 including Forkhead, c-myc, and the 
cyclin-d-CDK4/CDK6 complex.(122, 132)  In addition to its influence on AKT activity, 
PI3K activation by CD28 is likely to influence additional pathways involved in mediating 
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the pleiotropic effects of costimulation, including those involving mTOR and PKC 
activation(123, 133, 134).  The costimulatory mechanisms regulating these diverse 
pathways during T cell activation remain only partially characterized but imply a central 
role for specific signaling intermediates involved in the integration of signals resulting 
from upstream activation of the TCR and CD28. 
The TEC family kinases TEC and ITK are crucial mediators of activating signals 
delivered through the TCR, and were thought to be differentially regulated by CD28-
mediated costimulatory signals. More recently, ITK has been shown to operate 
independently of CD28 costimulation(135), but the central role TEC family kinases play 
in T cell responsiveness warrant further discussion of their role in T cell activation.  TEC 
and ITK are regulated by LCK or FYN-dependent phosphorylation, PIP3, PIP3 
independent VAV1 mediated mechanisms, and direct protein-protein interaction(65, 
136).  Positive regulation of PLC-γ by TEC and ITK is dependent on TCR-mediated 
phosphorylation of LAT-SLP76.  TEC and ITK activate PLC-γ to increase intracellular 
calcium, increasing PKC by DAG-dependent mechanism, and activating RAS/RAF/ERK 
through RAS-GRP(51, 129, 137).  Mutations in the tail of CD28 that prevent ITK 
activation abolish costimulatory enhancement of PLC-γ activity, calcium flux, and NFAT 
activation(51).  Mutant NFATc that is constitutively localized to the nucleus allows full 
activation of T cells activated through the TCR in the absence of CD28 costimulation, 
highlighting the central role TEC family kinases play in mediating distal effects of CD28 
signaling(15, 138).   
 Vav1 stabilizes the numerous protein-protein interactions required for productive 
proximal signaling by the TCR, and participates in nearly all TCR signaling 
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pathways(139).  Identification of costimulation-defective mutants of CD28 in which 
PI3K binding is unaffected but Vav1 phosphorylation is abolished highlights the central 
importance Vav1 plays in mediating CD28 costimulatory signals(125, 140, 141).  CD28 
recruits Vav1 to the membrane by unknown mechanisms, and Vav1 phosphorylation by 
CD28 activates GEF activity by removing intramolecular inhibition of the DBL-
homology domain by the pleckstrin-homology domain(142). Early reports indicated that 
membrane recruitment and activation of Vav1 by CD28 required TCR dependent 
phosphorylation of SLP76(50, 143, 144).  However, recent work indicates that B7 driven 
accumulation of CD28 at T cell:APC interfaces results in Vav1 activation in the absence 
of TCR ligation and correlates with increased calcium flux and NFκB p65 translocation 
to the nucleus(22).  In addition, CD28 signaling has been shown to result in 
posttranslational modification of Vav1 via a novel CD28-costimulatory pathway that 
results in Vav1 methylation and nuclear localization(145).  Vav1 mediates CD28 
induction of NFAT, Nf-kB, and AP1 activity,(146-148) and is crucial for Th2 
differentation independent of GATA3 expression(149).  Several reports have linked Vav1 
activity to Cbl-b, an essential downstream regulator of CD28 costimulation(150, 151).  
Absence of Cbl-b restores defective Ig class switching and germinal center formation in 
Vav1 deficient mice(152).  In addition to its role in peripheral T cell activation, Vav1 is 
critical for normal TCR and CD28 mediated signaling in lymphocyte development(153).  
The profound defects observed in Vav1-deficient thymocytes and mature 
lymphocytes(153-157) result in large part from the ability of Vav1 to regulate RAC-GTP 
production.  RAC-GTP participates in regulation of PI3K, which then regulates the 
activity of TEC PTK, PLC-γ1, AKT, and more distal downstream effectors including 
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nuclear import of NFAT, and activation of NF-kB and RAS/RAF/ERK(139, 154, 158, 
159). 
 The E3 ubiquitin ligase cbl-b proto-oncogene(160) is a key mediator of CD28 
costimulatory signals capable of direct interaction with proteins involved in signaling 
pathways downstream of the TCR and CD28(161, 162).  Moreover, cbl-b is a key 
negative regulator of T cell responsiveness in vivo(161, 163, 164), influences the CD28-
dependence of in vivo immunity(152),  and regulates the induction and maintenance of 
anergy(85, 86, 149, 165-168). Cbl-b deficiency results in spontaneous autoimmunity 
characterized by auto-antibody production, T and B lymphocyte activation, 
overproduction of IL-2, infiltration of peripheral tissues and parenchymal damage(167).  
Cbl-b deficiency bypasses CD28-costimulation requirements for upregulation of Il-2, and 
restores T-cell-dependent antibody responses in CD28-deficient mice(169).  Cbl-b 
regulates the activity of receptor protein tyrosine kinases as well as antigen and cytokine 
receptors that signal via associated cytoplasmic protein tyrosine kinases.  Cbl-b 
negatively regulates T cell responsiveness by numerous mechanism including inhibition 
of receptor clustering and lipid raft aggregation(163), proteolysis-dependent and 
independent regulation of PI3K(170, 171), promotion of ligand-induced TCR down-
modulation(172) and upregulation of receptor endocytosis(173), and ubiquitination-
dependent regulation of key receptors and signaling intermediates(174, 175).  Cbl-b 
contains an amino terminal Ring finger motif and putative phosphotyrosine binding 
domain, and carboxy terminal proline-rich region, conserved tyrosine residues, and a 
leucine zipper(176).  Cbl-b is rapidly tyrosine phosphorylated by Syk- (syk/Zap-70) and 
Src- (Fyn/lck) family kinases upon TCR engagement(177, 178) allowing direct regulation 
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of the RAC-1 GTPase GEF Vav1 in a trimeric complex involving ligand-stimulated 
tyrosine kinases, resulting in inhibition of TCR mediated Vav-1 activation(169, 172) and 
subsequent Vav-1-mediated activation of c-Jun N-terminal kinase(179).    CD28 
costimulation counteracts cbl-b-mediated inhibition of TCR signals by targeting cbl-b for 
ubiquitination-dependent downregulation(87, 180, 181).  Thus, regulation of cbl-b 
activation by CD28 is critical to the integration of TCR and costimulatory signals and 
broadly influences in vivo immunity by altering proximal signaling events and distal 
mediators of T cell activation(182). 
 
Integration of TCR and CD28 signals is a multifaceted process  
Cellular responses to immunological stimuli reflect the convergence of numerous, 
often contradictory, signaling pathways that necessarily operate to regulate distal 
outcomes via regulation of gene expression.  Shared targets of diverse pathways 
determine the qualitative responses manifested by integrating quantitative signal 
information.  The elucidation of pathways responsible for cellular activation in 
lymphocytes has often depended on non-physiological stimuli that might mask subtle 
relationships that exist between various signaling pathways, including the TCR and 
CD28.  The differential sensitivity of antigen receptor stimulated cells to CsA inhibition 
in the presence or absence of PMA or anti-CD28 antibody was interpreted as evidence of 
distinct pathways downstream of these two receptors.(183)  However, the 
supraphysiological stimulus provided by either anti-CD28 or PMA results in non-
physiological chromatin remodeling of the IL-2 gene locus and bypasses the requirement 
for c-Rel and the CD28 response element that are essential for IL-2 gene upregulation in 
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antigen receptor stimulated cells.(35, 102, 184)  More recent work has demonstrated that 
CD28 is, in fact, CsA sensitive under more physiological stimulation conditions,(15, 146) 
consistent with the ability of CD28 to enhance TCR induction of calcium flux and NFAT 
activity(51, 185).  Similarly, the apparent dependence of IL-2 production on CD28 
costimulation was thought to result from unique signal transduction pathways distinct 
from that used by the TCR(186, 187).  However, further characterization of transcription 
factors regulating IL-2 gene transcription, including NFAT, c-REL-AP1, and NF-kB, 
identifies them as common targets of both TCR and CD28 signaling(18, 48).  
Nonetheless, it is a common biological phenomenon that integration of complex 
quantitative signals can result in qualitatively different responses.   
 
 
Ctla-4 and Negative Costimulation in the Adaptive Immune Response 
 
Molecular genetics and expression of Ctla-4 
In addition to positive costimulation provided by CD28 ligation, regulation of 
peripheral lymphocyte responsiveness to antigen encounter is achieved by coinhibitory 
signaling mediated by negative regulators of T cell activation.  Ctla-4 provides an 
inhibitory signal that counteracts positive signals transmitted through the TCR and CD28, 
and is necessary for the maintenance of peripheral T cell tolerance(188).  Like CD28, 
Ctla-4 is a type 1 transmembrane glycoprotein of the immunoglobulin superfamily(189).  
The Ctla-4 gene is located on chromosome 1 in mice and chromosome 2 in humans 
within a locus containing both ICOS and CD28 (189-193).  The Ctla-4 gene contains four 
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exons encoding a signal sequence, an extracellular IgV-like domain containing the B7-
binding MYPPY motif, a transmembrane region, and a cytoplasmic tail(190, 194).(Figure 
1.2)  Human and murine Ctla-4 share 76% amino acid identity overall, and the 
cytoplasmic domain of Ctla-4 is 100% conserved across mammals(190).  The Ctla-4 gene 
product encodes a protein of 223aa with a 35aa signal peptide that exists as a covalently 
linked homodimer on the cell surface(195, 196).  Homodimerization is mediated by a 
conserved cysteine residue at position 122 in the stalk region and by N-glycosylation at 
position 78 and 110(196, 197).  The 36aa long cytoplasmic tail of Ctla-4 lacks enzymatic 
activity but contains a membrane-proximal lysine-rich region, tyrosine residues at 
positions 165 and 182, and a proline-rich region starting at position 169(198).   
The Ctla-4 transcript undergoes alternative splicing(Figure 1.3).  In humans, 3 
transcripts can be detected: a full-length transcript composed of exons 1-4, a transcript 
coding for soluble Ctla-4 that excludes exon 3, and a transcript that includes only exons 1  
and 4(191, 199-202)  Mice express an additional transcript that excludes exon 2 and 
codes for a ligand-independent (li) form of Ctla-4(199). 
In addition to thymocytes and mature T cells, Ctla-4 gene expression has been 
detected in a variety of cells including monocytes, B cells, CD34+ stem cells, fibroblasts,  
granulocytes, and mouse embryonic cells(203-208).  While Ctla-4 may signal in these 
cells, or provide signals to other cells via B7 ligands, no function has yet been attributed 
to Ctla-4 in non-T cells. 
Factors mediating transcriptional control of Ctla-4 gene expression in T cells have 
not been well defined, but are known to involve several signaling pathways. 
Transcriptional regulation of Ctla-4 is initiated 335bp upstream of the start codon, and the
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Figure 1.2: Structure of Ctla-4 gene  
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Figure 1.2:  Structure of Ctla-4 gene and protein sequence.  The Ctla-4 gene is located on 
mouse chromosome 1 and human chromosome 4.  The full-length transcript encodes 4 
exons corresponding to a gene length of 6.81Kb. (Panel A)  Human and mouse protein 
are 76% conserved at the amino acid level.  The cytoplasmic domain is 100% conserved. 
Potential phosphotyrosine residues are printed in yellow. (Panel B)  Binding sites for 
molecules known to associate with the cytoplasmic tail of Ctla-4. (Panel C)
 30
5’ upstream region of Ctla-4 contains several transcriptional regulatory sequences 
including sites for NFAT, Nf-κB, AP-1, STAT, GATA-1, and Oct-1.(191, 192, 209)   
NFAT in particular may be central to transcriptional regulation of Ctla-4 as NFAT levels 
correlate directly with levels of Ctla-4 mRNA, and cyclosporine A mediated inhibition of 
NFAT activation reduces Ctla-4 gene transcription.(210, 211)    
Ctla-4 mRNA expression is upregulated from nearly undetectable basal levels in 
naive T cells upon TCR-mediated activation, and its expression is further enhanced by 
CD28 signaling(25, 209, 211, 212).  Levels of Ctla-4 mRNA are regulated, in part, by 
alterations in mRNA stability that occur as a result of TCR and CD28 signaling.  Under 
conditions of TCR signaling alone Ctla-4 mRNA half-life is ~4.6 hours.  CD28 
costimulation increases the half-life to ~8.9 hours.(211, 213)  Ctla-4 mRNA stabilization 
is likely mediated by three 3’ UTR AUUUA motifs implicated as binding sites for  
proteins mediating mRNA degradation.(211, 214)    Maximal Ctla-4 expression is 
achieved 24-48 hours after activation in both primary and secondary responses, and 
memory cells maintain a higher level of basal expression. (213).  CD4+CD25+ regulatory 
T cells (Tregs) and anergized T cell clones express Ctla-4 constitutively(215) 
Regulation of Ctla-4 protein expression is complex and incompletely understood. Unlike 
CD28, which is constitutively expressed on T cells, Ctla-4 is undetectable on naïve T 
cells.  Ctla-4 is quickly upregulated subsequent to TCR ligation and reaches maximal 
expression at the cell surface 24-48 hours following activation.  In resting cells the vast 
majority of Ctla-4 protein is maintained intracellularly in vesicles located in the region of 
the microtubule organizing center (MTOC).  TCR engagement initiates cytoskeletal 
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Figure 1.3:  Ctla-4 undergoes alternative splicing 
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Figure 1.3:  Ctla-4 undergoes alternative splicing.  Ctla-4 contains four exons encoding a 
signal sequence, the ligand binding domain containing the B7-binding MYPPY motif, a 
transmembrane region, and the cytoplasmic domain.  Single nucleotide polymorphisms in 
non-coding regions of the Ctla-4 gene in humans and mice result in altered splicing.  In 
humans, common allelic variation results in reduced production of the soluble isoform of 
CTLA-4 which lacks the transmembrane region and is associated with increased risk of 
several common autoimmune diseases including Graves disease and type I diabetes.  In 
mice, increased risk of type I diabetes is associated with lower mRNA levels for the 
ligand-independent form of Ctla-4 which has been shown to transmit an inhibitory signal 
in T cells.  An alternative transcript lacking the cytoplasmic domain has also been 
reported in mice, but no function has yet been attributed to it. 
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rearrangement, reorientation of the MTOC towards the point of APC contact, and 
vesicular trafficking of CTLA-4 to a point proximal to the synapse where the 
 majority of Ctla-4 is retained in vesicles throughout lymphocyte activation(216).  In 
humans, only ~10% of total Ctla-4 is surface expressed following activation.(213, 217)  
However, translocation of Ctla-4 to the cell surface from intracellular vesicles and 
accumulation in the synapse is proportional to the strength of TCR signaling, suggesting 
that stronger TCR stimuli result in increased Ctla-4 mediated inhibition(216).  Enhanced 
Ctla-4 inhibition may serve to moderate responses of T cells experiencing high-affinity 
antigen-receptor interactions as a means of maintaining clonal diversity in a polyclonal 
response(218).  The half-life of Ctla-4 on the cell surface is regulated by the rate of 
internalization.  Once internalized, Ctla-4 is rapidly degraded in lysosomal 
compartments, with a half-life of two hours.(213, 219, 220)  Interestingly,  TCR signaling 
can induce recycling of Ctla-4 from the lysosome to the cell surface, providing an 
alternative method of increasing surface expression of Ctla-4(221).  Previously activated 
resting cells maintain higher levels of intracellular Ctla-4 and upregulate surface 
expression with faster kinetics.   
The binding properties of the B7 molecules, CD28, and Ctla-4 support a role for 
Ctla-4 in the attenuation of T cell activation(42).  Sequential expression of B7.2 and B7.1 
on APCs favors the sequential binding of CD28 and Ctla-4 (CD28/Ctla-4 Kd are ~8 and 
20 for B7,2 and B7.1 respectively).  In fact, the earliest costimulatory complexes formed 
between CD28 and B7.2 are estimated to be 10,000 fold less stable than the later B7.1: 
Ctla-4 complexes.  Complexes of B7.2:Ctla-4 and B7.1:CD28 are predicted to have 
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intermediate binding strengths and may allow fine tuning of the costimulatory or 
inhibitory signal.  Ctla-4, despite its low level of expression in naïve cells, is capable of 
regulating both primary and secondary immune responses and inhibits early events in T 
cell activation(222).  Temporal requirements of Ctla-4 mediated inhibition have not been 
defined, and it remains unknown how delayed or transient Ctla-4 ligation affects T cell 
activation. 
 
Ctla-4 inhibits T cell activation: The Ctla-4 knockout phenotype 
The central importance of Ctla-4 in the maintenance of self-tolerance is 
dramatically evident in the Ctla-4-/- mouse phenotype. Ctla-4 deficiency results in 
massive lymphoproliferation, multi-organ inflammatory infiltrates, and death by 3-5 
weeks(223, 224). Thymocyte development is normal in Ctla-4-/- mice and the disease 
appears to result from a defect in peripheral T cell tolerance and homeostasis(225-227).  
Moreover, in vivo anti-Ctla-4 antibody blockade permits development of autoimmune 
disease in normally resistant mouse strains(228), hastens the onset while increasing the 
severity of diabetes in genetically predisposed mice(229), exacerbates disease in 
experimental autoimmune encephalitis or neuritis(230-232), and augments responses to 
tumor vaccines(218, 233-241).  The clinical importance of such findings is already being 
investigated in clinical trials that utilize Ctla-4 blockade to augment endogenous anti-
tumor responses(237, 239, 242-245). 
 Complementing the observations in Ctla-4 knockout mice and models 
utilizing Ctla-4 blockade, Ctla-4 ligation by B7 molecules has been shown to result in 
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decreased activation and inhibits both cell cycle progression through G1 and IL-2 
synthesis(222, 246).  Investigators have shown alterations in the function of several 
known transcription factors following Ctla-4 ligation such as NFκB, IκB, and NFAT(95, 
97, 247-251).  Ctla-4 ligation also results in reduced phosphorylation of CD3(252) and 
differentially regulates mitogen activated protein kinases (MAPK) JNK and ERK(253).  
Targeted Ctla-4 engagement downregulates, or prevents, autoimmunity in animal 
models(254), and inhibits allograft rejection(230).  In addition to the observed role of 
Ctla-4 in determining T lymphocyte activation upon primary stimulation, there is 
growing appreciation for the effects Ctla-4 signaling has on subsequent immune 
responses that are distinct in some ways from its ability to inhibit stimulatory signals 
originating with the TCR or with CD28.  It has been shown that Ctla-4 signaling can 
affect the biology of cells in ways that determine susceptibility to subsequent infection by 
HIV(255), effector function(256), and threshold of activation upon restimulation(256).  
However, the mechanism by which Ctla-4 influences lymphocyte phenotype following 
activation is not known, and gene regulations that may be associated with enduring 
alterations in phenotype have not been investigated. 
 
Ctla-4 undergoes alternative splicing 
 Recently, common allelic variation in the relative expression of alternative splice 
forms of Ctla-4 has been linked to autoimmune disease in both humans and mice(199).  
In mice a translationally silent polymorphism within exon 2 has been linked to altered 
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expression of a Ctla-4 isoform lacking the B7 binding domain.  This ligand independent 
isoform (liCtla-4) is expressed in activated T cells from diabetes resistant strains at levels 
four-fold greater than that seen in the diabetes-prone NOD mouse and is proposed to be 
the Idd5.1 locus.  In humans, susceptibility to the common autoimmune disorders of 
Graves’ disease, autoimmune hypothyroidism, and type 1 diabetes was mapped to a 3’ 
region of the Ctla-4 gene and the disease susceptible haplotype associated with a 
significant reduction in expression of a soluble isoform of Ctla-4 that lacks the 
transmembrane region encoded by exon 3(199).  While these results indicate a central 
role for alternative Ctla-4 isoforms in determining susceptibility to autoimmune disease, 
the regulation of alternative isoform expression, target cells involved, and mechanism of 
action remain almost completely uncharacterized. 
 
Ctla-4 signal integration 
Ctla-4 inhibits some, but not all, signals generated by either TCR signaling or 
CD28 costimulation. Ctla-4 inhibits the CD28 mediated accumulation of NFAT, but not 
AP-1, in the nucleus, inhibiting NFAT-mediated gene regulations including IL-2 gene 
transcription (257).  In contrast, Ctla-4 signaling does not influence CD28-mediated 
stabilization of IL-2 mRNA, consistent with its inability to prevent CD28 mediated Bcl-
xL accumulation(13, 257).   In addition, Ctla-4 does not prevent trace amounts of IL-2 
produced by CD28 costimulation from degrading the cell cycle inhibitor p27(257).  Ctla-
4 does not alter the transcriptional profile of human peripheral blood leukocytes 
stimulated through the TCR alone as assayed by microarray analysis(54), but prevents the 
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TCR-induced upregulation of cyclin D3(which is CD28 independent) as well as cdk4 and 
cdk6 as determined by western blotting(257).  
 
Ctla-4 inhibits CD4+ lymphocyte activation by diverse mechanisms 
 Numerous models describing the mechanism of Ctla-4 function have been 
proposed and it is likely that Ctla-4 actively maintains T cell tolerance by acting at 
several levels to prevent dysregulated T cell activation.  Ctla-4 competes with CD28 for 
B7 ligands(258), and a tailless mutant of Ctla-4 expressed on the surface is capable of 
down-regulating lymphocyte responses.(259)  Furthermore, Ctla-4 forms a two-
dimensional lattice with bound B7.2 that may disrupt molecular organization within the 
immunological synapse(197, 260), and recruits phosphatases to the lipid rafts which 
counteract kinase activity resulting from TCR and/or CD28 ligation(252)(Figure 1.4).  
More distally, Ctla-4 ligation inhibits changes in gene expression triggered by TCR and 
CD28 signaling,(54) but the significance of Ctla-4 mediated gene regulation in the 
maintenance of tolerance remains unclear. 
A significant observation is that Ctla-4 mediates cell-extrinsic regulation.  
Transplantation of T cell depleted Ctla-4-/- bone marrow into RAG-deficient recipients 
reconstitutes the lymphoproliferation and multi-organ T cell infiltration characteristic of 
Ctla-4 deficiency.  However, transplantation of a 1:1 mixture of Ctla-4-/- and Ctla-4+ T 
cell deleted bone marrow produces healthy mice, stable chimerism within the myeloid 
and lymphoid compartments, and normal cellular phenotype(261).  Additionally, Ctla-4-/- 
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CD4+ and Ctla-4-/- CD8+ population became activated, expanded, and contracted in a 
manner indistinguishable from their WT counterparts in response to  lymphocytic 
choriomeningitis virus (LCMV), leishmania major, and mammary tumor virus which 
cause acute, chronic, and persistent infections, respectively(262).  Together, results from 
chimeric bone marrow experiments indicate Ctla-4-/- lymphocytes can be non-
autonomously regulated by Ctla-4 WT cells, implying that the pathology seen in Ctla-4-/- 
mice is likely to result from intrinsic defects in cell activation as well as extrinsic 
regulatory defects.  Work in our lab has shown that depletion of WT cells in established 
bone marrow chimerae initiates the characteristic lymphocyte activation, proliferation 
and tissue infiltration seen in Ctla-4 deficient mice.  However, depletion of either CD4+ 
or CD8+ WT cells alone fails to disrupt regulation of Ctla-4-/- cells.  Moreover, current 
evidence fails to support a dominant role for Tregs in extrinsic regulation by Ctla-4 in  
bone marrow chimerae.  To date the mechanism of regulation evident in mixed Ctla-4-/-
/Ctla-4+ bone marrow chimerae has not been elucidated. 
 The differential effects of Ctla-4 ligation in the regulation of TCR and CD28 
signaling pathways supports the notion that dynamic integration of Ctla-4 mediated 
signals is likely to occur at multiple points.  In addition, the role of Ctla-4 in regulating T 
lymphocyte activation and progression of immune responses is strongly influenced by 
extrinsic factors.  Published results support the notion that Ctla-4 regulation of T cell 
activation may depend on the relative availability of B7 ligands(114, 258, 263), TCR 
signal strength(264-266), and activational history(265, 267).  
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Figure 1.4:  Ctla-4 lattice formation with bound B7.1 
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Figure 1.4:  Ctla-4 interactions with B7.1 result in the formation of extended lattice 
arrays.  Unlike B7.2 which exists as a monomer on the surface of cells, dimeric B7.1 is 
capable of binding two ligands.  In addition, CD28 is most likely monomeric on the T 
cell surface, indicating that lattice formation is unique to Ctla-4:B7.1 interactions.  The 
avidity enhanced binding that results from extended formation of Ctla-4:B7.1 interactions 
results in affinities of interaction more than 104-fold more stable than CD28:B7.2 
interactions.
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Mechanisms of Ctla-4 Mediated Inhibition of T Cell Activation 
 Several non-mutually exclusive mechanisms have been proposed in order to 
explain the observed phenomena that result from Ctla-4 manipulation or deficiency.  The 
absence of pathological disease in Ctla-4-/- mice in the context of B7, CD28, class II 
MHC, or TCR deficiency implies a primary role for Ctla-4 in the attenuation or 
regulation of signals initiated by the TCR or CD28(268).  Overexpression of Ctla-4 on 
CD4+ or CD8+ T lymphocytes inhibits both in vitro and in vivo  T cell responses in a 
manner dependent on normal CD28 and B7 expression(269).  Interestingly, Ctla-4 may 
initiate inhibitory pathways that  utilize common signaling intermediates as indicated by 
the ability of alternative inhibitory receptors not normally expressed in CD4+ T cells to 
ameliorate disease in the context of Ctla-4 deficiency in CD4+ T lympohcytes(270).  
Moreover, observations in numerous experimental settings indicate that Ctla-4 operates 
to suppress or counteract TCR and CD28 mediated signals at several levels via distinct 
mechanisms. 
 
 
Cell Intrinsic Regulation of T Cell Activation by Ctla-4 
 
Ctla-4 inhibits CD28 signals by sequestering shared ligands 
 The recognition that CD28 and Ctla-4 share the ligands B7.1 and B7.2 suggest 
that Ctla-4 may compete with CD28 for ligands in situations where APC-expressed B7 is 
 42
limiting.  Mice expressing a mutant form of Ctla-4 that lacks the cytoplasmic domain are 
long-lived and show no evidence of lymphocytic infiltration of peripheral tissues, but did 
exhibit lymphadenopathy, increased numbers of activated T cells, and a predominantly 
Th2 phenotype(271).  The partial rescue was interpreted as evidence that ligand 
competition is a component of Ctla-4 action.  In separate experiments, expression of Ctla-
4 lacking the cytoplasmic domain resulted in defective IL-2 secretion, survival, and 
proliferation by naïve lymphocytes in response to antigen stimulation in vitro.  Addition 
of exogenous IL-2 rescued the proliferative and survival defect suggesting that 
suppression of Il-2 secretion, the upregulation of which is a hallmark of CD28 
costimulation, was the critical result of Ctla-4 surface expression in the absence of 
intracellular signaling that may be mediated by the cytoplasmic domain of Ctla-4.  
Moreover, adoptive transfer of lymphocytes expressing tailless Ctla-4 were compromised 
in their ability to expand when introduced into Rag-/- mice, a process at least partially 
dependent on CD28 signaling(259).  Finally, memory CD4+ T cells, which are known to 
be less dependent on CD28-mediated signaling for activation and proliferation, that 
expressed tailless Ctla-4 showed normal proliferative capacity in a lymphopenic 
environment(259).  As previously discussed, biochemical studies have shown that Ctla-4 
has a much higher affinity for B7 ligands than CD28, further supporting the notion that 
ligand competition may be central to Ctla-4 mediated inhibition(42).   
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Ctla-4 disrupts the immunological synapse 
 T cell activation through the TCR results in cytoskeletal rearrangement, 
aggregation of lipid microdomains, and coordinated partitioning of receptors into discrete 
membrane compartments at the site of T cell:APC contact.  The resulting immunological 
synapse stabilizes the intercellular interaction of multimolecular signaling complexes and 
may be essential for full cellular activation.  Ctla-4 has been shown to cocluster with the 
TCR and the lipid raft ganglioside GM1 after T cell stimulation in a process that was 
dependent on the cytoplasmic tail of Ctla-4(272).  Ctla-4 partitioning to lipid rafts was 
enhanced under conditions of TCR and Ctla-4 ligation, and could be forced by linking 
Ctla-4 to a GPI anchor.  Forced localization of tailless Ctla-4 to the lipid rafts, although 
necessary, was not sufficient for inhibition of activation in the absence of Ctla-4 
engagement by B7(272).  Crystallization of a B7.1:Ctla-4 complex indicates that Ctla-4 
homodimers bridge bivalent B7.1 homodimers in a periodic arrangement(273).  The 
zipper-like oligomerization can potentially lead to the avidity-enhanced stabilization of 
extended lattice-like formations of B7:Ctla-4 complexes, potentially disrupting the 
ordered intercellular ligand-receptor interactions that characterize the immunological 
synapse.  The potential ability of Ctla-4 ligand binding to result in mechanical disruption 
of activating receptor interactions within the synapse is compatible with the known 
characteristics of B7 ligation by CD28 and Ctla-4, and may function in parallel with 
ligand competition-mediated inhibition by Ctla-4. 
 Early reports suggested that B7.1 and B7.2 mediated similar costimulatory signals 
and suggested that unique roles for the related ligands was determined primarily by their 
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differential expression patterns.(274, 275)  However, despite numerous structural 
similarities, B7.1 and B7.2 possess distinct biochemical features, affinities for CD28 and 
Ctla-4, and oligomeric states. Ctla-4 has higher affinity for both B7 ligands relative to 
CD28, and a relative preference for B7.1 as compared to B7.2 (CD28/Ctla-4 Kd are ~8 
and 20 for B7.2 and B7.1 respectively)(42).  B7.1 exists on the cell surface as a 
homodimer, while B7.2 exists as a monomer(111, 276, 277).  B7.2 is constitutively 
expressed on mature APCs, while B7.1 is upregulated by activation stimuli via 
CD40:CD40L interactions(278).  The binding properties, oligomerization states, and 
expression kinetics of CD28, Ctla-4, and the B7 molecules suggest that attenuation of 
activation signals may require a coordinated interplay between T cells and APC.  
 
Ctla-4 sequesters signaling intermediates and recruits phosphatases to the IS 
In some settings, Ctla-4 mediates inhibition of T cell responses in B7 independent 
manner.  Mutant Ctla-4 incapable of B7 binding inhibits T cell proliferation, cytokine 
secretion, and ERK activation when expressed in Ctla-4 deficient T cells(279).  
Moreover, the naturally occurring ligand independent isoform of Ctla-4 suppresses T cell 
activation and delays the onset of lymphoproliferative disease when expressed in Ctla-4 
deficient mice(200, 279).  These data prove that Ctla-4 mediated inhibition of T cell 
activation is only partially dependent on ligand competition or disruption of the 
immunological synapse.  
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 TCR and CD28 engagement initiates signaling cascades that result in cellular 
activation via coordinated regulation of protein activity and gene transcription.  Ctla-4 is 
capable of modifying or attenuating signals initiated by TCR and CD28 engagement.  
The cytoplasmic tail of Ctla-4 and CD28 associate with common signaling intermediates 
regulating T cell activation.  Association of the serine/threonine phosphatase PP2A with 
the CD28 cytoplasmic tail is negatively regulated by tyrosine phosphorylation of the 
CD28 binding domain following TCR triggering, and inhibition of PP2A activity enables 
potent CD28-mediated costimulation of T cell activation(280).  Ctla-4 binds both the 
catalytic and regulatory subunits (PP2AA) of PP2A, and this association is abrogated by 
tyrosine phosphorylation of the Ctla-4 cytoplasmic domain resulting in enhanced Ctla-4 
mediated inhibition of T cell activation as measured by IL2 gene transcription(198).  
These results indicate that PP2A negatively regulates the function of both CD28 and 
Ctla-4 via phosphotyrosine dependent association with their cytoplasmic domains.  In 
addition to PP2A, Ctla-4 and CD28 also share binding infinity for Src homology domain-
containing tyrosine phosphatases (SHP-1 and SHP-2) and PI3K.  Early reports suggested 
that Ctla-4 recruited phosphatases to the immunological synapse resulting in reversal of 
TCR- and CD28-mediated phosphorylation events(281). The relative importance of these 
associations in the regulation of T cell activation remains controversial, but recent data 
suggest that they may mediate differential signaling based on their inclusion in 
multimeric signaling complexes whose organization is directed by CD28 and Ctla-4.  
Thus, association of Shp-2 or PI3K with Ctla-4 is not required for Ctla-4 mediated 
inhibition of T cell activation(282), but SHP-2 and PI3K associate with Gab2 to mediate 
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CD28 signaling that results in inhibition of TCR-mediated signaling events in a negative 
feedback loop(283).  While not definitively shown, it remains possible that Ctla-4 
functions in part by sequestering signaling intermediates required for efficient signal 
transduction by CD28.  Alternatively, regulated phosphorylation of CD28 and Ctla-4 
tyrosine residues by Src family tyrosine kinases(284-286) may alter the relative 
proportions of proteins associating with CD28 and Ctla-4, and thus change the balance of 
stimulatory and inhibitory signals they mediate.  
 
Cell-Extrinsic Mechanisms of Ctla-4 Function 
 
Wild-type T lymphocytes regulate Ctla-4-/- T cells in mixed bone marrow chimerae 
 Ctla-4 functions to maintain peripheral tolerance by cell extrinsic regulation of T 
lymphocyte responses by cell-contact-dependent and –independent mechanisms.  The 
most dramatic example of cell-extrinsic regulation by Ctla-4 is seen in bone marrow 
chimerae reconstituted with donor cells from Ctla-4-/- and Ctla-4 wild-type mice.  Bone 
marrow recipients reconstituted with T cell depleted Ctla-4-/-  donor cells develop the 
lymphoproliferative disease and tissue infiltration characteristic of native Ctla-4 
deficiency.  The pathogenesis of the observed disease recapitulates all aspects of the 
native disease and is initiated only upon thymic emigration of donor T cells.  In contrast, 
mixed bone marrow chimerae remain healthy and maintain a balanced ratio of naïve 
donor cells in the periphery(261).  Moreover, Ctla-4-deficient cells in mixed bone 
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marrow chimerae respond to several pathogens in a manner indistinguishable from their 
wild-type counterparts(262).  Numerous models have been proposed to explain cell-
extrinsic regulation by Ctla-4, but the dominant mechanism remains undefined.  Given 
the diversity of observations made about Ctla-4 function in various contexts, it is possible 
that numerous mechanisms mediated by Ctla-4 act cooperatively to maintain self-
tolerance at the population level. 
 
Regulation of cytokine production 
 Cytokines are critically important regulators of T cell activation, survival, 
differentiation, and effector function.  Cytokine activity is determined by the expression 
pattern of appropriate receptors and intracellular proteins involved in mediating cytokine 
signaling.  Thus, cytokines are capable of acting at a distance to coordinate varied 
responses in different cell types and serve to orchestrate immune responses at the 
population level.  CD28 costimulation concomitant with TCR triggering results in potent 
upregulation of IL-2 gene transcription.  IL-2 acts in both paracrine and autocrine fashion 
to enhance cell survival, proliferation, and effector function.  Il-2 deficiency results in 
dramatically reduced T cell survival following antigen receptor stimulation, markedly 
reduced proliferation, and inefficient T cell mediated immune responses.  Ctla-4 ligation 
inhibits CD28-mediated upregulation of IL-2 and IL-2R(287).  Signals initiated by TCR 
triggering and CD28 ligation regulate the activity and expression of numerous other 
transcription factors that determine cellular differentiation, coordinate T cell-dependent 
humoral responses, and influence antiviral immunity through stimulation of the innate 
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immune system.  In contrast, several cytokines result in potent immunosuppression of T 
cell responses and serve to maintain self-tolerance by inhibiting or attenuating 
unwarranted T cell activation.  TGF-beta and IL-10 inhibit T cell responses and have 
been examined for their ability to mediate Ctla-4 function.  Critically, no role for TGF-
beta has been reliably discerned in the intrinsic regulation of T cell responses mediated 
by Ctla-4(288).  However, a large body of evidence suggests that TGF-beta may mediate 
suppressive effects of regulatory T cells(289-294) and Ctla-4 has been shown to enhance 
the suppressive activity of CD4+CD25+ regulatory T cells(295).  Ctla-4-deficient mice 
have functional CD4+CD25+ regulatory T cells that are generated in the thymus, 
indicating that suppressor function is at least partially independent of Ctla-4 action.  In 
contrast, the generation of adaptive regulatory T cells in the periphery is dependent on 
TGF-beta induction of FoxP3(296-300) and may require permissive signaling through 
Ctla-4(301).  Moreover, several lines of evidence support the notion that Ctla-4 does 
mediate some suppressive effects of regulatory cells(302, 303), but not all.  The data 
suggest that Ctla-4 may regulate the development of a subset of adaptively generated 
regulatory T cells and contribute to specific mechanisms of suppression, thus explaining 
previous contradictions regarding the overlapping role of Ctla-4 and TGF-beta in 
maintaining immunotolerance.  However, the critical downstream mediators of Ctla-4 
signaling that control responses to TGF-beta and may result in phenotypic changes upon 
restimulation or long-term unresponsiveness to antigen receptor engagement have not 
been defined. 
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Ctla-4 maintains peripheral self-tolerance through tryptophan catabolism 
 Tryptophan catabolism and the consequent production of tryptophan catabolites 
mediates a suppressive effect on immune responses.  In the short-term, tryptophan 
deprivation and exposure to tryptophan catabolites results in CD3 down-regulation and 
impaired lymphocyte effector function.  Longer term, tryptophan catabolism results in the 
emergence of a regulatory phenotype in naïve CD4+CD25-  T cells mediated through 
TGF-beta dependent upregulation of FoxP3(304).  The CD4+CD25+CD62L+Ctla-
4+GITR+CD69-CD45RBLow cells that develop in the context of increased tryptophan 
catabolism are capable of suppressing diabetogenic responses in vivo(304). Thus, 
tryptophan catabolism is an effector mechanism regulating peripheral self-tolerance 
through direct suppression of T cell effector responses and generation of suppressive T 
cell function in naïve CD4+ T cells.  Ctla-4 signals through B7 on dendritic cells to 
upregulate the expression of indoleamineoxygenase resulting in increased tryptophan 
catabolism and suppression of immune responses(305).  TGF-beta is crucial for the 
development of a regulatory phenotype in peripheral CD4+CD25- cells(300).  Ctla-4 
ligation soon after activation is critically required for TGF-beta-mediated FoxP3 
induction, and Ctla-4 deficiency results in the inability to develop peripheral 
CD4+CD25+ suppressor cells(301).  Furthermore, upregulation of IDO expression in 
dendritic cells is regulated by suppressor T cells constitutively expressing Ctla-4(306).  
Thus Ctla-4 enables TGF-beta-mediated generation of regulatory T cells in the periphery 
and provides a mechanism by which suppressor T cells acquire the ability to regulate 
both effector T cell responses and further generation of regulatory cells via modulation of 
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tryptophan catabolism.  Interestingly, CD28 is also capable of signaling through B7 
molecules expressed on dendritic cells, but induces immunostimulatory signals that 
counteract the induction of tolerogenic properties that result from Ctla-4-B7 
interactions(307).  Recent work also suggests that additional ligand-receptor interactions 
involving CD40 and CD40L, expressed on dendritic cells and lympohcytes respectively, 
may be crucially involved in regulating dendritic cell responses to B7 engagement(308).  
Cumulatively, these data highlight the complex interplay of costimulatory signaling 
pathways in the regulation and determination of peripheral tolerance mechanisms.  
Moreover, the cyclical interdependence of mechanisms underlying development of 
regulatory T cells and induction of tolerogenic properties in dendritic cells is dependent 
on CD28 and Ctla-4 signaling. 
 
Ctla-4 regulates suppressor T cell function and signals through B7 on T cells 
 Ctla-4 enhances, and CD28 inhibits, the ability of regulatory CD4+CD25+ T cells 
to induce a tolerogenic phenotype in dendritic cells(295). In addition, this effect is 
differentially regulated by B7.1 and B7.2 and may reflect preferential binding to Ctla-4 
and CD28 respectively(295, 309).  A requirement for CD28 signaling in the generation of 
suppressor T cells is well established, but the role of Ctla-4 has been more 
controversial(310-312).  Contradictory data regarding the role of Ctla-4 in regulatory T 
cell function may reflect differing requirements as a result of alternative mechanism of 
suppression.  Thus Ctla-4 is reportedly necessary for the adaptive generation of 
regulatory cells developed in the periphery, but is not required during development of 
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thymic-derived regulatory T cells(313).  Thus, Ctla-4 deficient mice maintain a 
population of CD4+CD25+ regulatory cells that possess potent suppressive activity in 
vitro, but are not sufficient to prevent the lymphoproliferative disease that develops in 
Ctla-4-/- mice.   
B7-ligand interactions facilitate bidirectional signaling that serves to modulate 
immune responsiveness by various mechanisms.  As indicated, Ctla-4 and CD28 initiate 
tolerogenic and immunostimulatory signaling pathways in dendritic cells upon binding 
B7(307, 314).   Recent work has shown that T cell expressed B7 also regulates 
lymphocyte responses by engaging Ctla-4 in T-T interactions(315) in a manner analogous 
to Ctla-4 mediated inhibition by APC-expressed B7.  However, recent data also suggest 
that CD4+CD25+ regulatory T cells can suppress T cell responses by Ctla-4 mediated 
ligation of B7 molecules expressed on alloreactive effector cells(303).  Regulatory T cells 
are known to inhibit activation of effector T cells by altering the phenotype of dendritic 
cells and by secretion of inhibitory cytokines.  Thus, the diversity of mechanisms utilized 
by suppressor T cells results in intercellular interactions that are differentially dependent 
on Ctla-4.  Contact-dependent regulation of effector cells via B7 signaling represents a 
novel regulatory mechanism consistent with the known activity of B7 in dendritic cells, 
and may provide new opportunities for therapeutic manipulation.  The mechanism by 
which B7 signals in T cells is not known.  Our lab is currently in the process of exploring 
the role B7-mediated inhibition might play in various contexts of immune dysregulation.
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Ctla-4 and immunotolerance 
 Costimulatory signals are critical determinants of T cell activation and influence 
the specificity, magnitude, character, and duration of immune responses.  Alterations in 
CD28 and Ctla-4 function are associated with autoimmune pathology in humans, and 
therapeutic manipulation of costimulatory signals in the treatment of cancer is already 
being investigated in clinical trials(236, 316, 317).  Altered Ctla-4 function in particular 
has been shown to result in increased susceptibility to several common autoimmune 
disorders.  In humans, single nucleotide polymorphisms identified in the CTLA-4 gene 
influence alternative splicing and increase susceptibility to Hashimoto’s thyroiditis, 
Graves disease, and type I diabetes (TID)(199).  While definitive associations of CTLA-4 
polymorphisms with susceptibility to numerous other diseases remains controversial, a 
central role for Ctla-4 in regulating progression of established autoimmune disease has 
been identified(318).  In mice, Ctla-4 has been shown to control the severity and onset of 
numerous autoimmune diseases including experimental autoimmune 
encephalomyelitis(319, 320), autoimmune diabetes(200, 321), and chronic experimental 
colitis(322).  In conjunction with the observed phenotype of Ctla-4-/- mice(323) and other 
reports suggesting subtle contributions of Ctla-4 function to the development and 
progression of numerous diseases, these data suggest that Ctla-4 might represent a 
general susceptibility gene for autoimmune disease(324, 325).  The broad relevance of 
Ctla-4 to clinically relevant disease states makes it an ideal target for therapeutic 
manipulation. 
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TCR-triggering alters gene expression: CD28 amplification and Ctla-4 inhibition 
Two reports have published the results of global gene expression profiling in T 
lymphocytes following activation(15, 54).  According to both reports, TCR signaling 
alone results in the altered regulation of several thousand genes.  CD28 signaling alone 
results in few transcriptional alterations, but is capable of substantially magnifying the 
response to TCR ligation when simultaneously engaged.  For the vast majority of genes 
assayed, CD28 costimulation serves to enhance TCR initiated gene regulations although a 
number of genes are reported to be reciprocally regulated by CD28 costimulation in 
comparison with TCR ligation alone. In the one report that examined the influence of 
Ctla-4 ligation(54), Ctla-4 triggering was reported to inhibit gene regulations subsequent 
to CD28 costimulation but not TCR monostimulation.  However, both studies used 
antibody-coated microbeads to stimulate human peripheral blood leukocytes (PBLs) 
heterogeneous for activational history and antigen specificity.  Moreover, the stimulated 
cells were analyzed as bulk populations and undoubtedly contained cells with naïve 
phenotypes as well as cells undergoing both primary and secondary activation.  No 
studies have been published that profile global gene expression in stimulated 
lymphocytes using naïve populations homogenous for phenotype and activation status.  
As a result, it remains unclear whether Ctla-4 transduces a unique signal that results in 
specific changes in gene expression, or whether Ctla-4 functions primarily by inhibiting 
signals generated by the TCR and/or CD28. 
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Ctla-4 functions to maintain quiescence in peripheral lymphocytes 
Genes necessary for quiescence are necessarily downregulated upon T cell 
activation(326, 327).  CD28 costimulation has been shown to reciprocally regulate gene 
expression and results in the simultaneous upregulation of genes necessary for 
proliferation and effector function while repressing genes associated with a quiescent 
phenotype(15, 54).  Published reports also indicate nearly equal numbers of up and 
down-regulated genes in primary T cells stimulated ex vivo(15, 54).  These reciprocal 
regulations evidence the complex choreography involved in gene regulation that occurs 
upon T lymphocyte activation and reinforces the notion that maintenance of a naïve 
phenotype is an active process.  The balance between protective immunity and 
pathological autoimmunity is maintained by mechanisms that determine signaling 
thresholds of antigen and costimulatory receptors. Altered costimulatory pathways can 
result in enhanced activation of lymphocytes and autoimmunity, or antigen-specific 
tolerance induction through clonal anergy or active immunosuppression by regulatory T 
cells. The molecular mechanisms that underlie maintenance of immunotolerance in vivo 
and integrate co-stimulatory signals with antigen receptor signals in T cells are poorly 
understood. 
The overall objective of this thesis work was to gain additional insight into the 
mechanisms underlying costimulatory regulation of T cell responses.  Specifically, the 
present work sought to identify mediators of Ctla-4 function by assessing the genomic 
expression patterns that exist under varying conditions of Ctla-4 ligation and deficiency.  
To accomplish this necessitated a global characterization of the transcriptome of 
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activated naïve lymphocytes, thus providing additional insight into lympohocyte 
responses to antigen-receptor- and CD28-mediated signaling pathways.  The central 
importance of costimulatory signals in immune regulation has been shown in numerous 
disease models, and a greater understanding of the mechanisms underlying signal 
integration in T cells will provide novel opportunities for knowledge based approaches to 
combating autoimmune disease and pathology. Thus, a second goal of this work was the 
creation of a database of gene regulations occurring subsequent to T cell activation that 
will enable the identification of novel genes central to the maintenance of peripheral 
tolerance.  
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CHAPTER II 
 
MATERIALS AND METHODS 
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MATERIALS and METHODS: 
 
Mice: 
The phenotype and antigen specificity of 5C.C7 TCR-transgenic Rag-/- mice has been 
described previously(288, 328).  In brief, the 5C.C7 TCR is specific for moth cytochrome 
C (MCC88-103) oligopeptide presented in the context of the class II MHC molecule I-Ek.  
Expression of the 5C.C7 TCR transgene in developing thymocytes results in a 
predominantly (>95%) CD4+ peripheral T cell compartment.  Ctla-4-deficient mice(323), 
B7.1-/-/B7.2-/- mice(329), CD28-/-(26), and Rag1-/-(330) mice have also been previously 
characterized.  All mice were maintained in a specific-pathogen-free facility.  Unless 
otherwise specified, lymphocyte donor mice were used at 6-12 weeks of age.  All mice 
sacrificed were euthanized by CO2. 
 
T cell purification: 
CD4+ T cells were isolated from lymph nodes of donor mice by dissection and tissue 
homogenization in RPMI supplemented with penicillin, streptomycin, beta-
mercaptoethanol (2-ME), and 10% fetal bovine serum (FBS)(cRPMI).  As indicated, 
CD4+ lymphocytes were isolated by positive selection using α-CD4 magnetic bead 
purification or by fluorescence activated cell sorting (FACS).  5C.C7 lymph node cells 
were >90% CD3+CD4+CD44LowCD25- following homogenization and did not require 
further isolation steps prior to in vitro use.  Magnetic bead purification utilized 
AutoMACS LS+ columns according to the manufacturer’s protocols (Miltenyi Biotec, 
 58
Auburn, CA).  FACS isolation was performed by the University of Massachusetts 
Medical School Flow Cytometry Core Facility under sterile conditions subsequent to 
fluorochrome-conjugated antibody labeling.  Unless otherwise stated, purified 
populations were >95% pure by flow cytometry analysis. 
 
Bone marrow isolation and transfer: 
Femurs and tibiae from bone marrow donor mice were surgically dissected and cleaned 
of soft tissue.  Marrow was flushed from dyaphyses with RPMI supplemented with 5% 
FBS using a 25 gauge needle and syringe after removal of the epiphyses.  Marrow was 
homogenized by repeated aspiration through a 25 gauge needle before lysis of red blood 
cells in 1ml RBC lysis buffer at room temperature for 1 minute.  Cells were washed in 
5ml RPMI 5% FBS, counted, and resuspended in 3ml of sterile phosphate buffered saline 
(PBS).  Lymphocyte depletion was achieved using magnetic beads recognizing CD4, 
CD8, and either the Thy1 or Ly5 congenic markers.  Beads were washed twice in 4ml 
PBS to remove unconjugated antibody prior to use.  Six beads total were used per target 
cell, divided evenly among appropriate molecular target identities.  Ctla-4 wild-type 
(WT) and Ctla-4-deficient bone marrow typically consisted of <5% and 10-15% mature T 
cells respectively.  Antibody-conjugated magnetic beads were incubated with RBC 
depleted bone marrow preparation for 30 minutes at 4 degrees Celsius with rotation.  
Magnetic separation utilized a stationary magnet for two minutes.  Generally, 
lymphocytes were undetectable by FACS analysis following depletion protocols when 
analyzed for CD3, CD4, and CD8 expression.  Lymphocyte depleted bone marrow cells 
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were resuspended at 33x106 cells per ml in PBS.  150ul containing 5 x106 total cells was 
injected into the tail vein of recipient Rag-/- mice previously irradiated (within 36 hours) 
with 300 rads.  Mature donor lymphocytes were typically detectable in blood samples 4-5 
weeks after transplantation. 
 
In vitro stimulation assays 
Stimulation of isolated 5C.C7 Rag-/- lymph node cells by engineered antigen presenting 
cells (APCs) was accomplished as follows.  Chinese Hamster ovary (CHO) cells 
expressing I-Ek , and differentially expressing synthetic ligands for CD28 and Ctla-4 have 
been described previously(288). CHO cells were grown in DMEM supplemented with 
penicillin and streptomycin, L-glutamine, 2-ME, 10% FBS, 300ug/ml hygromycin, and 
300ug/ml zeocin.  Prior to coculture with 5C.C7 Rag-/- lymph node cells, CHO cells were 
removed from culture using PBS with 5mM EDTA and 5% FBS to maintain the integrity 
of surface proteins, and incubated for 90 minutes at 1.5x107 cells per milliliter at 37ºC in 
RPMI 5%FBS supplemented with 100ug/ml mitomycin C.  Following mitomycin C 
treatment, CHO cells were washed 4x in cRPMI, resuspended at 5x106 cells per milliliter 
of cRPMI containing the indicated concentrations of HPLC-purified moth cytochrome C 
(MCC88-103) oligopeptide, and incubated for 5 hours in 96 well round-bottom plates at 
37ºC with 5x104 cells per well to allow equilibrated MHC binding of MCC.  Excess 
MCC was removed after 5 hours, and 5C.C7 Rag-/- lymph node cells were added at a 1:1 
ratio with CHO cells in 200ul cRPMI.  Lymph node cells cocultured with CHO APCs 
were harvested at indicated times by gentle pipetting.   Isolation of phenotypically pure 
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in vitro activated lymphocytes was achieved by antibody-mediated staining and FACS 
isolation in the University of Massachusetts Medical School Flow Cytometry Core 
Facility as indicated.  Isolated populations were always >90% pure, and generally >95% 
pure, for CD4 and the specified activation markers.  Antibody-mediated stimulation of 
lymphocytes was accomplished using soluble, plate-bound, or polystyrene microbead-
conjugated antibodies to CD3, CD28, and/or Ctla-4.  Antibody-coated plates were 
prepared by incubating PBS containing antibody at the specified concentrations for 1 
hour at 37ºC and washing the plates with cRPMI immediately prior to addition of cell 
preparations.  Antibody-microbeads were prepared by incubation of 1.2x107 polystyrene 
microbeads (Interfacial Dynamics Corporation, Eugene, OR) at 37ºC with rotation for 20 
minutes in 1ml of PBS solution containing antibodies at the specified concentration.  
Conjugated microbeads were washed 3x in PBS, and resuspended in 1ml of cRPMI at 
room temperature a minimum of 1 hour before use in culture.  Conjugated beads were 
used at a ratio of 12 beads per cell.  Thymidine incorporation was measured in 
stimulated cells by the addition of 1uCi of Thymidine in 10ul of cRPMI per well in 96 
well plates for 12-16 hours.  Sample plates were frozen at -80ºC until analyzed. 
 
Lklf Overexpression Construct, Transfection, and Retroviral Infection of NFCs 
A retroviral expression construct was constructed that included a MSCV promoter, the 
protein coding region of Lklf, an internal ribosomal entry site (IRES), and the green 
fluorescent protein (GFP) gene.  XL1 Blue ultra-competent E.coli cells were transfected 
using a standard heat-shock protocol, and grown on agarose.  Selected colonies were used 
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to inoculate 5 ml cultures, and incubated overnight.  Plasmid was purified using Qiagen 
MiniPrep protocol, and restriction enzyme digests confirmed the integrity and orientation 
of the gene insert.  Large quantities of plasmid were prepared by bulk culture of 
transfected E.coli clones, and plasmid was isolated by Qiagen MaxiPrep protocol.  
Phoenix cells were transfected with the purified Lklf-construct or an empty MSCV 
plasmid using Lipofectamine.  The Phoenix cell packaging line was grown overnight 
before replacing the media with a minimal volume of fresh media.  NFCs, a double 
positive thymoma cell line capable of undergoing differentiation, were cocultured with 
Phoenix cells for several days and purified for positive GFP expression by FACS.   
 
Microarray analysis: 
RNA isolation was performed using either TriReagent (Molecular Research Center, Inc., 
Cincinatti, OH) or TRIzol (Gibco/BRL, Gaithersburg, MD) according to the 
manufacturer’s instructions.  A 260/280 spectophotometric ratio of 1.8-2.0 was required 
before samples could be labeled for microarray analysis.  Preparation of biotin-labeled 
cRNA for microarray analysis was performed using either single or double-amplification 
protocols, as indicated, that utilized either 4-8ug or 50-400ng of total RNA as the starting 
material respectively.  When >4ug of total RNA was available, a “standard” labeling 
protocol was followed.  Briefly, total RNA was converted into double-stranded cDNA 
using a two-step cDNA synthesis reaction utilizing a specific oligo(dT)24 primer 
containing a T7 RNA polymerase promoter site located 3’ of the poly T tract.  Biotin 
labeled cRNA was generated from the cDNA sample by in vitro transcription driven by a 
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T7 RNA polymerase.  When <4ug of total RNA was available, samples were amplified 
and labeled for microarray analysis using a two step protocol (Affymetrix SSvII Protocol) 
starting with 50-400ng of total RNA.  Briefly, double-stranded cDNA was generated 
using a two-step reverse transcription protocol with the same oligo(dT)24 primer used in 
the standard protocol.  In vitro transcription was performed on the cDNA to produce 
cRNA.  400-800ng of first-cycle cRNA product was utilized as the starting material for a 
second reverse transcription reaction utilizing random hexamer primers that yielded 
cDNA.  Amplified cDNA was used to generate biotin-labeled cRNA by in vitro 
transcription.  Biotin-labeled cRNA was purified using RNeasy spin columns (Qiagen, 
Germany).  Biotin-labeled cRNA samples were processed for microarray analysis by the 
University of Massachusetts Medical School Genomics Core Facility.  Briefly, about 
20ug of labeled cRNA were fragmented by mild alkaline treatment at 94ºC for 30 
minutes, and the product used to prepare the hybridization cocktail.  The hybridization 
cocktail includes 4 control cRNAs to inform subsequent image analysis and data 
normalization, and a biotinylated oligonucleotide marker to facilitate image orientation, 
microarray scanning, and probeset mapping.  cRNA samples were hybridized to 
MgU74Av.2 microarrays and scanned according to the manufacturer’s guidelines. 
Briefly, sample cocktails were heated to 99ºC for 5 minutes, equilibrated to 45ºc for 5 
minutes, and centrifuged at room temperature for 5 minutes.  A total of 10-15ug of each 
fragmented sample was hybridized to Affymetrix GeneChip according to the 
manufacturer’s protocol.  Arrays were washed with non-stringent buffered solution, 
stained with R-phycoerythrin streptavidin, washed again, and read by the GeneArray 
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Scanner.  Array data normalization was achieved by maintaining global array intensity 
within the linear bounds of detector sensitivity, and subsequent normalization of 
measured values to signal intensities of spike-controls included in the hybridization 
cocktail.  The resultant raw data was analyzed by MicroArray Suite 5.0 (MAS5.0) 
(Affymetrix), Genespring (Agilent Technologies), or Ingenuity Pathways Analysis 
(Ingenuity Systems).  The determination of signal intensity significance in relation to 
background signal detection was performed according to Affymetrix MAS5.0 standard 
algorithms and resulted in “present”, “absent”, or “marginal” calls (i.e. “flags”).  In order 
to allow rational determination of fold-change differences between sample conditions, 
sequential data normalization was applied as follows: measured probeset signal intensity 
values below 0.01 were set to 0.01; each measurement was divided by the 50.0th 
percentile of all measurements in that sample; when appropriate, specific samples were 
normalized to one another as indicated by dividing the median signal measurement of 
each gene in each experimental samples by the median values of that gene’s 
measurement in the corresponding control samples.  Measures of significance were 
obtained by calculating the standard deviation from the average expression value for each 
gene when sufficient replicates were available, or by use of the cross gene error model, as 
indicated.  The cross-gene error model provides reliable estimation of significance when 
fewer than three replicates are available by combining measurement variation and 
between-sample varation information.  For the analyses included herein, when two 
replicates were available the cross gene error model was configured to compute 
significance based on the assumption that variability between replicates is similar for all 
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genes with similar measurement levels. In contrast, in the few conditions assayed where 
only one chip was analyzed per condition, the cross-gene error model was configured 
based on the assumption that a minority of the genes measured were biological 
significance.  The cross-gene error model calculates deviation for each gene based on the 
appropriate assumption as outlined above and orders the values based on increasing 
control strength.  Medians of the deviation and control strength are calculated and the 
deviation on squared control strength is computed using the following equation expressed 
in terms of normalized data: 
S(norm)2=a2/C2+b2 
Where: 
 a = fixed (absolute) error (base) 
 b = proportional error (proportion), + 5% 
 C = control value (also referred to as the control strength) 
The control value is a synthetic value equal to the product of the values used in prior 
normalization steps.  In analyses included herein where a per-chip and per-gene 
normalization was applied, the control value is defined as: 
C=C(per-chip)*C(per-gene) 
In experiments with two samples per condition where variability between replicates was 
assumed similar for genes with similar measurements, a separate curve for each group of 
replicates was applied.  Where only one chip was analyzed per condition, and a minority 
of genes were considered to vary with biological significance, the error model applied a 
separate curve for each sample.  The number of replicates per condition, specific 
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characteristics of the included samples, labeling protocols utilized, and error models 
applied for each experimental approach are presented in the corresponding chapter.   
 
Lklf Real-time PCR 
Oligonucleotide primers with the sequences 
5’:CTATCTTGCCGTCCTTTGCCACTTTCG and 
3’:ATGGAGAGGATGAAGTCCACACACG were made by Integrated DNA 
Technologies to amplify a 132 base pair product. Realtime protocol was: hot start 95°C 
for 8’30”; melt at 95°C, 30”, anneal at 55.4°C, 30”, extend 72° 25” for 43 cycles; melt 
curve recorded from 55°C at increments of 0.5°C increase every 30” over 80 cycles.  
LKLF was normalized to beta-2-microglobulin using the primer sequences 
5’:AATCCAGTTTCTAATATGCTA and 3’:TATTGCTCAGCTATCTAGG. Realtime 
protocol was: 95°C for 3’; melt at 94°C, 20”, anneal at 50°C, 25”, extend 72° 25” for 40 
cycles; melt curve recorded from 55°C at increments of 0.5°C increase every 10” over 80 
cycles.  Biorad real-time PCR Super mix reagent was used for all reactions.  Data 
analysis, standard curve generation and copy number calculation was performed with 
MyiQ software. Time points including 0, 8, 12, 16, 20, 24, 35, 55, 60 and 65 hrs post-
stimulation were looked at in both mechanical and biological replicates.  
 
 66
CHAPTER III 
 
RESULTS 
 
Global Expression Profiling of Naïve CD4+ 
Lymphocytes in Steady-State Ctla-4-Deficient Model 
Systems 
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Identification of genes differentially regulated by Ctla-4 deficiency in naïve 
peripheral CD4+ lymphocytes in the absence of B7 ligands: 
 
 To provide a contextual framework for the analysis of expression profiles 
subsequent to differential Ctla-4 ligation, we utilized in vivo models that allowed for 
steady-state analysis of naïve Ctla-4 deficient CD4+ cells.  As an initial approach we 
utilized Ctla-4 deficient mice crossed onto the B7.1-/-/B7.2-/- double knockout.  As 
published, impaired CD28 costimulation subsequent to the absence of B7 ligand 
completely abrogates the lymphoproliferative disease that invariably results in Ctla-4 
single knockout mice(268).  The lack of positive costimulation in B7.1-/-/B7.2-/-/Ctla-4-/- 
mice results in healthy mice with naïve peripheral CD4+ lymphocytes capable of primary 
activation responses with normal kinetics and burst size, but heightened TCR sensitivity 
when stimulated by plate-bound or soluble antibody, pharmacologic activation by PMA + 
ionomycin, or coculture with antigen and splenic or engineered APC (Data not shown).  
Alternate approaches to the study of naive Ctla-4-deficient CD4+ lymphocytes can be 
achieved by the use of TCR-transgenic Ctla-4 knockout mice, or CD28-/-/Ctla-4-/- double 
knockout mice.  However, analysis of the resultant expression profiles in these strains is 
complicated by the absence of physiologic interaction of the TCR with self-antigen/MHC 
and the inability to verify the normal responsiveness of the lymphocytes to numerous 
stimuli in a primary activation, respectively.    In contrast, B7.1-/-/B7.2-/-/Ctla-4-/-   
lymphocytes remain sensitive to CD28 costimulation and reconstitute the 
lymphoproliferative disease seen in Ctla-4 deficient mice in Rag-/- bone-marrow 
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recipients upon thymic emigration of Ctla-4-/- donor lymphocytes (Figure 3.1).  For this 
reason, B7.1-/-/B7.2-/-/Ctla-4-/- mice provide a good model to investigate the possibility 
that absence of Ctla-4 genetically predisposes lymphocytes to pathologic activation by 
altering the baseline expression of genes involved in the determination of lymphocyte 
responsiveness.  Additionally, the global expression profile of naïve Ctla-4 deficient 
CD4+ lymphocytes can provide both a normative measure of gene expression for analysis 
of alternate models of Ctla-4 deficiency, and indicate a steady-state expression profile 
that will inform the analysis of any subsequent kinetic profile.   
As an initial approach in the identification of genes regulated by Ctla-4 ligation, 
we used microarray analysis to compare the global expression profile of ex vivo CD4+ 
lymphocytes from B7.1-/-/B7.2-/- (B7KO) double knockout mice and B7.1-/-/B7.2-/-/Ctla-4-
/- (B7CT) triple knockout mice.   CD4+ lymphocytes were MACS purified to >90% from 
lymph nodes, and analyzed for expression of the activation markers CD44, CD69, and 
CD62L.  All mice except one showed identically low expression of CD44, an absence of 
CD69 expression, and similar CD62L profiles.  Donor cells from two mice were pooled 
for each sample analyzed by microarray, with biological duplicates performed for both 
strains.  One B7CT mouse had a relatively higher CD44 expression (15% vs ~5-7%) and 
this sample was processed separately for later analysis.    
Microarray analysis utilized the Affymetrix MGu74Av2 Genechip covering 
12,422 gene probesets.  Results were normalized as follows:  values below 0.01 were set 
to 0.01; each measurement was divided by the 50th percentile of all measurements in that 
sample; each gene was divided by the median of its measurements in all samples; If the  
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Figure 3.1:  B7.1-/-/B7.2-/-/Ctla-4-/-  bone marrow recipients recapitulate 
immune pathology of Ctla-4-deficient mice and die by 8-10 weeks 
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Figure 3.1:  Rag-/- mice receiving B7.1-/-/B7.2-/-/Ctla-4-/-  bone marrow succumb to a 
lymphoproliferative disease with similar kinetics as mice receiving Ctla-4-/- marrow.  
5x106 T cell depleted bone marrow cells from Ctla-4-/-, B7.1-/-/B7.2-/-, B7.1-/-/B7.2-/-/Ctla-
4-/- , or wild-type B6 mice were transferred to minimally irradiated Rag-/- recipients.  The 
percentage of surviving recipients with respect to time is shown.  Recipients of wild-type 
B6 or B7.1-/-/B7.2-/- bone marrow remain healthy indefinitely and successfully 
reconstitute their peripheral lymphocyte compartment.  In contrast, recipients of Ctla-4-
deficient bone marrow succumb to a lymphoproliferative autoimmune disease upon 
thymic emigration of T cells that is identical to the disease seen in native Ctla-4-deficient 
mice.  B7.1-/-/B7.2-/-/Ctla-4-/- bone marrow recipients also develop disease in contrast to 
B7.1-/-/B7.2-/-/Ctla-4-/-   mice which remain healthy.  Disease in B7.1-/-/B7.2-/-/Ctla-4-/- 
bone marrow recipients recapitulates all aspects of disease seen in native Ctla-4 
deficiency including a high percentage of activated peripheral lymphocytes, lymphocytic 
infiltration of most tissues, and death within 3-5 weeks of initial thymic emigration. 
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median of the raw values was below 10 then each measurement for that gene was divided 
by 10 if the numerator was above 10, otherwise the measurement was thrown out.  5475 
genes were flagged as “present” or “marginal” in 2 or more samples by Affymetrix 
MAS5.0, representing 44% of the included genome.  Global comparison of the chips 
showed segregation of the sample conditions (B7KO or B7CT) as expected, but the 
B7CT sample with a greater percentage of CD44high lymphocytes was a relative outlier, 
and further analyses were performed twice to allow analysis with and without this 
sample.    
Globally, the expression profiles of naïve CD4+ lymphocytes in B7KO and B7CT 
mice are very similar, as expected from their phenotype and responsiveness to activating 
signals.  However, slight but consistent variation in the expression of nearly 100 genes 
was detected at a greater than two-fold difference.  Further analysis of significance, 
normalized expression, and flag calls resulted in the identification of 79 genes 
differentially regulated in naïve CD4+ cells in the absence of Ctla-4 with a statistically 
significant fold-changer greater than 1.5-fold.  84% of the identified genes were 
downregulated in the absence of Ctla-4, expressed at an average of 39% (~2.6 fold 
change) of expression in B7KO samples.  Upregulated genes in Ctla-4 deficient samples 
were, on average, more slightly altered at 215% of expression in B7KO samples.  As 
expected, Ctla-4 was dramatically altered, with the second highest calculated fold change, 
flagged as present and absent in B7KO and B7CT samples respectively with a signal 
strength 25-fold greater than background on the B7KO chips in spite of the minimal 
expression known to exist in naïve T cells.  Only four genes were altered more than four 
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fold, including Mela, Ctla-4, Ccr9, and Sel1h.  However, 64% of genes downregulated 
more than two-fold in B7CT cells were consistently flagged as present to absent calls. 
  Most genes identified as differentially regulated have not been extensively 
studied in lymphocytes but have been at least partially characterized in other cell types, 
and several of them are known to regulate T lymphocyte activation.  Genes differentially 
regulated in the absence of Ctla-4 that are known to regulate T cell responses to antigen 
receptor ligation include slfn4, an uncharacterized member of the schlafen family of 
putative quiescence factors, recognized for their role in regulating lymphocyte 
development and activation(331-333); lag-3(CD223), a CD4 homologue known to inhibit 
primary T lymphocyte activation localizes to the c-smac within the immunological 
synapse(334) and negatively regulates T cell expansion following antigen 
stimulation(335), influences susceptibility to multiple sclerosis(336), and appears to be a 
Treg marker involved in active suppression of effector T cells(337); the antiapoptotic Src 
regulator, ptpn13/FAP-1, is a putative tumor suppressor known to regulate NFκB(338) 
and is negatively regulated by activated p53(339) and IL-2(340, 341) ; the proto-
oncogene and transcriptional activator Mybl1 is known to upregulate Bcl-2(342) and 
influence proliferation in leukemic cells(343); the proto-oncogene and cell-cycle 
regulator, rb1; the retinoblastoma binding protein, Rbap46, is a tumor suppressor, a 
member of the WD-repeat protein family, and component of histone modifying and 
remodeling complexes, but has no known function in lymphocytes(344); the tumor 
suppressor and growth inhibitor Sel1L(345) has not been characterized in lymphocytes 
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but is associated with autoimmune-diabetes(346); TGF-beta inducible protein BigH3 is a 
suspected growth inhibitor not characterized in lymphocytes.   
Genes altered more than 1.5-fold in the absence of Ctla-4 with p-values less than 0.05 are 
shown in Table 3.1.  Importantly, a non-biased search for putative regulatory sequences 
failed to identify over-represented sequences in the 1kb upstream regions of the identified 
genes when limited to elements 10bp or less in length.  The preponderance of genes 
identified as differentially regulated in the absence of Ctla-4 in the context of B7 
deficiency that have known functions relating to growth regulation, signal transduction in 
lymphocytes, or tumor suppression are altered in ways that would be expected to increase 
the threshold of activation and resistance to cell cycle entry. This may reflect a non-
specific, generalized down-regulation of genes in the absence of Ctla-4, consistent with 
the observed ratio of up- and down-regulated genes.  Alternatively, the maintenance of a 
naïve phenotype in Ctla-4-deficient lymphocytes may require, or result from, 
compensatory changes in basal expression of additional determinants of T cell activation 
thresholds.  However, the controversial role of Ctla-4 in thymocyte development(203, 
226, 347-349) and the paucity of data regarding the function of genes differentially 
expressed in B7.1-/-/B7.2-/-/Ctla-4-/- CD4+ lymphocytes requires additional 
characterization of their potential relationship to Ctla-4 function.   
The identification of genes differentially expressed in naïve Ctla-4 deficient cells 
will allow comparative analyses with expression profiles in primary Ctla-4 sufficient 
cells subsequent to Ctla-4 ligation.  The data identifies a small number (<80) of genes 
displaying statistically significant changes in expression in the absence of Ctla-4.  Genes 
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Table 3.1:  Genes differentially expressed in naïve B7.1-/-/B7.2-/-/Ctla-4-/- 
CD4+ lymphocytes as a result of Ctla-4 deficiency 
 
Category Common 
Name 
Fold 
Change 
Characterization 
 
Cell Cycle Sugt1 -1.64 SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) 
 Nbn -1.57 nibrin 
 Cdc6 1.59 cell division cycle 6 homolog (S. cerevisiae) 
   
Anti-apoptotic Thy28 1.54 thymocyte protein thy28 
   
Pro-apoptotic Ifi16 -1.81 interferon, gamma-inducible protein 16 
 Bad 1.60 ES cell Mus musculus cDNA clone 2410088E21, mRNA  
 Sgpp1 1.94 sphingosine-1-phosphate phosphatase 1 
   
Signaling Lancl1 -2.24 LanC (bacterial lantibiotic synthetase component C)-like 1 
 Usp18 -1.98 ubiquitin specific protease 18 
 Stat5b -1.92 signal transducer and activator of transcription 5B 
 Stard7 -1.76 START domain containing 7 
 Gna11 -1.73 Mus musculus guanine nucleotide-binding protein (Gna11)  
 Nr4a2 -1.70  
 Cops3 -1.69 COP9 (constitutive photomorphogenic) homolog, subunit 3  
 Rhoc -1.62 ras homolog gene family, member C 
 Dtx1 -1.55 deltex 1 homolog (Drosophila) 
 Ccr2 -1.55 chemokine (C-C) receptor 2 
 Il6st -1.54 interleukin 6 signal transducer 
 Cd3g -1.51 Mouse CD3-gamma (T3-gamma) gene, exon 7. 
 Pik3cd 1.54 phosphatidylinositol 3-kinase catalytic delta polypeptide 
 Fzd3 1.64 frizzled homolog 3 (Drosophila) 
 Itm2a -1.69 integral membrane protein 2A 
 Ctla4 -17.67 cytotoxic T-lymphocyte-associated protein 4 
   
Transcription Trp63 -1.88 transformation related protein 63 
 Rnf20 -1.76 ring finger protein 20 
 AW547477 -1.60 thymopoietin 
 Nr3c1 -1.54 nuclear receptor subfamily 3, group C, member 1 
 Tceb1 1.67 transcription elongation factor B (SIII), polypeptide 1 
   
Translation Ebna1bp2 -2.86 EBNA1 binding protein 2 
 Eif5b -2.24 vs58d02.r1 Stratagene mouse skin (#937313 
 Styx -2.19  
 Ncbp2 -1.80 nuclear cap binding protein subunit 2 
 Eif1a -1.69 eukaryotic translation initiation factor 1A 
 Pa2g4 1.76 proliferation-associated 2G4 
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Category Common Name Fold 
Change 
Characterization 
 
Immune Ifit1 -2.05 interferon-induced w/ tetratricopeptide repeats 1 
 G1p2 -1.78 interferon, alpha-inducible protein 
 Ctsb -1.52  
 Kcnq1 1.51 3' similar to U70068 Mus musculus (KvLQT1)  
   
Cytoskeleton   Cd9 -1.91 CD9 antigen 
And Adhesion Tuba1 -1.71 tubulin, alpha 1 
 Slmap -1.54 sarcolemma associated protein 
 Plec1 -1.52 plectin 1 
   
Metabolism Idh1 -1.86 isocitrate dehydrogenase 1 (NADP+), soluble 
 Atp11a -1.58 ATPase, class VI, type 11A 
 Arsa -1.57 arylsulfatase A 
 Dhrs1 -1.57 dehydrogenase/reductase member 1 
 Mrpl12 -1.55 mitochondrial ribosomal protein L12 
 Glud -1.54 glutamate dehydrogenase 
   
Miscellaneous Slc29a1 -2.98 solute carrier family 2, member 1 
 Mrpl44 -2.35 mitochondrial ribosomal protein L44 
 Tnfaip1 -2.11 Mus musculus Edp1 protein (Edp1) gene,  
 1110004L07Rik -1.94 exportin, tRNA  
 G22p1 -1.84 thyroid autoantigen 
 B230312B02Rik -1.74 RIKEN cDNA B230312B02 gene 
 Rcl1 -1.72 RNA terminal phosphate cyclase-like 1 
 Ensa -1.69 endosulfine alpha 
   
Unknown Mela -52.36 melanoma antigen 
 Wt1 1.88 EST: 3' similar to M55512 Mouse Wilms' tumor  
 Gtrgeo22 -1.79 gene trap ROSA b-geo 22 
 Rnf138 -1.67 ring finger protein 138 
 Pabp4i1 -1.66
Similar to Poly(A) binding protein, cytoplasmic 4, 
isoform 1 (LOC216817) 
 Rnf149 -1.59 ring finger protein 149 
 Glo1 -1.58 CDNA clone IMAGE:4037400 
 DXImx46e -1.53 vw47f05.x1 Soares_mammary_gland_ 
 1500001L20Rik 2.17 WD repeat domain 40A 
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Table 3.1:  Genes whose expression is significantly altered in the absence of Ctla-4.  
Peripheral CD4+ lymphocytes from were purified by FACS from B7.1-/-/B7.2-/- and B7.1-
/-/B7.2-/-/Ctla-4-/- mice.  RNA was isolated from purified population and analyzed by 
Affymetrix MgU74Av2 microarray following single-step cRNA amplification and 
labeling starting with 5-8ug of total RNA.  Individual samples were obtained from 
starting populations representing pooled lymphocytes from 2-3 mice.  Biological 
replicates were isolated and processed at separate times.  Microarray sample processing 
and scanning was performed as described utilizing the Affymetrix MAS5.0 software and 
yielded “present” or “absent” flag calls based on signal intensity relative to background.  
Further analysis using Genespring allowed for identification of genes differentially 
expressed.  Briefly, data was normalized by setting values below 0.01 to 0.01 and 
dividing each measurement by the 50.0th percentile of all measurements in that sample. 
Average measurements in each condition were compared and genes differentially 
expressed at least 1.5 fold are listed in table 3.1.  Genes without statistically different 
expression when compared using the cross-gene error model were excluded.  Genes 
without statistically significant expression in at least one condition were excluded.  The 
majority of genes (84%) with detectable expression in both conditions were 
downregulated in the absence of Ctla-4.   
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involved in signal transduction are the most commonly affected, and several identified 
genes have known roles in regulating T cell activation.  The majority of genes identified, 
however, are relatively uncharacterized in lymphocytes.  The finding that a majority 
(>80%) of the genes identified were down-regulated may result from one of several 
mechanisms.  It is possible that experimental error introduced bias and suppressed 
expression levels as a whole.  This is unlikely given the standardization procedures 
involved in setting detector thresholds, the use of global expression patterns to detect 
outlying samples, and normalization steps that provide statistical data of specific genes 
relative to the whole transcriptome.  Biologically, several other mechanisms may explain 
the preponderance of down-regulated genes.  While B7 ligands are not required for 
thymocyte development, interactions between B7:CD28, and perhaps B7:Ctla-4, do 
influence aspects of thymic selection processes and are required for the development of 
specific subsets of peripheral T cells.  Thus, the absence of B7 may alter both central and 
peripheral tolerance mechanisms.  However, the decreased threshold of activation that 
accompanies Ctla-4 deficiency in B7-/- mice strongly suggests that Ctla-4 plays a critical 
role in regulating naïve T cell responsiveness in a manner analogous to that seen in Ctla-4 
wild-type mice.  Our data suggest that minor alterations in basal transcription may result 
from Ctla-4 absence allowing further investigation of the role these genes play in T cell 
activation. 
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Chapter III 
Results 
 
Global Gene Expression Analysis of Naïve, Extrinsically 
Regulated, Ctla-4-Deficient Cells in Bone Marrow 
Chimerae 
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Genomic expression patterns in extrinsically regulated Ctla-4 deficient T cells 
 Ctla-4 deficiency results in intrinsic defects in lymphocyte activation and self-
tolerance that are manifested in the CD28 costimulation dependent lymphoproliferative 
disease in Ctla-4 knockout mice(268).  Moreover, despite contradicting reports(203, 347, 
349), previous work, supported by results generated in our lab, indicates that Ctla-4-
deficient thymocyte development is normal(226), and that disease pathogenesis originates 
with uncontrolled CD4+ lymphocyte activation in the periphery as a consequence of TCR 
interaction with self-p/MHC in the context of CD28 costimulation.  Overt disease 
resulting from the lack of Ctla-4 is avoided in the context of B7 and/or CD28 deficiency, 
depletion of CD4+ peripheral lymphocytes(224, 268), or inactivating mutations of TCR 
signaling or MHC presentation pathways(224, 227, 323).  Similarly, limitation of the 
TCR repertoire in TCR-transgenic Ctla-4-/- mice prevents or delays autoimmune 
disease(227).  In conjunction with in vitro stimulation assays showing a decreased 
threshold of activation in Ctla-4-/- CD4+ lymphocytes, and biochemical evidence of 
alterations in proximal TCR signaling pathways in the absence of Ctla-4, these 
observations provide compelling evidence of an intrinsic regulatory defect.  However, 
published results have also indicated that defective regulatory mechanisms intrinsic to 
Ctla-4 deficient lymphocytes can be regulated extrinsically in the presence of Ctla-4 WT 
cells(261, 262).   
When transferred to Rag-/- recipients, T cell depleted Ctla-4-/- bone marrow 
reconstitutes the lymphoproliferation and multiorgan infiltration seen in Ctla-4-/- mice at 
4-8 weeks after transplantation.  However, when co-transferred with Ctla-4 WT bone 
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marrow, the recipient displays a stable, balanced chimerism of Ctla-4 WT and KO 
peripheral lymphocytes.  Bone marrow chimerae remain healthy, and Ctla-4-/- peripheral 
lymphocytes display none of the autoimmune reactivity characteristic of isolated Ctla-4 
deficiency.  Thus, Ctla-4 maintenance of peripheral tolerance is not limited to the down-
regulation of specific T cell responses in a T cell-autonomous fashion.  Work in our lab 
has demonstrated that depletion of WT lymphocytes using antibody to Ly5 or Thy1 
congenic markers in the chimera initiates the autoimmune phenotype seen in Ctla-4-/- 
mice, indicating a persistent and active regulation of the Ctla-4-/- cells by Ctla-4 sufficient 
cells is necessary for the maintenance of balanced chimerism (Data not shown).  
Moreover, the rapidity with which lymphoproliferation and pathology is observed 
following depletion of wild-type T cells suggests that altered thymic development in 
mixed chimerae does not underlie the tolerant phenotype of Ctla-4-/- cells in the 
periphery.   
To date, the phenotype of wild-type cells that mediate regulation of Ctla-4-
deficient T cells in mixed bone marrow chimerae has not been established.   Either CD4 
or CD8 WT lymphocytes provide sufficient regulation of Ctla-4-/- cells in the periphery.  
Moreover, the Ctla-4 deficient lymphocyte population maintains its ability to respond to 
antigenic stimuli, and becomes activated, expands, and contracts indistinguishably from 
WT cells in response to lymphocytic choriomeningitis virus, Leishmania major and 
mouse mammary tumor virus, which cause acute, chronic and persistent infections, 
respectively(262). Thus, regulation of Ctla-4-deficient cells restores normal immune 
responsiveness and does not require an antigen-independent, generalized suppression of 
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their function.  However, the mechanism by which Ctla-4+ T cells regulate their Ctla-4-/- 
counterparts remains unknown.  Again, using microarray analysis, we examined the 
global expression profiles of CD4+ Ctla-4-/- and CD4+Ctla-4+ cells from stably 
reconstituted bone marrow chimera. 
 
Generation of mixed bone marrow chimera and microarray sample preparation: 
 Minimally irradiated (300 rads) Rag-/- mice were injected with 5x106 T cell 
depleted bone marrow cells at a 1:1 ratio of Ctla-4+: Ctla-4-/- or Ctla-4+:Ctla-4+.  Donor 
cells were distinguishable by the expression of Ly5 or Thy1 congenic markers.  Thymic 
emigration, indicated by the presence of peripheral lymphocytes, was first detected at 3-4 
weeks after transfer.  In most cases, stable reconstitution is achieved by 12 weeks with 
nearly a 1:1 ratio of donor cells in the periphery.  Recipient mice were sacrificed at 12-16 
weeks, CD4+CD44 Low lymphocytes were isolated by FACS, and RNA was prepared 
using either Trizol or Ultraspec reagents.  CD44Low isolated cells were CD69- and CD25- 
by flow cytometry.  In one experiment, RNA samples from numerous mice were pooled 
to allow 5ug of total RNA to be labeled in a single-step amplification, and the resuling 
cRNA was analyzed on one chip per condition.  In two subsequent experiments, 1-2 mice 
were pooled to provide sufficient RNA for two-step amplification.  Affymetrix 
MgU74Av2 Genechips were utilized, representing 12,488 genes.  Identical labeling, 
sample preparation, and Genechip loading were used for the two-step amplification 
analyses, and samples were analyzed as replicates using the Genespring software 
package.  Samples prepared from 5ug of pooled RNA were analyzed separately and the 
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results of the two experiments cross-referenced for validity, taking into account 
differences in amplification magnitude and spectrum that result from the two protocols. 
 
Ctla-4-/-CD4+ lymphocytes in mixed bone marrow chimera display a unique 
transcriptional profile: 
  Because single step amplification of total RNA has shown more consistent and 
robust differential expression profiles in past experiments, initial analyses of global 
expression in Ctla-4-/-:Ctla-4+ bone marrow chimera was performed using pooled RNA 
from several mice analyzed on single Genechips.  6449 genes had detectable expression 
in at least one of the two samples, representing 52% of the included genome.  Overall, the 
expression profiles between Ctla-4-/- and WT samples correlated at 93 and 96 percent 
with and without weighting for signal intensity respectively.  In contrast, samples 
processed via two-step amplification correlated with single-step amplified products at 
only 46-52% when weighted for expression intensity, and 77-81% when unweighted, 
supporting the use of separate analyses.   
 Among genes with measurable expression in both 5ug samples labeled in a single-
step protocol, 317 genes, 75 genes, 33, and 21 genes evidenced a minimum of 2-, 3-, 5-, 
or 10-fold differences in expression respectively.  While there were almost identical 
numbers of genes up- and down-regulated more than two-fold in Ctla-4 deficient CD4+ 
lymphocytes (49% and 51% respectively), there was positive and consistent correlation 
between the magnitude of the differential expression and the likelihood of being 
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upregulated in Ctla-4-/- cells (60% and 71% of genes altered more than 5- and 10-fold 
respectively were upregulated in Ctla-4-/- cells).  A summary of genes regulated more 
than 5-fold  in extrinsically regulated Ctla-4-deficient cell, their expression profiles, and 
known functional ontology are listed in Table 3.2. 
 While 1117 genes were identified as having mixed calls in the two samples (P to 
A changes, or vice versa), only 225 of those genes had measurable signals more than 3-
fold over background and constitute reliable measurements (Figure 3.2).  However, a list 
of genes without detectable expression in one genotype can be ranked by the expression 
of the gene in the alternate sample (Table 3.3).  Together with genes identified as reliably 
altered in the absence of Ctla-4, these genes constitute a steady-state profile that can be 
reliably cross-referenced with replicative experiments using the less-sensitive two-step 
amplification.  However, 280 genes identified in the high-stringency screen of single-step 
amplified samples did not have consistently detectable expression in either Ctla-4-/- or 
WT samples that underwent double-amplification.  Among genes identified in our initial 
screen with sufficient expression in our second experiment, 35 of the 102 downregulated 
genes and 56 of 160 upregulated genes showed expression patterns confirming our initial 
screens.  In summary, using pooled samples in a high-stringency labeling protocol 
identified 542 genes differentially regulated in the absence of Ctla-4 as detected in naïve 
peripheral CD4+ lymphocytes from mixed bone marrow stably reconstituted with a 1:1 
ratio Ctla-4-/-:Ctla-4+ T cell depleted bone marrow cells.  282 identified genes were 
screened against the results of subsequent experiments using a lower sensitivity protocol, 
confirming the expression pattern in 91 genes, and leaving 280 genes unvalidated. 
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Table 3.2: Genes differentially regulated in naïve Ctla-4-deficient CD4+ T cells in 
mixed bone marrow chimerae 
 
Fold 
Change 
Common 
Name 
Description 
& Characterization 
 
Up-regulated Genes 
479.5 0610008N23Rik RIKEN cDNA 0610008N23 gene 
97.5 Pou2f1 Transcription Factor 
61.2 Hrb2 EST 
52.3 ORF6 EST 
27.6 Pigt Ribosomal Subunit 
26.7 Itsn intersectin (SH3 domain protein 1A) 
26.0 102130_f_at EST 
24.9 Hnrph3 EST; Diiferentially expressed in normal and neoplastic cells 
21.9 Mafk Transcription Factor 
17.3 2010200I23Rik cytochrome c oxidase, subunit VIIa 2 
16.4 161085_r_at EST 
14.1 Dnajc4 DnaJ (Hsp40) homolog, subfamily C, member 4 
12.6 Mfn1 EST 
11.1 Ttc1 tetratricopeptide repeat domain 1 
11.0 D3Ertd789e tetratricopeptide repeat domain 14 
8.6 Eif2s3y eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked 
8.3 Elovl1 EST 
7.8 Samhd1 EST 
6.6 160934_s_at Murine (DBA/2) mRNA fragment for gag related peptide. 
5.4 Akp5 Mouse embryonic alkaline phosphatase gene, complete cds. 
   
Down-regulated 
-189.0 Ercc1 excision repair cross-complementing rodent repair deficiency, complementation group 1 
-71.9 Il4 Intereukin4 
-66.2 5430432M24Rik EST 
-64.5 Prss11 protease, serine, 11 (Igf binding) 
-13.7 Limk1 LIM-domain containing, protein kinase 
-12.0 Slc30a4 zinc transporter; Mus musculus zinc transporter (ZnT4) gene, fragment 4, and partial cds. 
-7.2 4930517K11Rik ribosomal subunit 
-7.0 Pard6a cell cycle; cytokinesis; par-6 (partitioning defective 6,) homolog alpha (C. elegans) 
-6.0 Spock2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 
-6.0 Kcnj9 EST 
-5.8 Iga secreted form; Mouse Ig germline D-J-C region alpha gene and secreted tail. 
-5.5 Homer3 EST 
-5.2 Gpr132 G protein-coupled receptor 132 
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Table 3.2:  Genes with detectable expression in all samples regulated more than 5-fold in 
Ctla-4-deficient naïve CD4+ T cells relative to their wild-type counterparts in mixed bone 
marrow chimerae.  CD4+ Ctla-4 deficient and wild-type populations were isolated from 
stably reconstituted mixed bone marrow chimerae and analyzed by Affymetrix 
MgU72Av2 microarray.  Samples analyzed represent pooled RNA from populations 
isolated from >5 mice per condition.  Only one microarray per condition was analyzed 
utilizing a single-step amplification protocol.  The cross gene error model was applied to 
allow for statistical comparison in the absence of biological replicates.  Genes in Table 
3.2 were detectable in Ctla-4-deficient and wild-type CD4+ lymphocyte populations as 
determined by MAS5.0 software analysis of the microarray data.  Further analysis using 
Genespring allowed for identification of genes differentially expressed.  Briefly, data was 
normalized by setting values below 0.01 to 0.01 and dividing each measurement by the 
50.0th percentile of all measurements in that sample. 33 unique genes meeting these 
criteria displayed 5-fold or greater changes in expression in the absence of Ctla-4.  
Differential expression was significant at p<0.05 as determined by the cross-gene error 
model.  Red highlighted genes were called present in all samples but possessed extremely 
low signal strength in at least one sample that required transformation to a minimal 
baseline value (0.01), potentially skewing calculated fold-change values. 
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Table 3.3: Genes with mixed calls that possess the highest signal 
intensity levels in samples with detectable expression 
Calculated 
Fold Change 
Common Name Description and Characterization 
Upregulated Genes 
638.5 C330006A16Rik ES cells cDNA, RIKEN full-length enriched library, clone:C330006A16 product:unknown 
413.5 Nfatc2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2; regulation of transcription 
214.6 Dag1 dystroglycan 1; morphogenesis of an epithelial sheet 
178.9 Prkcz AV367375 RIKEN full-length enriched, similaro  to protein kinase C zeta mRNA 
88.5 Cbl Casitas B-lineage lymphoma 
7.3 Rn18s Mouse gene for 18S rRNA. 
5.2 Eif1a eukaryotic translation initiation factor 1A 
4.6 Hccs holocytochrome c synthetase 
4.1 Gpam  glycerol-3-phosphate acyltransferase gene, nuclear gene encoding mitochondrial protein 
3.8 Cdon cell adhesion molecule-related/down-regulated by oncogenes 
3.7 Kcna3 potassium voltage-gated channel, shaker-related subfamily, member 3 
3.6 160799_at UI-M-BH1-ann-g-07-0-UI.s1 NIH_BMAP_M_S2 Mus musculus cDNA clone 
3.1 2510010F15Rik RIKEN cDNA 2510010F15 gene 
 
 
Down-regulated Genes 
-204.9 D1Bwg1363e DNA segment, Chr 1, Brigham & Women's Genetics 1363 expressed 
-164.5 Pcbp4 UI-M-AQ1-aee-h-05-0-UI.s1 NIH_BMAP_MHI_N Mus musculus cDNA clone. 
-61.0 Prss15 protease, serine, 15 
-15.4 Arl4 ARF-like 4 protein; intracellular protein transport; small GTPase mediated signal transduction 
-11.9 102155_f_at EST 
-11.2 Ctsh cathepsin H; proteolysis and peptidolysis 
-10.4 Snai2 snail homolog 2;development; regulation of survival gene product activity; regulation of transcription 
-9.3 Kdap napsin A aspartic peptidase 
-4.5 Igl-V1 variable and contstant regions; V-J; Mus musculus immunoglobulin lambda-1 light chain precursor 
-3.8 2410015N17Rik RIKEN cDNA 2410015N17 gene 
-3.8 Bcl2l2 Bcl2-like 2; apoptosis; regulation of apoptosis 
-3.6 Tyk2 member of Jak (Janus) family; contains Jak homology regions 7 to 4; non-receptor tyrosine kinase. 
-3.6 Ptprv protein tyrosine phosphatase, receptor type, V 
-3.5 Dnalc4 dynein, axonemal, light chain 4 
-3.5 Cct2 Mus musculus Cctb gene for chaperonin containing TCP-1 beta subunit, complete cds. 
-3.4 Il1r2 interleukin 1 receptor, type II 
-3.1 Mela melanoma antigen 
-3.0 Itgb1bp1 integrin beta 1 binding protein 1 
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Table 3.3: Differentially expressed genes flagged as absent in one condition (Ctla-4-
deficient or wild-type) were ranked by their level of expression in the remaining 
genotypic sample as determined by normalized signal intensity.  31 genes with mixed 
calls (“present” to “absent” changes or vice versa) with the highest normalized signal 
intensities in the sample with detectable expression are shown.  Fold change values 
reflect approximate fold-increases in differential expression based on a comparison of 
signal strength value in the sample with detectable expression to background signal 
strength detected in the sample flagged “absent” by MAS5.0 software analysis of signal 
to noise ratios. Fold change numbers are demonstrative only and can not be construed as 
true ratios of expression due to the high signal:noise ratio in one of the samples.  Genes 
with known effects in lymphocytes are highlighted red.   
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Figure 3.2: Scatter plot of gene expression intensity in mixed bone 
marrow chimerae 
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Figure 3.2: Scatter plot of gene expression level in Ctla-4-deficient and-wild-type naïve 
CD4+ T cells from mixed bone marrow chimerae.  Minimally irradiated Rag-/- mice were 
transfused with 5x106 bone marrow cells consisting of a 1:1 mixture of T cell-depleted 
wild-type and Ctla-4-deficient donor cells.  Recipient mice successfully reconstituted 
their peripheral lymphocyte compartment with an approximate 1:1 representation of 
donor cells.  Recipient mice remained healthy and display no symptoms of 
lymphoproliferative disease or autoimmunity.  Recipient mice were sacrificed 12 weeks 
after bone-marrow transfer and donor CD4+CD44Low cells purified by FACS isolation 
using Ly5.1 or Thy1.1 congenic markers to discriminate Ctla-4-deficient and wild-type 
populations.   CD4+CD44Low populations represented 85-95% of peripheral CD4+ T cells 
and were also CD69-, CD62LHigh, and CD25-.  RNA from CD4+CD44Low populations of 
wild-type and Ctla-4-deficient donor cells was isolated and analyzed by oligonucleotide 
microarray using Affymetrix MgU74Av2 GeneChips.  Chip scanning, intensity 
normalization, and determination of “present” and “absent” calls were performed using 
Affymetrix MAS5.0 software.  Further data analsysis was performed using Genespring 
software and data normalization was achieved by setting values below 0.01 were to 0.01 , 
and dividing each measurement by the 50.0th percentile of all measurements in that 
sample.  The cross gene error model was applied to allow statistical comparison in the 
absence of biological replicates amplified by similar single-step labeling protocols.  Each 
dot in the scatter plot represents one gene where X-axis and Y-axis values correspond to 
the average level of expression in wild-type and Ctla-4-deficient CD4+ CD44 Low cell 
populations respectively according to normalized data values.  Gray colored genes have 
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levels of expression not statistically above background signal intensity in any sample.  
Red genes are present in all samples but are not changed more than two-fold.  Yellow 
genes (317) are present in both samples with measurable fold-changes greater than two 
fold.  Blue genes (225) are expressed in one sample at 3-times the control signal 
intensity, but are absent in the alternate genotype.  The central diagonal line indicates 
equivalence of expression.  The most proximal and distal pairs of parallel lines around 
the line of equivalence indicate 2-fold and 5-fold changes in expression respectively.  
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A comparison of genes differentially regulated in B7.1-/-/B7.2-/-/Ctla-4-/- CD4+ 
lymphocytes versus B7.1-/-/B7.2-/- CD4+ lymphocytes against genes differentially 
regulated in Ctla-4-/- cells in Ctla-4-/-:Ctla-4+ bone marrow chimerae could potentially 
reveal a mechanism by which Ctla-4-/- cells are regulated in the presence of Ctla-4 WT 
cells provided that alterations in gene regulation result from the interaction.  In total, only 
9 genes identified as differentially expressed in B7.1-/-/B7.2-/-/Ctla-4-/- versus B7.1-/-/B7.2-
/-  CD4+ cells ex vivo showed similar expression patterns in Ctla-4-/- versus Ctla-4+ CD4+ 
cells from stably reconstituted bone marrow chimera relative to Ctla-4 expression.  
Among these, only the decoy receptor Il1R2 and Ctla-4 have known regulatory function 
in lymphocytes.  Similarly, only 11 genes were inversely regulated in the bone marrow 
chimera relative to B7.1-/-/B7.2-/-/Ctla-4-/-:B7.1-/-/B7.2-/-  comparisons.  Of those, only 
Xlra3 and CD2ap are significant as determined by the cross-gene error model (See 
Materials and Methods). 
 
Discussion 
 Ctla-4 maintains peripheral T cell tolerance through cell-intrinsic and -extrinsic 
mechanisms that are only partially understood.  As previously discussed, intrinsic 
regulation of T cell responses by Ctla-4 involves potentially diverse mechanism that are 
likely to include ligand competition, mechanical disruption of activating interactions 
within the immunological synapse, and regulation of membrane proximal signaling 
events.  Mechanisms of cell-extrinsic regulation of T cell responses are not as well 
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studied, but may involve either cell contact-dependent or –independent interactions with 
Ctla-4 expressing cells. 
 Regulatory T cells (Tregs) are attractive candidates for mediators of non-
autonomous immune regulation by Ctla-4 given their well-established role in regulating 
lymphocyte responses to foreign and self-antigens both in vitro and in vivo(350).  
Mechanisms of Treg function are not well understood, but may involve regulation of 
APC function(304-306), secretion of regulatory cytokines(351), or direct suppression of 
effector T cells via cell-cell contact(352).  Ctla-4 is constitutively expressed on regulatory 
T cells and was initially considered to be essential for Treg function(353, 354) or 
development(301, 355).  However, published results(356) and work in our lab indicate 
that naturally occurring CD4+CD25+ peripheral lymphocytes in Ctla-4-deficient mice 
evidence potent immunoregulatory phenotypes indistinguishable from wild-type 
regulatory T cells in vitro.  In conjunction with the observation that CD8+ Ctla-4 wild-
type cells are capable of extrinsic regulation of Ctla-4 deficient lymphocytes in mixed 
bone marrow chimerae, the data suggest that non-autonomous regulation of Ctla-4 
deficiency can not be attributed solely to CD4+CD25+ suppressor T cell function.  
However, multiple lines of evidence suggest that regulatory T cells may utilize multiple 
mechanism to suppress effector T cells, some of which may require Ctla-4 
expression(301, 351, 356, 357). 
 A role for B7-mediated signaling in immunological tolerance was first recognized 
in dendritic cells.  Ctla-4 acts as  ligand for B7 receptor molecules that transduce 
intracellular signals resulting in upregulation of inoleamine-oxygenase, increased 
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tryptophan catabolism, and suppression of lymphocyte responses(305).  In contrast, 
simultaneous ligation of B7.1 and B7.2 on dendritic cells by soluble CD28 enhances T 
cell-mediated immunity by upregulating IL-6 and Ifn-gamma production(307), 
suggesting that B7 signaling may control functionally distinct effector responses as a 
result of differential ligand engagement.  Engagement of B7 expressed on effector T cells 
by regulatory T cells is also capable of inhibitory signaling, and may have a central role 
in autoimmune disease(303).  Together, these data suggest that Ctla-4 engagement of B7 
may provide a generalized mechanism of immunosuppression via bidirectional signaling.  
In the context of Ctla-4-/-:Ctla-4+ mixed bone marrow chimerae, inhibitory signaling 
through B7 on effector cells may explain numerous, previously unexplained, findings.  
For example, both CD4+ and CD8+ cells can express Ctla-4, potentially explaining the 
apparent sufficiency of either population in the regulation of Ctla-4-deficient cells.  
While B7-mediated inhibition of effector cells may operate independently of gene 
transcription, the regulation of tryptophan catabolism in dendritic cells indicates that, in 
some systems, B7 ligation regulates gene expression.  Genes identified in our system can 
be verified in vitro and in vivo to determine their regulation subsequent to B7 ligation on 
T cells.  Likewise, the importance of B7 signaling in the regulation of Ctla-4 deficient 
cells can be ascertained by transplantation of mixed Ctla-4+ and B7.1-/-/B7.2-/-/Ctla-4-/- 
bone marrow.  These experiments are already underway in our lab, and will inform our 
understanding of the gene expression patterns identified in extrinsically regulated Ctla-4-/- 
CD4+ T cells. 
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 Cytokines are important immunomodulatory signaling molecules involved in the 
regulation of autoimmune disease whose function is determined by the expression pattern 
and molecular associations of their respective receptors.  The role of cytokines, 
particularly, Il-10 and TGF-beta, in Ctla-4-mediated regulation of T cell responses has 
been controversial(288, 358), and a role for cytokine-mediated immunosuppression in 
extrinsic regulation of Ctla-4-/- T cells has not been elucidated.  Ctla-4-/- T cells actively 
regulated by wild-type cells maintain tolerance to self-antigen while maintaining normal 
antigen-specific responses to pathogens(262).  Consequently, indiscriminate 
immunosuppression by cytokines is an unlikely mechanism by which Ctla-4-/- T cells 
could be regulated.  Moreover, cytokine signaling regulates gene transcription via 
characterized pathways and activation of transcription factors with known target 
specificities.  Over-represented regulatory sequences consistent with these pathways were 
not detectable in genes differentially regulated in Ctla-4-/- CD4+ cells suggesting that 
suppression of autoimmune disease development in mixed bone marrow chimera does 
not result from canonical signaling pathways operating downstream of cytokine 
receptors. 
 Vesicular transport of active protein constituents between cells of the immune 
system has been described(359-362).  The transfer of Ctla-4 between lymphocytes has 
not been demonstrated, and is being investigated in our lab.  While Ctla-4 has not been 
detected on Ctla-4-/- cells in bone marrow chimerae, uptake of exogenous Ctla-4 could 
restore tolerance to self-antigen without detectable surface expression in a manner 
consistent with the native function of Ctla-4.  It is likely that such a mechanism would 
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not result in appreciable changes in gene expression as Ctla-4 functionsto suppress T cell 
activation, in part, by inhibiting membrane proximal signaling events that do not require 
regulation of gene transcription.  Despite growing evidence that intercellular protein 
exchange occurs in the immune system, there is currently no evidence to support models 
of immunoregulation involving intercellular vesicular transport of native Ctla-4 protein.  
 We have characterized the global expression pattern of Ctla-4-deficient CD4+ 
lymphocytes extrinsically regulated by wild-type T cells in order to elucidate the 
mechanism involved.  Numer genes involved in intracellular signaling, transcriptional 
regulation, or cell-cycle control are differentially regulated in Ctla-4-deficient CD4+ T 
cells.  Table 3.4 summarizes genes with known functions related to these processes that 
are differentially expressed between Ctla-4-deficient or wild-type cells in mixed bone 
marrow chimerae displaying either a statistically significant two-fold change in 
expression or detectable expression in only one condition of either Ctla-4-deficiency or 
wild-type Ctla-4 exprssion.  Notably, NFATc is upregulated to a greater relative degree 
than any other gene.  NFAT is centrally involved in the regulation of genes mediating T 
cell survival, activation, cytokine production, and anergy induction.  Thus, NFAT may be 
centrally involved in the regulation of Ctla-4-deficient responses by wild-type cells.  The 
majority of differentially regulated genes identified have not been characterized in T 
cells.  However, their role in T cell activation can be examined within the context of a 
kinetic study of T cell activation.  
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Table 3.4:  A selected list of genes involved in T cell immune responses 
that are differentially regulated in Ctla-4  KO/WT mixed bone marrow 
chimerae. 
 
Fold 
Change 
Common 
Name 
Description and Characterization 
413.5 Nfatc2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 
152.8 Xlr3a X-linked lymphocyte-regulated 3b 
97.5 Pou2f1 POU domain, class 2, transcription factor 1 
88.5 Cbl Casitas B-lineage lymphoma 
62.8 Zfp326 zinc finger protein 326 
29.4 Ncoa6 nuclear receptor coactivator 6 
26.1 Rpo2tc1 RNA polymerase II transcriptional coactivator 
24.8 MVA5T T cell receptor alpha chain AV20S1 precursor, mRNA, partial cds. 
22.1 Ptk2 PTK2 protein tyrosine kinase 2 
21.9 Mafk v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K  
19.5 Sox6 AV246999 RIKEN full-length enriched, 0 day neonate head Mus musculus cDNA clone  
17.0 Meox1 mesenchyme homeobox 1 
15.8 Cdc7 gene for muCdc7 
12.2 Rock2 Rho-associated coiled-coil forming kinase 2 
9.9 Hoxc5 homeobox protein (Hoxc-5) gene 
9.3 Ccr1 chemokine (C-C motif) receptor 1 
7.0 Zfx M.musculus Zfa gene. 
5.3 Il9 P40 T-cell and mast cell growth factor precursor;  
4.7 Ptpra protein tyrosine phosphatase, receptor type, A 
4.3 Cnot7 CCR4-NOT transcription complex, subunit 7 
4.1 Prrx1 paired related homeobox 1 
3.9 Tmpo thymopoietin 
3.3 Trp53bp1 transformation related protein 53 binding protein 1 
3.1 Eomes eomesodermin homolog  
2.8 Tbx6 T-box 6 
2.8 Btrc beta-transducin repeat containing protein 
2.6 Pnn pinin 
2.6 Il11ra1 interleukin 11 receptor, alpha chain 2 
2.5 5730497N03Rik trans-acting transcription factor 4 
2.4 Zfp148 zinc finger protein 148 
2.4 Zfp95 zinc finger protein 95 
2.4 Itpr1 inositol 1,4,5-triphosphate receptor 1 
2.3 Plk2 polo-like kinase 2 (Drosophila) 
2.2 Nfyb nuclear transcription factor-Y beta 
2.2 Cdk4 cyclin-dependent kinase 4 
2.2 Pou6f1 POU domain, class 6, transcription factor 1 
2.2 Zfp68 zinc finger protein 68 
2.1 Tec cytoplasmic tyrosine kinase, Dscr28C related (Drosophila) 
2.1 Sox10 SRY-box containing gene 10 
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Fold 
Change 
Common 
Name 
Description and Characterization 
-112.6 Figla factor in the germline alpha 
-82.0 Gadd45b growth arrest and DNA-damage-inducible 45 beta 
-71.9 Il4 interleukin 4 
-70.9 Fem1a Mus musculus sex-determination protein homolog Fem1a gene, complete cds. 
-64.9 Csf1r colony stimulating factor 1 receptor 
-45.5 Ccnb1 cyclin B1 
-32.1 Rgnef Rho-guanine nucleotide exchange factor 
-26.1 Hck hemopoietic cell kinase 
-12.2 Gna12 guanine nucleotide binding protein, alpha 12 
-10.4 Snai2 snail homolog 2 (Drosophila) 
-9.0 Creg cellular repressor of E1A-stimulated genes 
-6.5 Snx5 sorting nexin 5 
-5.2 Gpr132 G protein-coupled receptor 132 
-4.3 Ctla4 cytotoxic T-lymphocyte-associated protein 4 
-4.2 Cd44 CD44 antigen 
-3.6 Uhrf1 ubiquitin-like, containing PHD and RING finger domains, 1 
-3.6 Tyk2 member of Jak (Janus) family; Mus musculus non-receptor tyrosine kinase (Tyk2) gene. 
-3.6 Ptprv protein tyrosine phosphatase, receptor type, V 
-3.5 Ptprk protein tyrosine phosphatase, receptor type, K 
-3.4 Il1r2 interleukin 1 receptor, type II 
-3.3 Nek2 NIMA (never in mitosis gene a)-related expressed kinase 2 
-2.9 Cd79a CD79A antigen (immunoglobulin-associated alpha) 
-2.7 Ccr6 Mus musculus CCR6 gene. 
-2.6 Tnfsf5 tumor necrosis factor (ligand) superfamily, member 5 
-2.6 Tnfrsf4 tumor necrosis factor receptor superfamily, member 4 
-2.6 Nfyc nuclear transcription factor-Y gamma 
-2.6 Cd79b CD79B antigen 
-2.6 Itga4 integrin alpha 4 
-2.5 Bcl3 B-cell leukemia/lymphoma 3 
-2.5 Batf basic leucine zipper transcription factor, ATF-like 
-2.5 Ly6d lymphocyte antigen 6 complex, locus D 
-2.4 Il2rb interleukin 2 receptor, beta chain 
-2.4 Pglyrp1 peptidoglycan recognition protein 1 
-2.4 Rras Harvey rat sarcoma oncogene, subgroup R 
-2.4 Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog 
-2.4 Bcl2l1 Bcl2-like 1 
-2.3 Gadd45a Mus musculus GADD45 protein (gadd45) gene, complete cds. 
-2.3 Maz MYC-associated zinc finger protein (purine-binding transcription factor) 
-2.2 Cd19 Mus musculus cell surface protein CD19 gene, complete cds. 
-2.1 Smarcb1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 
-2.1 Blr1 Burkitt lymphoma receptor 1 
-2.0 Inpp5d inositol polyphosphate-5-phosphatase D 
-2.0 Itgal integrin alpha L 
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Table 3.4:  Genes differentially expressed in Ctla-4-deficient cells in mixed bone marrow 
chimerae.  Minimally irradiated Rag-/- mice were transfused with 5x106 bone marrow 
cells consisting of a 1:1 mixture of T cell-depleted wild-type and Ctla-4-deficient donor 
cells.  Recipient mice successfully reconstituted their peripheral lymphocyte 
compartment with an approximate 1:1 representation of donor cells.  Recipient mice 
remained healthy and display no symptoms of lymphoproliferative disease or 
autoimmunity.  Recipient mice were sacrificed 12 weeks after bone-marrow transfer and 
donor CD4+CD44Low cells purified by FACS isolation using Ly5.1 or Thy1.1 congenic 
markers to discriminate Ctla-4-deficient and wild-type populations.   CD4+CD44Low 
populations represented 85-95% of peripheral CD4+ T cells and were also CD69-, 
CD62LHigh, and CD25-.  RNA from CD4+CD44Low populations of wild-type and Ctla-4-
deficient donor cells was isolated and analyzed by oligonucleotide microarray using 
Affymetrix MgU74Av2 GeneChips.  Chip scanning, intensity normalization, and 
determination of “present” and “absent” calls were performed using Affymetrix MAS5.0 
software.  Further data analsysis was performed using Genespring software and data 
normalization was achieved by setting values below 0.01 were to 0.01 , and dividing each 
measurement by the 50.0th percentile of all measurements in that sample.  The cross gene 
error model was applied to allow statistical comparison in the absence of biological 
replicates amplified by similar single-step labeling protocols.  Genes with a minimum 2-
fold differential expression in the absence of Ctla-4 in mixed bone marrow population or 
displaying detectable expression in only one genoptypic condition were screened for 
known functions relating to cell-cycle regulation, transcriptional regulation, or T cell 
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activation and survival.  The differential regulation observed is statistically significant as 
determined by the cross-gene error model.   
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CHAPTER IV 
 
RESULTS 
 
Kinetic Analysis of Global Expression Profiles in TCR-
Transgenic CD4+ Lymphocytes During Primary 
Activation 
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Kinetics of T Cell Activation, Division, and Commitment 
 
Temporal constraints on costimulatory signal integration 
Although it is well established that T cells require antigen-independent 
costimulation in addition to TCR triggering for efficient activation, the temporal and 
spatial parameters of signal integration that occur in lymphocytes are incompletely 
understood.  Rapid increases in intracellular calcium(363) and regulated phosphorylation 
of signaling intermediates occur within minutes of TCR engagement(364).  
Transcriptional, post-transcriptional, and post translational regulation of gene 
transcription, mRNA stability, and protein activity and degradation respectively are 
detectable within hours of T cell activation.  However, in vivo, commitment to activation 
and integration of costimulatory signals influencing T cell differentiation and effector 
function are postulated to require formation of stable intercellular contact via the 
immunological synapse and extended periods of receptor engagement(365-369).  
However, the precise temporal constraints affecting costimulatory signal integration 
following TCR engagement have not been well defined.  Moreover, the effect of transient 
or delayed CD28 or Ctla-4 engagement on T cells stimulated through the TCR has not 
been clearly examined.  A greater understanding of parameters governing costimulatory 
signal integration will aid the development of strategies manipulating T cell signaling 
pathways for therapeutic benefit.  In addition, a greater understanding of the mechanisms 
involved in costimulatory signaling will facilitate the identification of key signaling 
intermediates involved in the determination of lymphocyte respnsiveness. 
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Optimization of an in vitro, antigen-specific stimulation protocol 
To better understand how costimulatory signals delivered by CD28 or Ctla-4 
ligation are temporally integrated with TCR-mediated activation signals, we utilized an 
established in vitro stimulation system that allows discriminatory signaling through CD28 
and Ctla-4(288).  Synthetic ligands composed of the transmembrane region of B7.2 
linked to the scFV region of antibodies specific for CD28 or Ctla-4 were stably expressed 
in CHO cells capable of presenting MCC88-103 in the context of I-Ek, either singly or in 
combination.  Expression of T cell ligands were determined by staining with anti-I-Ek, 
CD28Ig, or Ctla-4Ig.  Repeated purification of populations matched for ligand expression 
by FACS yielded stable lines expressing equivalent levels of their respective ligands. 
(Figure 4.1)  5C.C7 Rag-/- lymph node cells were cocultured with peptide pulsed, 
mitomycin C treated CHO cells under conditions of TCR monostimulation, CD28 
costimulation, or Ctla-4 ligation. Increasing responder frequency correlated with 
increasing APC:T cell ratios below 1:1 suggesting that APC ligands could be limiting 
(data not shown).  All subsequent experiments utilized a 1:1 ratio of APC:T cell 
cocultured in 96 well round-bottom plates containing 105 cells total.  The stability of 
ligand expression on CHO cells in culture following mitomycin C treatment was 
assessed.  Downregulation of surface ligands was insignificant over the first 36 hours 
(data not shown).  Increasing the duration of peptide preincubation with APC also 
increased responder frequency significantly up to 5 hours (data not shown), and all 
subsequent experiments were performed after a 5 hour peptide prepulse with removal of 
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excess peptide.  The stability of peptide presentation in culture was assessed by 
prepulsing APCs with varying concentrations of peptide and culturing them for intervals  
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Figure 4.1: Engineered APCs express equivalent T cell ligands 
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Figure 4.1:  Engineered APCs expressing I-Ek and a combination of synthetic ligands for 
CD28 and Ctla-4  were repeatedly FACS purified for stable, homogenous expression of 
surface-expressed T cell ligands.   Synthetic ligands for CD28 and Ctla-4 were stained 
with CD28-Fc orCtla-4-FC as appropriate followed by a goat anti-human FITC 
conjugated secondary antibody.  Relative to CD28 scFV, higher Ctla-4 scFV levels were 
obtained in order to maximize Ctla-4-mediated inhibition.  The biological relevance of 
CD28 ligation by the chimeric CD28 ligand expressed on the CHO cells is evident in the 
enhancement of TCR-mediated T cell stimulation assessed by responder frequency.  The 
binding affinities of both chimeric ligands for their T cell-expressed ligands are expected 
to be similar based on the affinities of the antibodies from which they were derived. 
Preincubation of the CHO cells with CD28-Fc or Ctla-4-Fc failed to significantly affect 
the apparent enhancement or inhibition of T cell responses seen after stimulation with 
CHO cells expressing CD28 and/or Ctla-4 ligands respectively.  Thus, the low median 
fluorescent intensity (MFI) detected for the CD28 and Ctla-4 ligands may reflect poor 
binding characteristics of the chimeric Fc linked molecules in culture as revealed by their 
inability to reverse the stimulatory and inhibitory properties induced in T cells by their 
cognate receptors on engineered CHO cells. 
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up to 48 hours prior to addition of responder cells.  Minimal decreases in responder 
frequency were observed over the first 36 hours of coculture, reflecting stable antigen 
presentation in culture for extended times (data not shown).    
 
Parameters of activation: dose response, kinetics, and costimulation 
 Because ex vivo 5C.C7 Rag-/- T cells are homogenous for activational history and 
TCR specificity, responder frequency reflects the average strength of signals received by 
lymphocytes in a given system.  The magnitude of the responder frequency correlated 
with peptide prepulse concentration over a wide range of concentrations. (Figure 4.2)  
Kinetics of early activation marker CD69 expression, upregulation of CD4, and cell 
division following activation was characterized in cells receiving TCR monostimulation, 
CD28 costimulation, and Ctla-4 ligation.  (Figure 4.3)  Critically, maximal responder 
frequencies at most antigen concentrations were generally achieved by 8-12 hours, 
suggesting a high-degree of synchronicity existed in activated populations.  TCR 
monostimulation resulted in markedly diminished responder frequencies relative to CD28 
costimulated cells over the entire range of antigen concentration tested as measured by 
CD69 upregulation.  Amplification of TCR-mediated activation signals by CD28 ligation 
was most pronounced at lower and intermediate antigen concentrations when measured 
as percentage increase in responder frequency.  A reduction in thymidine incorporation at 
very high doses of antigen following CD28 costimulation was inconsistent with the 
expression of CD69 at early times and could be explained by either increased cell death 
or reduced burst size in CD28 costimulated cells at high antigen concentrations (Figure 
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4.2).  TCR monostimulation resulted in slightly delayed kinetics with regards to CD69 
expression, CD4 upregulation, cell cycle entry, and rates of cellular division.  Ctla-4  
ligation resulted in a reduction in responder frequency that was greatest at lower antigen 
concentration, and became negligible at the highest concentration tested.  Dose response 
curves were only marginally shifted by Ctla-4 ligation, and the kinetics of activation 
marker expression and cellular division at the population level were unchanged relative to 
cells receiving only CD28-mediated costimulation.  Maximal CD28 costimulation, 
measured as an absolute increase in responder frequency relative to TCR monostimulated 
cells, was greatest at intermediate antigen concentration.  Ctla-4 mediated inhibition of 
CD28 costimulation was also greatest at an intermediate antigen concentration of 5x10-4 
uM MCC88-103.   Because Ctla-4 only marginally inhibited activation induced by TCR 
monostimulation, we chose to quantify Ctla-4 mediated inhibition relative to CD28-
mediated enhancement of TCR activation signals according to the following equation: 
[(RFCD28)-(RFCtla-4)]/[RFCD28)-(RFTCR)] 
where RF denotes “responder frequency” and TCR, CD28, and Ctla-4 indicate conditions 
of TCR monostimulation, TCR+CD28 ligation, and TCR+CD28+Ctla-4 ligation 
respectively. 
 Temporal constraints on costimulatory signal integration are not well known.  To 
define the critical time period in which CD28 and Ctla-4 must be engaged to respectively 
enhance and inhibit T cell responses in our system, we utilized a cell transfer protocol 
that allowed for quantitative and qualitative changes in stimulation conditions over time.  
T cells were cultured under varying conditions of TCR monostimulation, and CD28 or 
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Figure 4.2: Dose response of curve of TCR-tg T cells stimulated with 
engineered APCs prepulsed with antigen 
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Figure 4.2:  TCR-transgenic CD4+ lymphocytes respond to TCR stimulation, CD28 positive 
costimulation, and Ctla-4 mediated inhibition over a wide range of antigen concentrations.  5x104 
5C.C7 TCR-transgenic CD4+ T cells were co-cultured in 96-well round-bottom plates with 5x104 
mitomycin C-treated Chinese hamster ovary (CHO) antigen presenting cells (APCs) engineered 
to express surface ligands for TCR, CD28 and Ctla-4 in varying combination that were prepulsed 
for five hours with the indicated concentration of moth cytochrome C oligonucleotide (MCC88-
103). 56 hours after the start of co-culture, 1µCi of tritiated Thymidine was added per well.  
Culture plates were frozen rapidly at -80º Celsius 16 hours after the addition of Thymidine.  
Individual culture conditions were performed in triplicate, and measured Thymidine 
incorporation represents the average of replicate wells.  Data shown is representative of numerous 
experiments.  CD28 resulted in the greatest relative enhancement of TCR-mediated activation at 
low doses of antigen.  Similarly, Ctla-4 ligation was most effective in counteracting CD28 
costimulatory signals at low doses of antigen.  Bulk culture stimulations were performed with 
5x10-4 uM MCC prepulse concentration to improve yields in both activated and naïve populations 
while ensuring adequate inhibition by Ctla-4. 
 110
.Figure 4.3:  TCR-tg T cells exhibit consistent responder frequency and 
reliable kinetics of activation and division when stimulated by 
engineered APCs. 
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Figure 4.3:  TCR-tg T cells stimulated in vitro by engineered APCs reveal antigen-dose-
dependent costimulation responses to CD28 and Ctla-4 ligands.  5x104 5C.C7 TCR-
transgenic CD4+ T cells were co-cultured in 96-well round-bottom plates with 5x104 
mitomycin C-treated Chinese hamster ovary (CHO) antigen presenting cells (APCs) 
engineered to express surface ligands for TCR, CD28 and Ctla-4 in varying combination 
that were prepulsed for five hours with the indicated concentration of moth cytochrome C 
oligonucleotide (MCC88-103). CD4+ T cells were harvested from triplicate wells at 
specific times after the start of co-culture, pooled, and analyzed for the expression of the 
early activation marker CD69.  CD69 expression is predictive of commitment to 
activation and cell-cycle entry.  The top, middle, and bottom panels display the 
percentage of CD69+ CD4+ T cells at serial timepoints after stimulation with engineered 
APCs prepulsed with 5x10-5, 5x10-4, or 5x10-3 µM MCC respectively.  Responses to 
CHO APCs expressing ligands for the TCR, the TCR+CD28, or the TCR+CD28+Ctla-4 
are shown in blue (clone V), green (clone M37), and red (clone M14/37) respectively.  
5x10-4 uM MCC prepulse concentration results in roughly 50% inhibition of CD28-
mediated costimulation by Ctla-4.  In addition, irreversible commitment to activation, as 
indicated by CD69 upregulation, is determined early after TCR triggering as reflected in 
relatively stable responder frequencies from 6 hours post-stimulation until first division.  
First division in the presence of CD28 occurs around 32-36 hours.  TCR monostimulation 
results in delayed entry into cell-cycle and the majority of activated cells do not divide 
until 40-50 hours.  Values shown are from pooled triplicates.  Representative experiment 
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is shown.  
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Ctla-4 costimulation for defined intervals, removed from culture, and cocultured with 
APCs providing all possible combinations of TCR, CD28, and Ctla-4 ligation in the 
presence or absence of antigen.  Flow cytometry analysis revealed that less than 10% of 
transferred cells were APCs from initial cultures (data not shown).  Internal controls were 
provided by T cells that remained in initial cultures, and by transfer of T cells between 
identical culture conditions.  The influence of costimulatory signals received by T cells 
was measured by CD69 expression 20-24 hours after initial stimulation, or after 16 hours 
in secondary culture conditions.  No difference was seen between measurements taken at 
those times.  Moreover, responder frequency in samples transferred between identical 
conditions was similar to that seen in unmanipulated cultures.   
As shown, T cells cultured under conditions of TCR monostimulation became 
increasingly refractory to activation by CD28 costimulation over time(Figure 4.4).  T 
cells were consistently and maximally responsive to CD28 ligation at any time up to 6 
hours following TCR monostimulation.  However, CD28 ligation occurring later than 6 
hours potentiated TCR activation signals in a decreasing manner over time, and CD28 
ligation after 16 hours of TCR monostimulation failed to increase responder frequency at 
all.  Decreased responsiveness resulted from interaction with APC ligands.  T cells 
initially cultured with APC in the absence of antigen did not become significantly 
refractory to stimulation over the initial 12 hours in culture (data not shown).  Ctla-4 
coligation with CD28 following TCR monostimulation inhibited CD28-mediated 
costimulation, but did not appear to produce independent effects on responder frequency 
apart from CD28.  Importantly, maximal T cell responses to TCR monostimulation were 
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evident after 1 hour when transferred between identical culture conditions, or transferred 
to cultures lacking antigen and costimulation.  This suggests that, in this system, T cell 
activation as a result of isolated TCR stimulation utilizes mechanisms that commit cells 
to become activated within one hour of TCR triggering.  In contrast, CD28 and Ctla-4 
costimulation can be integrated over an extended period.   
Responder frequencies in cultures initially receiving TCR and CD28 signals also 
suggest that persistent costimulatory signals influence T cell responsiveness for several 
hours after TCR triggering (Figure 4.5).  Our results show equivalent responses to TCR 
monostimulation and the absence of TCR ligation following one hour of combined TCR 
and CD28 stimulation, supporting the notion that TCR ligation activates all relevant 
pathways within one hour.  Moreover, increasing the duration of CD28 ligation increases 
responder frequency up to 12 hours, at which point, no difference is seen in comparison 
to cultures maintained under conditions of CD28 ligation throughout.  This suggests that 
CD28 engagement is stable for at least 12 hours and provides persistent enhancement of 
TCR signals.  Abrogation of CD28 ligation at any time prior to 12 hours reduced 
responder frequency.  Likewise Ctla-4 ligation inhibits T cell responses to TCR and 
CD28 coligation up to 12 hours after stimulation, supporting the idea that mechanisms of 
Ctla-4 inhibition of T cell activation are not relevant in the absence of CD28 
costimulation.  Moreover, the similar temporal constraints seen with CD28 and Ctla-4 
signal integration as assessed by responder frequency support models of Ctla-4 function 
that emphasize shared signaling pathways with CD28. 
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Figure 4.4:  Submitogenic TCR signaling results makes T cells increasingly refractory to 
costimulatory signals over time. 
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Figure 4.4:  TCR monostimulation makes T cells increasingly refractory to costimulatory 
signals.  Serial–coculture conditions under varying condition of TCR, CD28, and Ctla-4 
ligation conditions define the temporal parameters of TCR monostimulation and CD28 
and Ctla-4 costimulatory signal integreation as assessed by CD69 expression.  5x104 
5C.C7 TCR-transgenic CD4+ T cells were co-cultured in 96-well round-bottom plates 
with 5x104 mitomycin C-treated Chinese hamster ovary (CHO) antigen presenting cells 
(APCs) engineered to express I-Ek.  APCs were prepulsed for five hours with 5x10-4 µM 
moth cytochrome C oligonucleotide (MCC88-103) prior to start of coculture. T cells were 
removed from initial co-culture conditions at indicated times (X-axis) by gentle pipetting 
and co-cultured with CHO APCs prepulsed with 5x10-4 µM MCC under varying 
conditions of TCR monostimulation, CD28 costimulation, and CD28+Ctla-4 
costimulation (blue, green, and red curves respectively).  In addition, T cells were 
removed from initial culture conditions and co-cultured with CHO APCs expressing I-Ek 
in the absence of MCC peptide (black curve).  T cells were generally greater than 93% 
pure after removal from initial culture conditions.  T cells were analyzed for CD69 
expression 20 hours after start of co-culuture in initial conditions.  Cells stimulated by the 
TCR alone displayed maximal responder frequency by 1-2 hours and were not activated 
further by sustained TCR stimulation.  In contrast, CD28 costimulation could fully 
restore maximal responder frequencies at any time up to 6-8 hours.  In addition, Ctla-4 
was capable of inhibiting CD28-mediated costimulation to a degree that paralleled the 
magnitude of CD28 enhancement of TCR activation.  Costimulatory signals produced no 
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alteration in responder frequency beyond 16 hours. Results reflect average of three 
experiments performed in triplicate. 
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Figure 4.5:  CD28 costimulatory signals are integrated over a period of 
12 hours 
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Figure 4.5:  CD28-mediated signals are incorporated over a period 12 hours after initial T 
cell stimulation.  Serial–coculture conditions under varying condition of TCR, CD28, and 
Ctla-4 ligation conditions define the temporal parameters of TCR monostimulation and 
CD28 and Ctla-4 costimulatory signal integreation as assessed by CD69 expression.  
5x104 5C.C7 TCR-transgenic CD4+ T cells were co-cultured in 96-well round-bottom 
plates with 5x104 mitomycin C-treated Chinese hamster ovary (CHO) antigen presenting 
cells (APCs) engineered to express I-Ek and a CD28 ligand.  APCs were prepulsed for 
five hours with 5x10-4 µM moth cytochrome C oligonucleotide (MCC88-103) prior to start 
of coculture. T cells were removed from initial co-culture conditions at indicated times 
(X-axis) by gentle pipetting and co-cultured with CHO APCs prepulsed with 5x10-4 µM 
MCC under varying conditions of TCR monostimulation, CD28 costimulation, and 
CD28+Ctla-4 costimulation (blue, green, and red curves respectively).  In addition, T 
cells were removed from initial culture conditions and co-cultured with CHO APCs 
expressing I-Ek in the absence of MCC peptide (black curve).  T cells were generally 
greater than 93% pure after removal from initial culture conditions.  T cells were 
analyzed for CD69 expression 20 hours after start of co-culuture in initial conditions.  
Abrogation of CD28 ligation at any time prior to 12 hours reduces responder frequency.  
Similarly, Ctla-4 ligation is capable of inhibiting CD28-mediated over a similar time 
frame in support of models emphasizing shared signaling pathways downstream of CD28 
and Ctla-4. Results reflect average of 3 experiments performed in triplicate. 
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Figure 4.6:  Ctla-4 signals are integrated over a period of 8-12 hours 
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Figure 4.6:  Ctla-4 signals are integrated over a period of 8-12 hours.  Serial–coculture 
conditions under varying condition of TCR, CD28, and Ctla-4 ligation conditions define 
the temporal parameters of TCR monostimulation and CD28 and Ctla-4 costimulatory 
signal integreation as assessed by CD69 expression.  5x104 5C.C7 TCR-transgenic CD4+ 
T cells were co-cultured in 96-well round-bottom plates with 5x104 mitomycin C-treated 
Chinese hamster ovary (CHO) antigen presenting cells (APCs) engineered to express I-Ek 
as well as ligands for CD28 and Ctla-4  APCs were prepulsed for five hours with 5x10-4 
µM moth cytochrome C oligonucleotide (MCC88-103) prior to start of coculture. T cells 
were removed from initial co-culture conditions at indicated times (X-axis) by gentle 
pipetting and co-cultured with CHO APCs prepulsed with 5x10-4 µM MCC under 
varying conditions of TCR monostimulation, CD28 costimulation, and CD28+Ctla-4 
costimulation ( blue, green, and red curves respectively).  In addition, T cells were 
removed from initial culture conditions and co-cultured with CHO APCs expressing I-Ek 
in the absence of MCC peptide (black curve).  T cells were generally greater than 93% 
pure after removal from initial culture conditions.  T cells were analyzed for CD69 
expression 20 hours after start of co-culuture in initial conditions.  Abrogation of Ctla-4 
ligation prior to 8 hours results in CD28-mediated increases in responder frequency.  
However, elimination of both CD28 and Ctla-4 signaling prior to 8 hours results in 
decreased responder frequency reflecting ongoing positive costimulation by CD28.  
Collectively, the data suggest that TCR-mediated and costimulation-mediated signals use 
distinct mechanism and signaling pathways. Results reflect average of three experiments 
performed in triplicate.
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Ctla-4 inhibition of T cell activation can be reversed by attenuation of Ctla-4 
ligation prior to 8-12 hours after initial TCR stimulation (Figure 4.6).  In conjunction 
with previous results, this observation suggests that Ctla-4 alters the threshold of 
activation by mechanisms that primarily counteract CD28 mediated signals.  However, 
there is a slight difference between the temporal parameters of signal integration seen 
with CD28 and Ctla-4.  The critical period for ligation in the determination of activation 
threshold appears to be somewhat more constrained for Ctla-4 relative to CD28 
suggesting that Ctla-4 may initiate unique signaling pathways that are independent of 
CD28 and can not be overridden by CD28 ligation at later times despite evidence 
supporting a continued role for CD28 signaling.   
 
Discussion 
 The mechanisms underlying signal integration from antigen and costimulatory 
receptors is only partially understood.  CD28 functions primarily to enhance signaling 
through the TCR(12, 50, 54).  However, CD28 also mediates signaling that is 
independent of TCR triggering and results in qualitatively different immunological T cell 
responses(370).  The immunological synapse may provide the necessary biophysical 
environment for prolonged signaling through receptors on the T cell surface, and may be 
essential for costimulatory signal integration and gain of effector function(371).  In 
support of this model, our data suggests that TCR monostimulation leading to activation 
requires only transient (<1 hour) TCR engagement.  In contrast, CD28 alters the 
threshold of activation by persistent signaling over several hours, indicating a 
 123
fundamentally different mechanism leading to cell activation is involved.  Relative to 
TCR signaling, CD28 is unique in its ability to selectively stabilize mRNA transcripts(15, 
17, 186, 372).  T cell activation results in transcriptional upregulation of genes necessary 
for coordinated regulation of diverse processes involved in survival, cell growth, 
intercellular communication, and effector function.  The ability of CD28 signaling to 
amplify expression of key regulatory molecules involved in these processes by 
coordinated transcriptional, post-transcriptional, and post translational regulation is, in 
some instances, distinct from TCR signaling pathways and may serve to explain why 
continued CD28 ligation is an important determinant of threshold of activation.  
Similarly, the ability of Ctla-4 and CD28 to influence responder frequency profiles over 
similar timeframes and with opposing results is suggestive of a shared mechanism of 
regulation that is operative over extended periods of time.  Costimulatory signals are 
critical regulators of immunity and tolerance, with roles in T cell differentiation and 
effector function.  The diversity of lymphocyte responses that can result from TCR 
triggering may require additional time, beyond that required for TCR ligation and, 
perhaps, commitment to activation, to sufficiently integrate the array of costimulatory 
signals that are often temporally and spatially distinct.  Importantly, the consistency of 
our findings with current models of T cell activation and receptor signaling paradigms 
supports the use of engineered APCs as a physiologically relevant model system that 
recapitulates some published findings related to T cell activation, and may provide clarity 
in answering questions obscured by the use of supraphysiological stimuli and 
heterogeneous lymphocyte populations. 
 124
 Our in vitro system provides stringent control of TCR signal strength and 
differentially signals through CD28 and Ctla-4.  Moreover, the kinetics of activation 
indicates that cells identified by activation marker expression are highly synchronized for 
activation status and provide ideal samples for the characterization and isolation of 
phenotypically homogenous populations. 
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Chapter IV 
Results 
 
Kinetic Analysis of Global Expression Profiles in TCR-
Transgenic CD4+ Lymphocytes During Primary 
Activation 
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Kinetic Analysis of Genomic Expression Patterns in Activated TCR-tg CD4+ 
Lymphocytes 
 
TCR-tg lymphocytes and engineered APCs allow tight control of activation stimuli 
 Ctla-4 and CD28 utilize the same B7 family members, B7.1 and B7.2, as ligands, 
complicating the characterization of the two opposing costimulatory pathways.  Using an 
established in vitro stimulation system, we optimized a protocol of primary stimulation in 
CD4+ cells that allowed tight control of TCR signal strength, synchronous activation of 
TCR-tg lymphocytes, and differential signaling through either CD28 or Ctla-4.  
Numerous experiments delineated the parameters of T cell activation using this system, 
and allowed us to specify a degree of TCR stimulation that allowed for moderate 
activation in the absence of costimulation, significant positive costimulation by CD28, 
and apparent inhibition by Ctla-4. 
 To facilitate the identification of genes potentially regulated by Ctla-4, it was 
crucial that the kinetics of T cell commitment to activation and integration of CD28- or 
Ctla-4-mediated costimulatory signals be well defined.  Using expression of the very 
early activation marker CD69, upregulation of CD4, and the division marker CFSE, we 
established a normative profile of T cell activation with reproducible kinetics and 
responder frequency.  Importantly, maximal responder frequency was routinely achieved 
by 12 hours, implying a high degree of synchronicity in the activated populations. 
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 To determine the predictive value of CD69 expression in T cell activation, we 
stimulated ex vivo 5C.C7 lymphocytes with CHO APC prepulsed with 5x10-4 uM MCC, 
harvested the cells at 4, 8, and 12 hours, and sorted the cells by FACS for expression of 
CD69.  Sorted cells were then cocultured with CHO APC expressing I-Ek without MCC 
and analyzed at 24 and 72 hours for expression of activation markers and division status.  
CD69 expression was highly predictive of commitment to activation and eventual cell 
division.  It was noted that CD69+ cells isolated at earlier timepoints were more 
susceptible to cell death as indicated by Trypan blue staining and cell yield at subsequent 
timepoints.  While it was clear that a small fraction of sorted CD69- lymphocytes were 
capable of becoming activated when put back into culture, there was no evidence that 
interruption of stimulation ever reversed the activation status of cells as evidenced by the 
absence of naïve cells at late timepoints in cultures sorted for positive CD69 expression.  
In addition, while it is possible that sparse cell recovery at 4-8 hours after TCR 
stimulation alone skewed the results of subsequent analyses, the trend towards longer 
times to commitment in the absence of CD28 costimulation are consistent with activation 
marker expression data indicating a more prolonged and gradual achievement of maximal 
responder frequency with TCR stimulation alone.  These results again reflect a high 
degree of synchronicity in lumphocyte activation kinetics when using this system. 
 Having established the kinetics of activation in our system, the predictive and 
sequential nature of activation marker expression, and the temporal parameters of 
costimulatory signal integration, we scaled our activation assay up to allow purification 
of homogenous populations by FACS as indicated by CD69 expression, CD4expression, 
 128
and the cell-division marker, CFSE.  Figure 4.8 shows the sort protocols for samples 
isolated prior to 32 hours, 32-48 hours, and 60 hours and beyond.  As shown previously, 
the populations identified are expected to be highly synchronized and homogenous for 
activation history, activation status, and commitment to division. 
 As an initial screen for the utility of this protocol, we sorted a large quantity of 
cells and performed the standard single step amplification and labeling procedure 
available at the time, using 5-8ug of starting total RNA.  Microarry analysis using 
Affymetrix MgU74aV2 Genechips showed robust changes in global expression profiles.  
RT-PCR verification of select gene expression levels verified the results seen on 
microarray  (Data not shown).  Because the amount of RNA isolated was limiting for 
most experiments, a single sample was amplified in both a single- and double-step 
amplification procedure, and the results compared.  Figure 4.9 summarizes the results 
seen with both labeling protocols, and suggests that despite some flattening of signal 
intensity over the entire expression profile relative to single-step amplification, the limits 
of detection and linearity of amplification were not sufficiently altered with double 
amplification to significantly alter the profile seen.  As a result, all subsequent 
experiments were performed using the double amplification protocol. 
 Samples were isolated at 4 hour intervals up to 24 hours based on CD69 
expression. At 36 hours, 4 population were isolated per stimulation condition based on 
CD4 expression and CFSE staining, allowing additional characterization of the changes 
that occur during cell-cycle entry.  At 60 hours, populations were sorted based on 
division status.  It is noteworthy that despite a high degree of consistency in the responder 
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Figure 4.8:  Sort protocols for in vitro-stimulated T cells at varying 
times after activation 
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Figure 4.8:  Sorting protocols used to isolate CD4+ populations homogenous for 
activation status.  5x104 5C.C7 TCR-transgenic CD4+ T cells were co-cultured in 96-
well round-bottom plates with 5x104 mitomycin C-treated Chinese hamster ovary (CHO) 
antigen presenting cells (APCs) engineered to express surface ligands for TCR, CD28 
and Ctla-4 in varying combination that were prepulsed for five hours with 5x10-4 µM 
moth cytochrome C oligonucleotide (MCC88-103). 5C.C7 lymphocyte activation, as 
measured by responder frequencey (CD69 upregulation) correlates with antigen prepulse 
concentration and is enhanced or inhibited by CD28 and Ctla-4 ligands respectively.  A)  
At timepoints up to 24 hours CD4+ T cells co-cultured with CHO APCs under varying 
conditions of TCR, CD28 a, and Ctla-4 ligation were sorted for activation status based 
solely on expression of the early activation marker CD69.  Representative sort protocol 
shown.  Responder frequency (percent of CD69+ lymphocytes) is indicated in the pre-
sort histogram.  B) At timpoints from 32-48 hours, CD4+ T cells were sorted into 4 
populations based on the sequential upregulation of CD69 and CD4 and subsequent 
division.  Division status was determined by staining the cells with the cytoplasmic dye 
CFSE prior to stimulation.  Populations isolated were CD69-, CD69+CD4Low, CD4High-
undivided, and divided.  C) At timepoints beyond 48 hours, CD4+ T cells were isolated 
based solely on their division status as determined by CFSE intensity, and sorted into 
undivided and divided populations. 
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frequency seen with TCR and TCR+CD28 stimulation, TCR+CD28+Ctla-4 ligating 
condition produced a more variable activation response.  Because the greatest influence 
of the Ctla-4 binding M14 molecule is seen in the context of simultaneous CD28  
stimulation, the degree of Ctla-4 mediated inhibition was defined as (M37RF-
M14/37RF)/(M37RF-VRF), where “RF” indicates the responder frequency indcated by 
CD69 expression seen with the corresponding CHO APC.  Or more generally, “Ctla-4-
mediated inhibition” was defined as the percentage of CD28-mediated increase in 
responder frequency apparently reversed by Ctla-4 ligation.  To increase the likelihood of 
detecting consistent changes in gene expression subsequent to Ctla-4 ligation, 
lymphocytes stimulated in the presence of TCR, CD28 and Ctla-4 ligands were selected 
to maintain a roughly consistent 50% inhibition by Ctla-4 for samples analyzed by 
microarray.   A summary of in vitro 5C.C7 CD4+ T cell samples isolated by FACS for 
the production of RNA and subsequent microarray analysis is documented in Table 4.1 
 
TCR-Mediated T cell Activation Results in a Dynamic Regulation of Several Thousand 
Genes 
 TCR-signaling in the absence of positive costimulation has been reported to result 
in anergy, abortive activation, cellular death via apoptosis induction, and tolerance 
induction.  As shown previously, our in vitro stimulation system utilizing engineered 
APCs presenting MCC to 5C.C7 TCR-tg lymphocytes is capable of initiating T cell 
activation by TCR monostimulation, or T cell signaling with positive and negative 
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Figure 4.9:  Comparison of amplification protocols 
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Figure 4.9:  Expression values obtained from alternate amplification protocols that 
utilized the same starting RNA sample were analyzed.  5C.C7 Rag-/- T cells were 
activated in vitro by co-culture with peptide pulsed APCs for 16 hours in the presence of 
ligands for TCR, CD28, and Ctla-4.  Non-activated CD4+CD69- lymphocytes were 
isolated by FACS and used to prepare total RNA.  RNA was labeled for microarray 
analysis by both single- and two-step amplification and labeling protocols, and products 
of both protocols analyzed on Affymetrix MgU74Av2 oligonucleotide microarrays.  One 
chp per condition was analyzed.  Microarray scanning and qualitative determination of 
expression (“present” or “absent”) based on signal to noise ratios was performed using 
Affymetrix MAS5.0 software.  Further analysis was performed using Genespring analysis 
software.  Data was transformed and normalized by setting signal intensity values below 
0.01 were to 0.01 and dividing each measurement by the 50.0th percentile of all 
measurements in that sample.  The cross-gene error model was applied to provide 
statistical measures of significance in the absence of replicates.  6480 transcripts, 
representing 52% of the total probeset array utilized, were detectable in at least one of the 
two conditions (amplification protocols) examined.  5653 genes out of 6480, representing 
88% of the identified transcriptome were flagged as present on both samples.  This 
indicates that only 0.6% of all probesets were differentially flagged on the microarrays.  
Of the 5653 genes present in both samples 550, 147, and 39 genes indicated fold 
differences of 2, 3, or 5 respectively, corresponding to 10, 3, and 0 percent of genes 
expressed.
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costimulation.  T cell responses to TCR monostimulation in our system, while diminished 
with respect to responder frequency and displaying slightly delayed kinetics, still results 
in full commitment to activation, cell division, and did not result in increased cell death 
in culture.  In vitro blockade of potential T-T costimulation via anti-B7 antibody 
blockade did not alter responder frequency or entry into the cell cycle during primary 
stimulation as assessed by CD69 expression, CD4 upregulation, and CFSE staining. 
(Data not shown)  Moreover, naïve lymphocytes activated by TCR monostimulation, 
TCR ligation plus CD28 costimulation, or the combined ligation of the TCR, CD28 and 
Ctla-4 did not display dramatically different responses upon restimulation, and 
differences observed upon restimulation appeared to correlate with the overall strength of 
activation signals in the primary activation as assessed by responder frequency, and not 
the specific combination of TCR and costimulatory signals received.  (Dat not shown)  
Together, these data indicate that TCR ligation alone is capable of initiating a robust T 
cell response when sufficiently strong, and this observation correlates with the global 
expression profile assayed by microarray. 
 2129 genes were identified as present in a minimum of 4 of the samples receiving 
monostimulation alone and as having undergone a 3-fold change in expression in at least 
2 samples relative to ex vivo naïve cells.  Figure 4.10 shows a box plot representation of 
these genes in TCR-monostimulated samples segregated according to time and activation 
status.  Perhaps surprisingly, unactivated populations evidenced numerous significant 
gene regulations in culture despite receiving sub-mitogenic signals.  Although this could 
be attributed to bystander effects in the presence of activated cells, attrition of normal 
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Table 4.1: Summary of in vitro stimulated 5C.C7 CD4+ lymphocyte sample analyzed by microarray 
Hours 
Stimulated 
Stimulation Conditions Activation Phenotypes 
Isolated per Stimulation 
Condition 
# of 
Replicates 
Total Number of Samples per timepoint Average 
Inhibition in 
Presence of Ctla-4 
Ligands 
0 NA (Ex Vivo) CD69-CD25-CD44low 2 2 NA 
4 TCR 
TCR+CD28 
TCR+CD28+Ctla-4 
CD69- 
CD69+ 
2 12  
8 TCR 
TCR+CD28 
TCR+CD28+Ctla-4 
CD69- 
CD69+ 
2 11 
(Missing one TCR stimulated CD69-) 
44% 
12 TCR 
TCR+CD28 
TCR+CD28+Ctla-4 
CD69- 
CD69+ 
2 11 
(Missing one TCR stimulated CD69-) 
47% 
16 TCR 
TCR+CD28 
TCR+CD28+Ctla-4 
CD69- 
CD69+ 
2 12 40% 
20 TCR 
TCR+CD28 
TCR+CD28+Ctla-4 
CD69- 
CD69+ 
2 10 
(Missing one CD69+ sample from 
TCR+CD29 and TCR+CD28+CTLA-4) 
76% 
24 TCR 
TCR+CD28 
TCR+CD28+Ctla-4 
CD69- 
CD69+ 
1 6 53% 
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32 TCR 
TCR+CD28 
TCR+CD28+Ctla-4 
CD69- 
CD69+CD4Low 
CD69+CD4HighUndivided 
Divided 
1 11 ~50% prior to 
start of division 
60 TCR 
TCR+CD28 
TCR+CD28+Ctla-4 
Undivided 
Divided 
1 6 ~55% prior to 
start of division 
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Table 4.1:  Summary of in vitro stimulated 5C.C7 CD4+ lymphocyte sample analyzed by 
microarray.  5C.C7 Rag-/- CD4+ T cells were stimulated in vitro by APCs engineered to 
differentially express ligands for the TCR, CD28, and Ctla-4.  APCs were prepulsed with 
5x10-4 MCC for 5 hours prior to coculture with T cells.  At the indicated times, T cells 
were harvested, sorted for the indicated activation and division markers, and their 
transcriptome analyzed by microarray subsequent to RNA isolation, amplification, and 
labeling.  All isolated populations were greater than 93% pure by flow cytometry analysis 
after FACS purification.  Two ex vivo CD69-CD25-CD44Low samples were isolated to 
provide baseline gene expression measurements.  From 4-60 hours, samples were isolated 
at 8 timepoints under all three conditions of TCR, TCR+CD28, and TCR+CD28+Ctla-4 
ligand stimulation.  From 4-24 hours, naïve and activated populations were purified based 
on CD69 expression.  At 32 hours, 4 populations were isolated including CD69-, 
CD69+CD4Low, CD69+CD4High, and divided.   At 60 hours, cells were isolated into 
undivided and divided populations.  Biological replicates were produced for the majority 
of sample conditions isolated prior to 24 hours.  From 24-60 hours, only one sample per 
condition was processed for microarray analysis.  TCR monostimulation induced 
responder frequencies (assessed by CD69 expression) of 11-22%.   CD28 costimulation 
increased responder frequencies up to ~45-75%.  T cells stimulated in the presence of 
Ctla-4 ligands displayed varying responder frequencies between those seen with TCR 
monostimulation and CD28 costimulation.  Samples processed for microarray analysis 
were chosen to maintain a roughly 50% inhibition of CD28-mediated costimulation as 
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determined by responder frequencies.  In total, 78 stimulated samples and two ex vivo 
samples were analyzed by microarray.
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signals received in a more physiological environment, or unanticipated effects of the 
specific culture conditions irrespective of activating stimuli, it is also a potential result of 
penetrant but sub-mitogenic signaling.  This is an important possibility as sub-mitogenic 
signaling has been reported to confer a lasting phenotype on naïve cells.  These 
possibilities will be more fully explored in the comparison of expression profiles between 
stimulation conditions.  As expected, activated conditions displayed a greater amplitude 
and diversity of gene regulation across all timepoints relative to unactivated populations.  
Interestingly, while activated populations showed a mean increase in gene expression at 
all other timepoints, samples isolated 8 hours after activation displayed a large 
generalized downregulation of numerous genes, suggestive of active gene suppression.  
This phenomenon was unlikely to be due to spurious effects of microarray sample 
processing as it was unique to the activated populations and consistent across duplicates.  
The nearly 1200 genes downregulated at this time were characterized by an oscillatory 
pattern of regulation occurring over the initial 20 hours of activation.   Genes involved in 
metabolic processes were highly overrepresented in this group.  In contrast to the general 
downregulation observed at this timepoint, cell surface molecules and signaling 
intermediates were predominantly upregulated to a great degree.   The majority of known 
transcription factors were upregulated at 8 hours, but a significant minority was 
transiently downregulated.     A quick overview of genes identified as key regulators or 
participants in T cell activation indicated that most were highly regulated over numerous 
timepoints.  As a result, genes were further segregated into those showing a >10-fold 
change in expression over a minimum of 3 samples, and those showing a 5- to 10-fold 
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change over at least 3 samples.  A combined condition tree and gene tree of a 
combination of these groups indicated a linear divergence of the expression profile of 
unactivated populations from ex vivo samples over time. Among activated samples, the 
12 hour and 20 hour sample segregated in a non-linear fashion with respect to time, being 
found most similar to each other as a result of distinct upregulation of a cluster of 120 
genes. When a similar analysis is performed on the 122 most regulated genes, known to 
include numerous key mediators of T cell activation, the linearity of progression is 
improved and only the 16 hour sample mis-segregates, being identified most closely with 
the 24 hour sample. (Figure 4.11) 
Visual editing of genes identified as significantly regulated (>5-fold change in 
three timepoints in either activated or unactivated populations) yielded 418 genes.  
Hierarchical clustering of these genes in the activated samples provides a clear indication 
of the grouping of coordinately regulated genes over time, and K means clustering 
identified the 19 most significantly related groups of coordinately regulated genes in TCR 
activated samples over 60 hours of activation (Figure 4.12). 
A search for putative regulatory sequences within the 19 gene clusters identified by K-
means clustering indicated a heterogeneous pattern of overly represented sequences in the 
500bp upstream sequences of included genes.  Overall, 168 sequences 5-10bp in length 
were over-represented (p<0.05) in the upstream sequences of the 360 most highly 
regulated genes with known sequence relative to the rest of identified genes in the 
genome.  Moreover, principal component 1 of the K-means clustering includes only 36 
genes, but statistical analysis identified 304 over-represented putative regulatory 
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Figure 4.10: Box-plot representation of gene regulation in TCR-
monostimulated populations 
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Figure 4.10:  Box plot diagram showing magnitude of regulation in genes expressed in 
TCR monostimulated cells that remain naïve or become activated.  5C.C7 TCR-tg 
lymphocytes were stimulated in vitro by CHO APCs expressing I-Ek and prepulsed with 
5x10-4 µM MCC.  Lymphocytes were purified based on expression of activation markers 
(CD69, upregulation of CD4) and division status at numerous intervals from 4 to 60 
hours.  Total RNA isolated from the purified populations was labeled in a two-step 
amplification and labeling protocol, and subsequently analyzed on Affymetrix 
MgU74Av2 microarrays using the Affymterix MAS5.0 sorftware.  Duplicate biological 
samples were obtained for all timepoints prior to 24 hours.  Single samples were analyzed 
at 24, 36, and 60 hours.  6041 genes had detectable expression in at least 4 of the 23 
samples included in this analysis.  Further analysis utilizing Genespring analysis software 
was performed.   Unactivated samples are color-coded red, activated samples are green.  
Median gene expression is indicated by indents, boxed regions indicate quartile gene 
distributions, and feathered extensions equal 1.5 times the interquartile distance.  Data 
was transformed and normalized by setting signal intensity values below 0.01 were to 
0.01 and dividing each measurement by the 50.0th percentile of all measurements in that 
sample.  Measurements for each gene in each sample were divided by the average value 
of that gene’s measurement in two samples of untreated and purified 5C.C7 Rag-/- CD4+ 
lymphocytes isolated ex vivo.  Thus, expression values (Y-axis) are equivalent to fold-
change values relative to untreated ex vivo samples.  Box plots indicate the magnitude 
and scope of gene regulation occurring in naïve and activated populations in vitro from 4-
60 hours in culture.  Indents indicate the median gene expression value for genes detected 
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in at least 4 of 23 samples relative to its ex vivo expression value.  The length of the 
upper and lower segments of the boxes reflect interquartile distances among all genes 
analyzed.  The dotted line segments are arbitrarily set to 1.5 times the interquartile 
distance.  Outlying highly regulated genes are indicated by individual dots.  Thus, 5C.C7 
CD4+ lymphocytes activated by TCR monostimulation display broad gene regulations.  
More than one-third of all detectable genes display at least 3-fold changes in expression 
in two of 17 conditions (involving time after stimulation and activation status).  504 
genes display 5-fold or greater changes in expression in at least 3 of the 17 conditions.  
At eight hours, the general trend is towards downregulation of gene expression in 
activated cells.  At all other timepoints assayed, gene upregulation predominates.  The 
greatest global change in expression occurs ~20 hours after stimulation. 
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sequences (p<0.05), with 264 sequences significant at p<9e-5.  Longer upstream 
sequences tended to be the most statistically significant with 40 of the 50 most significant 
sequences (all p<9.1e-27) being 10bp in length.   In contrast, only 3 sequences were 
identified in component 10 (15 genes) and only 36 in component 14 (31 genes).  No 
overrepresented sequences were found in any of the other components (4-33 genes).  The 
search for putative regulatory sequences is independent of the clustering analysis 
performed.  Thus, the uniquely large number of over-represented sequences identified in 
the upstream region suggestive of shared mechanisms of regulation may reflect a 
common role for these genes in T cell activation.  The analysis is made more robust 
however by the inclusion of costimulated samples, and will be reconsidered in that 
context. 
 
TCR-Mediated Stimulation Results in Robust T Lymphocyte Activation 
 Global expression profiling of naïve CD4+ TCR-activated TCR-tg lymphocytes 
in vitro reveals a coordinated pattern of global gene regulation involving several thousand 
genes (Figure 4.13).  TCR monostimulation has previously been reported to result in 
abortive activation, anergy, or cell death.  While a severe reduction in responder 
frequency was observed following TCR monostimulation relative to CD28 costimulated 
cells, no defect in subsequent responsiveness or increased cell death was observed in our 
system.  These results are suggestive of a primarily quantitative effect of costimulation in 
setting the threshold for activation. 
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Figure 4.11:  Combination gene and condition tree of TCR 
monostimulated samples 
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Figure 4.11:  A combination gene and condition tree reveals complete segregation of 
activated and unactivated population stimulated by TCR ligation alone across all 
timepoints.  Hierarchical clustering was performed on all naïve and activated samples 
isolated from 5C.C7 CD4+ T cell activated in vitro by engineered APCs expressing I-Ek 
for 4-60 hours.  Global gene expression data was normalized to naïve, unstimulated 
CD4+ peripheral 5C.C7 ex vivo samples based on average values in replicates when 
available.  504 genes consistently up- or down-regulated more than five-fold in activated 
populations for three of the eight timepoints examined were used to generate the cluster 
analysis and condition tree in Panel A.  The majority of genes reported to regulate 
lymphocyte activation, cell-cycle entry, and apoptosis are included in this analysis.  
Statistically, the global expression patters reveal almost perfect linear segregation of 
activated population and identifies coordinately regulated genes.    Restricting the 
clustering analysis to genes displaying a minimum ten-fold change in expression in 3 of 
the eight timepoints analyzed from 4-60 hours improves the linearity of segregation 
according to (Panel B). 
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Figure 4.12: Prinicpal components analysis identifies coordinately 
regulated genes in TCR monostimulated populations 
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Figure 4.12:   A K-means clustering analysis identified the 19 most determinative 
expression profiles contributing to the overall patterns identified across all relevant 
samples stimulated by TCR ligation alone. The analysis was performed using normalized 
values for all genes displaying a minimum 5-fold change in expression in at least 3 
timepoints when normalized to naïve unstimulated 5C.C7 CD4+ lymphocytes isolated ex 
vivo.  Parameters used in the analysis: 19 clusters, maximum 100 iterations, Pearson 
correlation similarity measure.  The clusters converged after 22 iterations and 5 randomly 
chosen cluster failed to improve on the initial clustering results.  The 19 clusters 
contained from 8-44 genes each.  Panels A, B and C display the 3 dominant expression 
patters determinig the global expression profile of TCR stimulated 5C.C7 CD4+ T cells.  
Panel A contains the dominant component in TCR activated lymphocytes.  Searches for 
putative regulatory sequences identified numerous overrepresented elements in the 1kb 
upstream region of genes in 3 of the 19 clusters identified, validating their classification 
as coordinately regulated genes (Panels A, B, and C).  Genes comprising these clusters 
were analyzed further to identify signaling pathways involved in their regulation using 
Ingenuity Pathways Analysis software. 
 149
Costimulatory Signal Integration 
 CD28 alters the threshold of activation and serves to potentiate TCR-mediated 
signals.  By itself, CD28 ligation is reported to transiently alter the expression level of  
several genes, primarily by mechanisms that serve to stabilize mRNA transcripts 
transcribed at a basal level(15).  In the presence of simultaneous TCR ligation, CD28 has 
been shown to dramatically enhance the TCR-mediated alterations in gene expression, 
and is reportedly necessary for the expression of a subset of genes not reliably regulated 
by TCR monostimulation.  In contrast, Ctla-4 inhibits signals transmitted through the 
TCR and CD28 and reduces T cell responsiveness through mechanisms that reportedly 
alter the magnitude of transcriptional response but result in no qualitative changes.  Using 
our in vitro stimulation system, CD4+ TCR-tg lymphocytes were provided with either 
TCR monostimulation alone or in conjunction with CD28 ligation and/or Ctla-4 ligation.  
The CD28 and Ctla-4 ligands expressed on engineered APCs consisted of the scFV 
region of the relevant antibody linked to the B7 transmembrane region, were stably 
expressed, and at our chosen concentration of antigenic peptide resulted in a 3-5 fold 
increase in responder frequency by CD28 costimulation and a 50% Ctla-4-ligation-
mediated inhibition of CD28-mediated costimulation as assessed by responder frequency.  
Consistent with its known role, CD28 ligation served to enhance the magnitude of CD4+ 
lymphocyte responsiveness in a manner dependent on the strength of TCR signaling, with 
relatively greater effects on responder frequency evident at lower doses of antigenic 
peptide.   
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 CD28 ligation initiates a signaling cascade that is, relatively speaking, well 
established and defined.  However, the numerous points of interaction between signaling 
pathways makes it likely that downstream effectors of CD28 function are not all known, 
and the distal mediators of CD28 costimulation remain to be defined.  Ctla-4 has not been 
reported to regulate a unique subset of genes independent from those involved in TCR 
and CD28 signaling.  Using global expression profiling, we attempted a characterization 
of the transcriptome subsequent to varying condition of TCR,CD28 and Ctla-4 ligation.  
Using expression profiles of TCR-monostimulated cultures over several days as our 
baseline, we defined the magnitude and scope of changes in gene expression that result 
from CD28 costimulation.  We then characterized changes in global expression patterns 
that result from simultaneous Ctla-4 ligation concomitant with CD28.  Keeping in mind 
the results of our in vitro stimulation assays defining the temporal limitations of 
costimulatory signal integration, we sought to identify genes specifically regulated by 
CD28 and Ctla-4 ligation that can account for lasting phenotypic changes reported in the 
literature, and attempted to characterize subsequent alterations in transcriptome profiles 
that may be causally related. 
 
Serial timepoint analysis of the relative magnitude and similarity of gene regulation 
subsequent to TCR and costimulatory signal integration 
 The following pages comprising Figure 4.14 detail several facets of signal 
integration as they pertain to global expression patterns that result in the first twenty 
hours of T cell activation.  For each timepoint from 4-20 hours, screens were used to 
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Figure 4.13: TCR monostimulation results in robust gene regulation 
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Figure 4.13:  TCR stimulation results in robust gene regulation in activated cells in the 
absence of costimulation. 5C.C7 CD4+ lymphocytes were stimulated in vitro with 
engineered APCs prepulsed with MCC and expressing I-Ek.  At discrete intervals from 4- 
60 hours after initial stimulation, CD4+ lymphocytes were sorted for activation status 
based on expression of CD69, upregulation of CD4, and division status as described. 
Microarray analysis of RNA from populations purified for activation status was 
performed and the data normalized to naïve, unstimulated, peripheral CD4+ lymphocytes 
from 5C.C7 Rag-/- mice.  Biological replicates were obtained for all samples isolated 
prior to 24 hours.  Single samples were isolated at 24, 32, and 60 hours.  The cross gene 
error model was apllied (see Materials and Methods).  26 samples representing 17 
conditions of activated and naïve populations stimulated in vitro for 4-60 hours were 
obtained.  A)  Kinetic profile of 6041 genes with detectable expression in a minimum of 
4 TCR-stimulated samples is shown.  TCR ligation in the absence of costimulation results 
in a minimum two-fold regulation of more than 1500 genes within 4 hours after 
activation.  B) TCR triggering in the absence of costimulation delays gene expression 
changes over the first four hours, but results in comparable numbers of genes regulated 
more than two fold at all subsequent time points relative to lymphocytes stimulated in the 
presence of Ctla-4 and/or CD28 ligands that results in enhance responder frequency.
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identify genes regulated two-fold or more under varying conditions of stimulation.  
Genes were grouped by the pattern of responsiveness they showed to TCR, CD28 and 
Ctla-4 ligation as shown in the Venn diagrams.  Box plots demonstrate the predominant 
quality (up or down) and the relative magnitude of gene regulation.  Scatter plots, colored 
by the respective categories identified in the Venn diagram, illustrate the relative 
influence of CD28 and Ctla-4 signaling on the global expression pattern.  Together, these 
data indicate a predominantly quantitative influence of costimulation, but also indicate 
that subtle differences do result from differential ligation of costimulatory receptors. 
 
CD28-signaling accelerates changes in gene transcription mediated by the TCR 
 Differences in gene transcription that result from CD28 costimulation are most 
significant at earlier times.  As indicated in the box plots, CD28 results in robust gene 
regulation by four hours that is significantly greater than is seen with TCR signaling 
alone.  From 8-20 hours, however, there is no substantial difference in the overall 
magnitude of regulation occurring.  TCR stimulated and CD28 costimulated T cells both 
regulate the greatest number of genes at 8 hours.  CD28 signaling is unique in that it 
produces a transient, but significant downregulation of several hundred genes by 4 hours 
that is not recapitulated at any other timepoint regardless of activation condition.  CD28 
signaling also maintains numerous transcripts at higher levels at late timepoints relative 
to TCR ligation alone as indicated by the relative interquartile distances observed in the 
box plot at 12-24 hours.  
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Figure 4.14.1: Global Expression Patterns 4 Hours After Activation 
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Figure 4.14.2: Global Expression Patterns 8 Hours After Activation 
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Figure 4.14.3: Global Expression Patterns 12 Hours After Activation 
A: B: 
C: D: 
                   V      M37 M14/37  V     M37 M14/37 
                          CD69-         |         CD69+ 
 157
CD69- TCR CD69- TCR+CD28 CD69+ TCR CD69+ TCR+CD28
16.0 Naive 16.0 Activated
0.01
0.1
1
10
100
0.01 0.1 1 10
0.01
0.1
1
10
100
Time(Hours) 16.0 , Activation Status CD69+ , Treatment Type TCR+CD28 , Activated(Y/N) Activated  (normalized)
TCR+CD28 
T
C
R
+
C
D
2
8
+
C
t
l
a
-
4
 
0.01 0.1 1 10
0.01
0.1
1
10
100
Time(Hours) 16.0 , Activation Status CD69+ , Treatment Type TCR , Activated(Y/N) Activated  (normalized)
TCR 
T
C
R
+
C
D
2
8
 
234 218
138
89
105 418
1851
T16 V 2X
X
0
T16 2
T16 M37 2X
T16 M14-37 2X
TCR TCR+CD28 
TCR+CD28+Ctla-4 
  
Figure 4.14.4: Global Expression Patterns 16 Hours After Activation 
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Figure 4.14:  Comparisons of global expression patterns in 5C.C7 CD4+ lymphocytes 
stimulated in vitro by engineered APCs differentially expressing ligands for the TCR, 
CD28, and Ctla-4 were performed.  Figures 4.14.1-4 show comparisons of global 
expression profiles at 4 hour intervals from 4-16 hours respectively.  V, M37, and 
M14/37 designations correspond to the use of engineered APC clones expressing ligands 
for the TCR, TCR+CD28, and TCR+CD28+Ctla-4 respectively during stimulation.  All 
gene measurements reflect the average of two biological replicates normalized to 
expression in unstimulated, naïve, peripheral 5C.C7 CD4+ lymphocytes.  Panel A shows 
a box plot representation of the overall magnitude of gene regulations that occur in naïve 
and activated populations under the three conditions of stimulation in the presence of 
TCR, CD28, and Ctla-4 ligand expression.  The analysis included all genes with 
detectable expression in at least one of the six conditions displayed.  Box indents indicate 
the median change in gene expression.  Upper and lower box segments reflect the 
interquartile distance of all genes analysed.  Dashed extensions are set to 1.5 times the 
interquartile distance.  Highly regulated genes are represented by individual dots.  Panel 
C is a Venn diagram showing the number of genes regulated uniquely or in common by 
lymphoyctes stimulated in the presence of varying combinations of ligands for the TCR, 
CD28, and Ctla-4.  Panel B and D show scatter plots of genes regulated at the 
corresponding time under conditions of TCR+CD28 vs. TCR monostimulation or 
TCR+CD28+Ctla-4 vs. TCR+CD28 respectively.  The average expression values of 
individual genes are indicated by colored dots.  The color of gene dots corresponds to 
colors in the Venn diagram.  The medial blue line represents equivalent expression in the 
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two conditions displayed.  Outer parallel lines reflect two-fold changes in gene 
expression. 
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Figure 4.15:  Increasing convergence of target genes regulated by TCR 
and CD28 with time  
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Figure 4.15:  Expression patterns initiated by TCR and TCR+CD28 signaling converge 
over time.  5C.C7 CD4+ lymphocytes were stimulated with engineered APCs presenting 
MCC in the context of I-Ek in the presence or absence of CD28 costimulation.  
Populations purified for the positive expression of CD69 allowed for subsequent 
microarray analysis of the transcriptome and identification of gene regulation occurring 
over time in activated lymphocyte populations.  Biological duplicates were obtained and 
average gene expression at each time interval normalized to expression in naïve, 
unstimulated, peripheral CD4+ 5C.C7 lymphocytes.  Genes regulated more than two-fold 
were identified in both TCR monostimulated and CD28 costimulated samples.  Of all 
genes regulated more than two-fold at a a given timepoint, the percentages of genes 
regulated uniquely or in common by TCR and CD28 signaling are shown.  At all 
timepoints the majority of genes regulated at least two-fold are regulated under 
conditions of either TCR monostimulation or CD28 costimulation.  CD28 signaling 
uniquely regulates the greatest number of genes at early times after stimulation.  
However, subsets of genes remain uniquely regulated by TCR and CD28 signals beyond 
20 hours, suggesting that long-term differences in phenotype or responsiveness may 
result from altered costimulatory signaling during primary activation.   
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Additional evidence for accelerated regulation by CD28 is also evident in the trend 
towards increasing commonality of regulated genes over time.  At 4 hours, TCR and 
TCR+CD28 signaling resulted in a minimum 2-fold regulation of 1547 and 2555 genes 
respectively.  1103 genes were regulated in common, representing 71% and 43% of all 
genes regulated by TCR monostimulation or TCR+CD28 costimulation, respectively. As 
indicated in Figure 4.15, there is an increasing convergence of target genes regulated by 
TCR and CD28 signaling from 4-20 hours.  This trend is quantitative as well as 
qualitative, as scatter plots of regulated genes reveal reduced numbers of genes 
differentially regulated by CD28 costimulation over time relative to their level of 
expression in TCR monostimulated cells.  Thus, CD28 signaling results in a qualitatively 
different phenotype at early times by regulating the expression of genes not altered by 
TCR triggering.  In addition, CD28 mediates a quantitative effect on TCR-induced gene 
transcription by enhancing the level of expression of TCR regulated genes.  However, 
these differences in expression pattern and magnitude become increasingly less 
significant over time. 
 Delayed gene regulation in the absence of costimulation is a general trend 
that is also seen in the expression pattern of individual genes that are regulated upon T 
cell activation.  It has been proposed that CD28 costimulation is essential for the 
upregulation of genes that are necessary for cell-cycle entry and T cell survival.  Il-2 
upregulation, in particular, is considered a hallmark of CD28-mediated costimulation and 
was considered a primary mechanism by which CD28 augments T cell responses.  Our 
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data suggests that IL-2, and other known CD28 target genes are only affected by the 
absence of CD28 signaling to a relatively small degree. (Figure 4.16) 
CD28 has modest effects on the expression of numerous genes regulated by TCR 
ligation.  In contrast CD28 uniquely regulates only a very small subset of genes.  
Identification of genes differentially expressed upon CD28 ligation over numerous 
timepoints indicated that very few genes were consistently altered in a CD28-specific 
manner or inversely regulated relative to isolated TCR stimulation. Only 4 genes were 
more than 2-fold altered by CD28 ligation at all six timepoints from 4-24 hours.  20 
genes, 83 genes, and 315 genes were differentially expressed following CD28 ligation in 
5, 4, and 3 timepoints respectively.   A search for putative regulatory sequences identified 
33 elements (p<0.05) 5-10bp in length that were over-represented to a significant degree 
in the 1kb upstream of the 424 genes identified after multiple testing correction.  Thus, 
these genes are likely regulated in a coordinated manner by specific mediators of CD28 
signaling. 
Altered gene expression subsequent to CD28 signaling is dependent on 
transcription factor activity.  While it is possible that CD28 alters transcriptional profiles 
exclusively by post-translational control of transcription factor activity, CD28 may also 
mediate its pleiotropic effects on T cell phenotype via targeted regulation of transcription 
factor expression.  In addition, the rapidity with which CD28 regulates gene transcription 
suggests that specific mediators of CD28 function are active at early times.  To identify 
potential mediators of CD28 function, we screened genes differentially regulated by 
CD28 over at least three timepoints for known or potential transcription factors based on 
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Figure 4.16:  Isolated TCR ligation potently upregulates genes necessary 
for activation and survival 
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Figure 4.16:  TCR signaling is capable of potently upregulating numerous genes involved 
in T cell activation and survival.  5C.C7 CD4+ lymphocytes were activated in vitro by 
APCs engineered to express TCR ligands alone or in conjunction with CD28 ligands.  
Purified populations of naïve and activated T cells were obtained at time intervals from 4-
60 hours and analyzed by microarray.  Expression data was normalized to unstimulated, 
naïve, peripheral CD4+ 5C.C7 lymphocytes.  Expression profiles for genes reportedly 
regulated in a primarily CD28-dependent manner are shown on a log scale.  These 
include interleukin-2, CD25, NFκ-B, and the Bcl2 family member Bcl2sl1.  Expression 
profiles in TCR-stimulated naïve, TCR-stimulated activated, CD28 costimulated naïve, 
and CD28-costimulated activated population are shown left to right as indicated.  Error 
bars indicate standard deviation across biological replicates.  The absence of error bars 
indicates only one sample was analyzed for the corresponding condition of time, 
stimulation condition, and activation status.  In general, TCR monostimulated cells 
achieve peak expression of highly regulated genes at levels greater than 80% of maximal 
expression in CD28-costimulated cells.  The majority of genes show little appreciable 
difference in peak expression in the absence of CD28 signaling, but a significant minority 
of genes show consistently lower levels of expression across numerous timepoints.   
Broad screens for genes uniquely, or inversely, regulated by CD28 reveal few CD28-
speciific targets. 
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published information, homology to known proteins, and domain identity.  Using a non-
stringent screen intended to identify proximal regulators of transcription in addition to 
DNA-dependent transcription factors resulted in the identification of 57 unique genes.  
Hierarchical clustering of these genes based solely on their expression in naïve and 
activated populations under condition of TCR or TCR+CD28 stimulation shows several 
unique patterns of expression and identify subsets of genes displaying coordinate 
regulation (Figure 4.17). The 57 genes identified as transcriptional regulators specifically 
controlled by CD28 costimulation are shown in Table 4.2.1 and Table 4.2.2.  Only 27 of 
the 57 identified transcriptional regulators potentially mediating CD28 signaling are 
known to bind DNA.  These 27 genes display unique temporal expression patterns 
suggesting a potential hierarchy of regulation may exist between some of them.   
An examination of the stability and magnitude of expression changes mediated by 
CD28 upon differentially regulated transcription factors revealed that Lklf/Klf2 was the 
most significantly altered target over the first 24 hours of activation.  Because Lklf 
expression is downregulated by CD28 costimulation and maintained at low levels for the 
duration of activation, restricting a similar analysis to earlier intervals yields slightly 
different results.  However, across all early intervals (4-12 hours, 4-16 hours, and 4-20 
hours) the same five TF genes are ranked as the most highly regulated. (Table 4.3)  These 
include Myb, Zfp46, Batf, Ahr, and Lklf.  Of these five only Myb and Lklf are 
downregulated by CD28 costimulation, implying that they may serve to restrict processes 
involved in T cell activation.  Expression profiles further reveal that Lklf is unique in its 
Activated:  
TCR Stimulated 
Naïve:  
CD28 Co-stimulated 
Activated: 
CD28 Co-stimulated 
Naïve:  
TCR Stimulated 
167
Figure 4.17:  Hierarchical clustering reveals coordinated expression of CD28-induced transcriptional 
regulators 
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Figure 4.17:  Hierarchical clustering of 60 transcriptional regulators differentially 
expressed by CD28 ligation.  Microarray analysis was performed on TCR 
monostimulated and CD28 costimulated 5C.C7 CD4+ lymphocytes stimulated in vitro 
and purified for expression of activation markers at eight imepoints from 4-60 hours.  
Biological replicates were obtained for samples isolated prior to 24 hours in culture.  
Average expression values were normalized to unstimulated, naïve, peripheral CD4+ 
5C.C7 lymphocytes.  423 genes were regulated more than two fold by CD28 
costimulation at at least 3 of 6 timepoints analyzed prior to 24 hours relative to TCR 
monostimulation.  60 of the 423 genes are known or putative quiescence factors.  
Hierarchical clustering of the transcription factor expression profiles under condtions of 
TCR monostimulation and CD28 costimulation over time is shown.  The expression 
pattern of transcriptional regulators reflects the gene programs initiated upon T cell 
activation.  In this instance, clustering revealed several coordinately regulated patterns 
temporally offset over a period of 12 hours suggesting that causal relationships between 
them might exist.  Public database mining was used to guide predictions about relevant 
pathways that might relate observed expression via known associations, both direct and 
indirect.
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Table 4.2.1:  Transcriptional regulators potentially mediating CD28 
signaling effects 
 
 
Table4.2.1:  DNA-dependent/binding transcriptional regulators 
 
Probeset ID Common Name Description 
   
92703_at 2310032M22Rik RIKEN cDNA 2610016F04 gene 
97438_r_at 4631416I11Rik Mus musculus cDNA clone UI-M-BH2.2-aou-f-01-0-UI 3', mRNA  
97437_f_at 4631416I11Rik Mus musculus cDNA clone UI-M-BH2.2-aou-f-01-0-UI 3', mRNA. 
160495_at Ahr Mouse (strain C571) Ah-receptor (Ah) mRNA  
93444_at Batf basic leucine zipper transcription factor, ATF-like 
101475_at Bmi1 minor transcript; Mouse zinc finger protein (bmi-1) gene, complete cds. 
95755_at Csda cold shock domain protein A 
99917_at Ezh2 enhancer of zeste homolog 2 (Drosophila); vertebrate polycomb-group  
93250_r_at Hmgb2 high mobility group box 2 
98465_f_at Ifi16 interferon, gamma-inducible protein 16 
92440_at Irf6 interferon regulatory factor 6 
96109_at Klf2 Kruppel-like factor 2 (lung) 
99024_at Mad4 Max dimerization protein 4 
92644_s_at Myb myeloblastosis oncogene 
102209_at Nfatc1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
99076_at Nr1d2 nuclear receptor subfamily 1, group D, member 2 
104070_at Pcaf p300/CBP-associated factor 
94319_at Rab18 RAB18, member RAS oncogene family 
97948_at Rb1 Mouse retinoblastoma susceptibility protein (pp105 Rb) mRNA,  
104476_at Rbl1 retinoblastoma-like 1 (p107) 
98335_at Recc1 replication factor C 1 
92399_at Runx1 runt related transcription factor 1; AML1 homologue 
92199_at Stat5b signal transducer and activator of transcription 5B 
95536_at Tceb3 transcription elongation factor B (SIII), polypeptide 3 
102882_at Zfp46 zinc finger protein 46 
102872_f_at Zfp51 zinc finger protein 51 
95521_s_at Zfp68 zinc finger protein 68 
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Table 4.2.2:  Genes regulating transcription via DNA-independent mechanisms 
Probeset ID Common Name Description 
93055_at 1110054N06Rik RIKEN cDNA 1110054N06 gene 
103071_at 2810429C13Rik topoisomerase (DNA) II beta binding protein 
93204_r_at 3230402J05Rik RIKEN full-length enriched library, clone:E030006G18  
92992_i_at 5730497N03Rik trans-acting transcription factor 4 
93104_at Btg1 M.musculus btg1 mRNA. 
101583_at Btg2 TIS21; Mouse TIS21 gene, complete cds. 
101878_at Cd72 CD72 antigen 
100533_s_at Crem  
94395_at D3Ertd330e DNA segment, Chr 3, ERATO Doi 330, expressed 
160248_at D3Ertd330e DNA segment, Chr 3, ERATO Doi 330, expressed 
93493_at Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
103532_at Eomes eomesodermin homolog (Xenopus laevis) 
94332_at Ets1 cDNA clone IMAGE:1396445 5', mRNA sequence. 
160662_r_at Gata6 GATA binding protein 6 
102705_at Il2 interleukin 2 
103657_i_at Mtf2 Mus musculus cDNA clone UI-M-AP0-abe-e-08-0-UI 3', mRNA  
96152_at Narg1 NMDA receptor-regulated gene 1 
92248_at Nr4a2  
93915_at Pou2af1 POU domain, class 2, associating factor 1; BOB1/OBF1; coactivator 
160793_at Pou6f1 Mus musculus cDNA clone UI-M-BH0-akf-h-09-0-UI 3', mRNA sequence. 
92356_at Ptpn8 protein tyrosine phosphatase, non-receptor type 8 
104125_at Rnf12 ring finger protein 12 
100974_at Ssbp4 musculus cDNA clone UI-M-AL1-ahk-g-10-0-UI 3', mRNA sequence. 
94292_at Strap serine/threonine kinase receptor associated protein 
97238_at Tacc3 transforming, acidic coiled-coil containing protein 3 
94008_at Tceb1 transcription elongation factor B (SIII), polypeptide 1 
102681_at Tnfrsf4 tumor necrosis factor receptor superfamily, member 4 
94809_at Tsg101 tumor susceptibility gene 101 
102263_at Zfp143 zinc finger protein 143 
103753_at Zzz3 zinc finger, ZZ domain containing 3 
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Table 4.2:  57 transcription factor were identified as stably and differentially regulated 
upon CD28 ligation. 5C.C7 CD4+ lymphocytes were stimulated with engineered APCs 
presenting MCC in the context of I-Ek in the presence or absence of CD28 costimulation.  
Populations purified for the positive expression of CD69 allowed for subsequent 
microarray analysis of the transcriptome and identification of gene regulation occurring 
over time in activated lymphocyte populations.  Biological replicates were obtained, and 
average gene expression levels were normalized to unstimulated, naïve, peripheral CD4+ 
5C.C7 lymphocytes.  57 known or suspected transcriptional regulators displayed a 
minimum two-fold change in expression in at least 3 of the six timepoints analyzed 
between 4 and 24 hours upon CD28 costimulation.  Table 4.2.1 lists the 27 transcription 
factors differentially regulated by CD28 signaling that are known to operate via DNA-
dependent mechanisms.  Table 4.2.2 lists the 30 transcriptional regulators known to 
function by DNA-independent mechanism that are differentially expressed subsequent to 
CD28 costimulation.
     Timepoint 
Probeset ID Common Name Average FC Abs FC T4 T8 T12 T16 T20 T24 
96109_at Klf2 0.19 -5.40 5.40 0.696 0.215 0.0681 0.0353 0.0681 0.029
92644_s_at Myb 0.22 -4.62 4.62 0.0586 0.451 0.0797 0.117 0.238 0.353
160495_at Ahr 3.46 3.46 3.46 0.406 8.743 2.589 4.14 2.853 2.03
102882_at Zfp46 3.28 3.28 3.28 0.611 12.77 0.297 3.081 0.747 2.166
97438_r_at 4631416I11Rik 2.95 2.95 2.95 0.564 4.914 0.448 1.198 0.519 10.03
99076_at Nr1d2 2.80 2.80 2.80 0.349 5.78 0.874 1.127 0.932 7.724
93444_at Batf 2.77 2.77 2.77 7.104 2.892 2.184 1.618 1.658 1.183
97437_f_at 4631416I11Rik 2.23 2.23 2.23 0.33 7.331 0.666 1.363 0.942 2.745
95521_s_at Zfp68 2.20 2.20 2.20 0.409 7.048 0.823 1.058 0.833 3.036
99024_at Mad4 0.46 -2.17 2.17 0.572 0.39 0.512 0.453 0.439 0.405
98335_at Recc1 2.06 2.06 2.06 0.417 1.508 1.127 2.91 2.062 4.359
92199_at Stat5b 1.96 1.96 1.96 3.566 2.218 2.319 1.189 1.657 0.834
95536_at Tceb3 1.88 1.88 1.88 0.805 2.978 2.619 2.351 1.481 1.04
95755_at Csda 1.85 1.85 1.85 2.486 2.274 1.434 1.45 2.164 1.318
102872_f_at Zfp51 1.82 1.82 1.82 2.513 3.13 0.759 0.809 0.709 2.984
102209_at Nfatc1 0.56 -1.77 1.77 0.953 0.432 0.339 0.467 0.52 0.678
99917_at Ezh2 1.67 1.67 1.67 0.678 0.783 2.003 2.464 1.806 2.275
92440_at Irf6 0.63 -1.59 1.59 0.943 0.923 0.781 0.442 0.322 0.362
104070_at Pcaf 0.66 -1.51 1.51 0.125 1.29 0.385 0.551 0.474 1.157
97948_at Rb1 1.50 1.50 1.50 0.141 1.125 0.66 2.802 1.325 2.921
104476_at Rbl1 1.41 1.41 1.41 0.48 2.373 0.748 1.113 1.001 2.766
101475_at Bmi1 1.39 1.39 1.39 0.101 2.615 0.935 1.64 0.758 2.314
93250_r_at Hmgb2 1.39 1.39 1.39 0.386 0.465 1.288 0.828 1.993 3.379
92703_at 2310032M22Rik 1.39 1.39 1.39 0.458 0.174 1.351 2.218 1.202 2.926
98465_f_at Ifi16 1.29 1.29 1.29 1.665 0.592 0.155 0.422 0.505 4.401
94319_at Rab18 1.27 1.27 1.27 0.193 2.014 0.896 1.362 0.984 2.173
92399_at Runx1 1.25 1.25 1.25 0.339 0.31 0.444 0.893 2.647 2.871
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Table 4.3: Lklf is the most significantly and stably altered transcription factor regulated by CD28 
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Table 4.3:  Analysis of the magnitude and stability of CD28 mediated transcriptional 
regulation of transcription factors.  27 DNA-dependent transcription factors (TFs) were 
differentially expressed following CD28 signaling in activated 5C.C7 CD4+ lymphocytes 
stimulated by engineered APCs in vitro.  (minimum two-fold change in expression 
relative to TCR-monostimulated cells for >3 timepoints from 4-24 hours).  Only 6 TFs 
were, on average, downregulated during the first 24 hours of T cell activation, and only 
two, Myb and Lklf/Klf2, were stably downregulated more than two-fold.  However, Lklf 
and Myb were the most significantly regulated transcription factors upon CD28-
costimulation over the first 24 hours of activation. Bolded common names denote the 5 
genes that are the most highly regulated over any interval from 4-20 hours.  
 
FC: Fold change. 
Abs FC: Absolute Fold Change 
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ability to maintain differential expression by CD28 signaling over the long term. (Figure 
4.18)   
CD28 enhances T cell activation by amplifying proximal signaling events and by 
induction of gene transcription leading to enhanced survival, quickened cell-cycle entry, 
and more efficient effector function.  Moreover, CD28 signaling may abrogate 
mechanisms of tolerance such as anergy induction.  The identification of genes 
specifically regulated by CD28 in the context of antigen receptor stimulation provides 
novel opportunities for therapeutic manipulation of the pathways involved and will lead 
to a greater understanding of T cell tolerance.  It is an intriguing possibility that the  
the ability of CD28 to modestly enhance the expression of numerous genes may have 
unrecognized biological significance.  It is clear that TCR stimulation is capable of 
activating all pathways necessary for activation, cell cycle entry, and survival.  Moderate 
increases in these processes, along with the increase in responder frequency that results 
from CD28 engagement, could potentially lead to physiologically significant changes in 
the context of a clonally expanding population of T cells.  Thus, modest changes in gene 
expression resulting from CD28 ligation can be significant if the differential expression is 
maintained long term.  Identifying factors that might mediate such an effect may reveal 
the mechanisms by which CD28 influences numerous processes in immunoregulation.   
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Figure 4.18:  Stable, long-term CD28 mediated regulation of Lklf 
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Figure 4.18:  Expression profiles reveal that CD28-mediated regulation of Lklf provides 
stable changes in gene expression relative to TCR monostimulation.  5C.C7 CD4+ 
lymphocytes were activated in vitro by APCs engineered to express TCR ligands alone or 
in conjunction with CD28 ligands.  Purified populations of naïve and activated T cells 
were obtained at time intervals from 4-60 hours and analyzed by microarray.  Expression 
data was normalized to unstimulated, naïve, peripheral CD4+ 5C.C7 lymphocytes.  60 
known or suspected transcriptional regulators were differentially expressed at least two-
fold by CD28 signaling in a minimum of 3 of 6 timepoints analyzed between 4 and 24 
hours.  Expression profiles for the four most highly and consistently regulated 
transcription factors are shown.  Expression profiles in TCR-stimulated naïve, TCR-
stimulated activated, CD28 costimulated naïve, and CD28-costimulated activated 
population are shown left to right as indicated.  Error bars indicate standard deviation 
across biological replicates.  The absence of error bars indicates only one sample was 
analyzed for the corresponding condition of time, stimulation condition, and activation 
status.  The apparent decline of Lklf in TCR monostimulated samples at late timepoints 
could result from activation-induced downregulation independent of CD28, or may 
reflect inappropriate data normalization as a result of the magnitude of expression 
changes that occur in dividing cells relative to naïve cells or activated cells at early 
timepoints. 
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Ctla-4 Influences the Global Expression Profile of CD28-costimulated T Cells 
 One report has investigated the role of Ctla-4 in modifying the global 
transcriptional response to activating stimuli delivered throught the TCR and CD28(54).  
The results suggested that Ctla-4 ligation in the absence of CD28 costimulation did not 
alter the genomic expression pattern subsequent to TCR ligation.  In addition, the effect 
of Ctla-4 ligation was limited to a partial suppression of CD28-mediated gene regulation 
and did not result in qualitative differences in gene expression.  Our system of in vitro 
stimulation has been designed to allow tight control of stimulating and inhibitory 
signaling in TCR-tg T cells while allowing for physiologically relevant interactions with 
APC-expressed ligands.  Moreover, purification of naïve and activated cells increases the 
likelihood of detecting subtle changes in gene expression that might be masked by the 
homogeneity of unsorted cells under varying conditions of costimulation.  In vitro, cells 
become activated despite the absence or presence of of CD28 and and Ctla-4 
respectively.  Moreover, some cells remain naïve by ignorance in the absence of Ctla-4 
signaling resulting in identical phenotypes maintained by different mechanisms.  We 
propose that Ctla-4 maintains peripheral tolerance, in part, by up-regulating factors 
necessary for the maintenance of self-tolerance and quiescence.  In the context of T cell 
activation, the activity of such factors may be manifested in the maintenance of a naïve 
phenotype, altered parameters of T cell activation and division, or long-term phenotypic 
changes. Thus, detecting transcriptional regulation subsequent to Ctla-4 ligation may 
require higher stringency protocols than have been used previously. 
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Ctla-4 inhibits CD28 mediated changes in gene transcription 
 The influence of Ctla-4 on the magnitude of CD28-mediated transcriptional 
regulation is seen in Figures 4.14.1 to 4.14.4.  Box plots reflect the ability of Ctla-4 to 
inhibit transcriptional regulation to much greater degree at early times after activation.  
At the genomic level, the ability of Ctla-4 to influence the scope of gene regulations is 
abolished by 12 hours.  This is reflected graphically in Figure 4.13 panel B.  As indicated 
by the Venn diagrams in Figure 4.14, the majority of gene expression changes occurring 
subsequent to TCR+CD28 ligation are not qualitatively affected by Ctla-4, suggesting 
that Ctla-4 functions to inhibit the progressive nature of CD28 transcriptional regulation.  
Over time, this is reflected in the convergence of target gene identities regulated in the 
presence or absence of Ctla-4 (Figure 4.19).  The decreasing relevance of Ctla-4 ligation 
over time, as it relates to the global expression profile is best seen in the serial scatter 
plots comparing gene expression levels in samples experiencing different combinations 
of CD28 or CD28+Ctla-4 costimulation. (Figure 4.14)  In contrast to the broadly 
distributed levels of relative expression seen at 4-8 hours, later times reveal a 
predominant 1:1 expression ratio reflected in the close grouping of genes around the axis.  
However, a subset of genes remains differentially regulated by Ctla-4 at every time point 
investigated. 
 We have proposed that Ctla-4 maintains immunotolerance, in part, by inducing 
the expression of transcriptional regulators that impose lasting phenotypic changes.  Ctla-
4 coligation with CD28 resulted in a minimum 2-fold change in expression of 11, 23, 
102, and 322 genes in 6, 5, 4, or 3 of the six timepoints between 4 and 24 hours.  Of these 
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Figure 4.19: Ctla-4 differentially regulates a small subset of genes 
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Figure 4.19:  Ctla-4- and CD28-signaling pathways converge on the same set of target 
genes.  5C.C7 CD4+ lymphocytes were stimulated with engineered APCs presenting 
MCC in the context of I-Ek in the presence or absence of Ctla-4 ligands in conjunction 
with CD28 costimulation.  Populations purified for the positive expression of CD69 
allowed for subsequent microarray analysis of the transcriptome and identification of 
gene regulation occurring over time in activated lymphocyte populations.  Biological 
duplicates were obtained and average gene expression at each time interval normalized to 
expression in naïve, unstimulated, peripheral CD4+ 5C.C7 lymphocytes.  Genes 
regulated more than two-fold were identified lymphocytes activated in the presence of 
Ctla-4 and/or CD28 ligands.  Of all genes regulated more than two-fold at at a given 
timepoint, the percentages of genes regulated uniquely or in common by Ctla-4 and 
CD28 signaling are shown.  At all timepoints the majority of genes regulated at least two-
fold are regulated under conditions of either CD28 costimulation or combined CD28 and 
Ctla-4 costimulation.  CD28 signaling uniquely regulates the greatest number of genes at 
early times after stimulation.  However, subsets of genes remain uniquely regulated by 
Ctla-4 and CD28 signals beyond 20 hours, suggesting that long-term differences in 
phenotype or responsiveness may result from altered costimulatory signaling during 
primary activation.  Over time there is increasing convergence of genes regulated more 
than two-fold under isolated CD28 costimulation or combined CD28/Ctla-4 ligation.  
Ctla-4 suppresses CD28 mediated transcriptional regulation to a greater degree at very 
early times after activation.   
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Table 4.4:  Transcriptional factors stably regulated by Ctla-4 ligation 
 
Probeset ID Timepoints 
Observed 
Common Name Description 
92344_at 6 Smarca3 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 3 
99076_at 5 Nr1d2 nuclear receptor subfamily 1, group D, member 2 
96109_at 5 Klf2 Kruppel-like factor 2 (lung) 
92992_i_at 5 5730497N03Rik trans-acting transcription factor 4 
101528_at 5 Tcea1  
92934_at 4 Zfp90 zinc finger protein 90 
104669_at 4 Irf7 interferon regulatory factor 7 
102959_at 4 Tle4 transducin-like enhancer of split 4 
101919_at 4 Zfx zinc finger protein X-linked 
99001_at 4 Zfp292 zinc finger protein 292 
95530_at 4 6330549H03Rik general transcription factor II A, 1 
99950_at 3 Tbp TATA box binding protein 
99558_at 3 Ccnc cyclin C 
98628_f_at 3 Hif1a hypoxia inducible factor 1, alpha subunit 
98465_f_at 3 Ifi16 interferon, gamma-inducible protein 16 
98030_at 3 Trim30 tripartite motif protein 30 
95617_at 3 Rbl2 retinoblastoma-like 2 
94467_at 3 Cebpz CCAAT/enhancer binding protein zeta 
93611_at 3 Tbx6 T-box 6 
93250_r_at 3 Hmgb2 high mobility group box 2 
92991_at 3 Sp4 trans-acting transcription factor 4 
92468_at 3 Gbif globin inducing factor, fetal 
104476_at 3 Rbl1 retinoblastoma-like 1 (p107) 
101180_at 3 Atm ataxia telangiectasia mutated homolog (human) 
100130_at 3 Jun Jun oncogene 
99462_at 3 Top2b topoisomerase (DNA) II beta 
98855_r_at 3 A930001N09Rik RIKEN cDNA A930001N09 gene 
98629_f_at 3 Hif1a  
95879_at 3 Asf1a ASF1 anti-silencing function 1 homolog A  
94325_at 3 Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
103074_f_at 3 Taf9 TAF9 RNA polymerase II, (TBP)-associated factor 
101529_g_at 3 Tcea1  
101439_at 3 Arl6 myc induced nuclear antigen 
100533_s_at 3 Crem  
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Table 4.4:  TCR and CD28-mediated stimulation of 5C.C7 CD4+ lymphocytes in 
thepresence of Ctla-4 ligands results in the differential expression of known transcription 
factors.   5C.C7 CD4+ lymphocytes were stimulated with engineered APCs presenting 
MCC in the context of I-Ek in the presence or absence of Ctla-4 ligands in conjunction 
with CD28 costimulation.  Populations purified for the positive expression of CD69 
allowed for subsequent microarray analysis of the transcriptome and identification of 
gene regulation occurring over time in activated lymphocyte populations.  Biological 
duplicates were obtained and average gene expression at each time interval normalized to 
expression in naïve, unstimulated, peripheral CD4+ 5C.C7 lymphocytes.  Table 4.4 lists 
transcription factors displaying more than two-fold differential expression identified in 
lymphocytes activated in the presence of Ctla-4 and/or CD28 ligands in the first 24 hours 
of in vitro stimulation.  Six timepoints from 4-24 hours after stimulation were examined, 
and the number of timepoints at which a minimum two-fold differential expression was 
detected in the presence of Ctla-4 ligands is indicated for each transcription factor 
identified.
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genes, 34 are known or suspected transcriptional regulators.  (Table 4.4)  In addition, 8 of 
these genes were identified as specific targets of CD28 signaling in previous screens, 
suggesting that the balance of stimulatory and inhibitory costimulation may define 
genomic expression patterns through the action of these transcription factors.  When 
weighted by the average change in expression seen over increasing intervals from 4-12 
hours up to 4-24 hours, the same 8 genes are ranked highest.  These include Lklf, Rbl2, 
Hmgcs1, Hif1a, cyclin C, Zfx, Tcea1, and a Riken clone (probeset ID 92992_i_at). 
In contrast to the rapid downregulation of Lklf that occurs with unopposed CD28 
costimulation, Lklf appears to be downregulated in activated cells at later timepoints 
(beyond 32 hours) under conditions of Ctla-4 ligation (Data not shown).  However, the 
statistical significance of Lklf differential regulation by Ctla-4 increases over time, in 
apparent contrast to its expression profile.   This may reflect the difficulty involved in 
choosing appropriate normalization standards when comparing vastly different biological 
samples.  This analysis makes use of data normalized to expression levels in ex vivo 
CD4+ lymphocytes.  The magnitude and scope of gene regulation that occurs during T 
cell activation makes standard microarray normalization steps insufficient over long 
periods of time.  Screens used to identify differentially regulated genes in samples 
processed at the same timepoint are internally controlled.  In contrast, gene expression 
profiles normalized to the ex vivo sample are not internally controlled.  Thus, the trends 
observed, and the relative expression observed under varying stimulation conditions at 
any given time remains reliable, but the magnitude of long-term trends in gene expression 
will not necessarily correlate with direct measurements of fold change.   
 184
 
Discussion 
 Transcriptional changes during lymphocyte activation have been previously 
characterized.  Our system improves on previous reports by utilizing phenotypically pure 
sample populations homogenous for activational history and stimulated by engineered 
APCs capable of differentially signaling through the TCR, CD28, and Ctla-4.  In 
addition, we have investigated genomic-scale expression patterns at numerous timepoints 
prior to cell-cycle entry allowing for identification of downstream mediators of 
costimulatory function that may determine distal outcomes of proximal integration of 
TCR, CD28, and Ctla-4 signals.  Our results provide the most comprehensive and 
stringently controlled kinetic study of genomic expression patterns in activated 
lymphocytes yet available.  While an exhaustive categorization of observed changes is 
beyond the scope of this work, our data does provide numerous findings that inform our 
understanding of signal integration as it occurs during lymphocyte activation. 
 The temporal parameters governing antigen-receptor and costimulatory signal 
integration have not been well defined.  In our system, TCR triggering activates all 
relevant pathways within the first two hours and can result in commitment to activation 
as early as one hour after stimulation.  In contrast, signals through CD28 and Ctla-4 are 
persistent over 12-16 hours and are integrated accordingly.  This suggests a distinctly 
different mechanism of signaling is utilized.  However, CD28 is also capable of 
significantly enhancing responder frequency to TCR engagement as early as one hour 
after stimulation.  Thus, CD28 functions to lower the threshold of activation in response 
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to antigen receptor engagement over an externded period, accelerates the rate of 
transcriptional regulation leading to cell-cycle entry at the population level, and 
marginally amplifies the transcriptional response of the majority of genes regulated by 
TCR signaling in activated cells.  However, alterations in gene regulation occurring as a 
result of CD28 ligation are heterogeneous, and a subset of genes is specifically sensitive 
to CD28-mediated regulation.  In contrast, the availability of Ctla-4 ligands serves to 
counteract CD28-mediated costimulation primarily by raising the threshold of activation 
without shifting the peak of the antigen-dose response curve or altering the kinetics of 
activation or cell-cycle entry.  In addition, the availability of Ctla-4 ligands has minor 
effects on the global expression profile of naïve or activated CD4+ T cells, and only a 
small number of genes are differentially regulated in the presence of Ctla-4 ligands for 
any appreciable amount of time.  Like CD28, Ctla-4 modifies the transcriptional response 
to the greatest degree at very early times after stimulation, and the effect is largely 
abrogated by twenty hours post-stimulation.   Thus, both CD28 and Ctla-4 appear to 
regulate membrane-proximal signaling events controlling T cell activation prior to one 
hour, yet also serve to modify the clonal response to TCR engagement over prolonged 
periods in a TCR-independent manner.  Numerous models have been proposed to explain 
the disparate effects of costimulation on T cell activation, and our results support the 
notion that CD28 and Ctla-4 function at multiple levels to regulate T cell resonses.   
TCR ligation results in rapid changes in the phosphorylation status of numerous 
proteins and triggers rapid fluxes in intracellular calcium with the net effect of initiating 
changes in gene transcription through the activation of specific transcription factors(373-
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375).  Using in vitro stimulated TCR-transgenic CD4+ lympohcytes we have shown that 
TCR ligation alone results in antigen dose-dependent activation of primary T cells 
leading to broad transcriptional regulation and commitment to cell-cycle entry and 
division.  In contrast to published reports, TCR ligation in the absence of CD28 
costimulation resulted in robust upregulation of genes essential for cell survival, division, 
and effector function including interleukin-2 and Bcl-xL.  Moreover, the lack of CD28-
mediated signaling did not result in altered secondary responses or increased cell death.  
Thus, TCR signaling was capable of activating all pathways necessary for CD4+ T cell 
activation within 1-2 hours resulting in a minimum two-fold regulation of nearly 50% of 
all genes with detectable expression by 8 hours after stimulation suggesting that TCR 
engagement is sufficient for productive activation in CD4+ lymphocytes. 
CD28 ligation lowers the threshold of activation and results in increased 
responder frequency within one hour of TCR-mediated signaling.  In addition, CD28 
signaling potentiates TCR-mediated activation signals over a prolonged period of 12-16 
hours and enhances the expression patterns initiated by TCR engagement.  However, In 
contrast to published reports, our data indicates that CD28 does not enhance expression 
of TCR-induced genes to the degree reported.  The observed difference is likely a result 
of the use of purified populations in our analysis.  In our system, TCR signaling is 
generally capable of regulating gene expression to 80% or more of the maximal level 
observed with CD28 costimulation.  Moreover, CD28 has the greatest qualitative 
influence on genomic expression patterns in activated CD4+ lymphocytes at very early 
times after TCR stimulation, with diminishing effect over time. Thus, the primary effect 
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of CD28 is to lower the threshold of activation by influencing membrane proximal 
signaling events while sustaining TCR-mediated activation signals over an extended 
period.  In addition, our results suggest that CD28 uniquely regulates a very small subset 
of genes not altered by isolated TCR engagement.  The functional result of CD28 ligation 
is increased responder frequency at the population level, accelerated kinetics and 
amplified magnitude of transcriptional regulation at the cellular level, and specific 
regulation of a small subset of genes such as Lklf and Batf.  Thus, CD28 has a primarily 
quantitative effect on T cell responsiveness and clonal activation, but does induce 
qualitatively unique gene programs of unknown significance via regulation of genes that 
are, generally, not well characterized in lymphocytes. 
CD28 is postulated to increase T cell activation by numerous mechanisms.  CD28 
ligation has been shown to enhance phosphorylation of key signaling intermediates 
operating downstream of the TCR, to activate specific signaling pathways involving 
PI3K independent of TCR ligation, and to stabilize T cell interaction with APCs resulting 
in enhanced activation and gain of effector function by TCR-dependendent and –
independent mechanisms.  The ability of CD28 to enhance responder frequency to TCR 
stimulation within one hour of antigen encounter supports the notion that CD28 functions 
to potentiate membrane proximal signaling events.  However, we have also shown that 
CD28-signaling is capable of enhancing responder frequency when ligated up to 12 hours 
after initial TCR stimulation.  These results suggest that CD28 ligation permits T cell 
activation in response to otherwise sub-mitogenic TCR signaling.  In conjunction with 
the identification of genes uniquely regulated by CD28 in activated CD4+ lympohocytes, 
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these data also suggest that CD28 transmits a signal that operates independently from 
TCR signaling pathways.  While our system can not address the relevance of additional 
costimulatory signals that may result from prolonged T cell interaction with an APC, the 
extended kinetics of CD28 signal integration support a model of costimulation in which 
rapid sub-mitogenic signaling resulting from TCR triggering allows for the relatively 
slow development of an unresponsive state that can be rescued by subsequent 
costimulatory signals.  Thus, prolonged low affinity TCR interactions may program T 
cells to become unresponsive with kinetics that allow for extended integration of 
costimulatory signals. 
 Ctla-4 ligand-expressing APCs suppressed CD28-mediated amplification of TCR-
induced transcriptional changes and counteracted CD28-mediated increases in responder 
frequency.  In addition the availability of Ctla-4 ligands delayed the rapid increase in 
gene regulation enabled by CD28 following antigen recognition.  The delay in 
trancscriptional responsiveness may allow time for the integration of additional 
costimulatory signals prior to commitment.  However, the availability of Ctla-4 ligands 
did not shift the antigen-specific dose response curve of TCR-tg CD4+ T cells,  alter the 
kinetics of transcriptional regulation beyond eight hours,  delay cell-cycle entry, or 
change the kinetics of CD28-signal integration.  Thus, the critical effect of Ctla-4 was to 
increase the threshold of activation in a primarily CD28-dependent manner.  
Interestingly, four hours after stimulation CD4+ T cells activated in the presence of Ctla-
4 ligands displayed a global suppression of transcriptional regulation that was more 
pronounced than TCR monostimulation when compared with cells receiving CD28 
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costimulation.  This suggests that Ctla-4 is capable of differentially regulating 
transcriptional responses to TCR ligation and CD28-mediated effects on threshold of 
activation.  Moreover, while expression patterns resulting from CD28 and Ctla-4 ligation 
converge over time, a small subset of genes remains differentially expressed at late 
timepoints.  Thus, it remains likely that Ctla-4 differentially influences CD28 signaling 
pathways and may provide unique signals independent from CD28.  It is tempting to 
speculate that the stable differential expression of these genes may mediate a long-term 
phenotypic change reflecting costimulatory conditions.  However, during secondary 
stimulations in vitro, we did not detect changes in activation responses that correlated 
with the presence or absence of costimulation in the primary stimulation.  Instead, T cell 
recall responses were altered to reflect the overall strength of signals they received in the 
primary stimulation as measured by responder frequency (Data not shown).  Thus. we 
have failed to identify a lasting phenotype reflective of primary stimulation conditions 
with regards to CD28 and Ctla-4 ligation.   However, our results suggest that Ctla-4 alters 
the threshold of activation soon after TCR triggering by counteracting CD28-mediated 
signals, and that this effect persists as long as CD28 signaling is maintained.   
 At the transcriptional level, we were able to detect significant and stable 
differential regulation of a small subset of genes by both CD28 and Ctla-4.  Interestingly, 
the most significantly altered transcription factor identified is also a putative quiescence 
factor.  Lklf was specifically downregulated by CD28 ligation in activated CD4+ T cells, 
and it’s expression was maintained in the presence of available Ctla-4 ligands.  Thus, 
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Lklf regulation may reflect the sum of signals received through CD28 and Ctla-4, and the 
stability of regulation over time indicates that it may mediate long-lasting effects.   
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Lklf is putative T cell quiescence factor 
 Cellular quiescence is a state characterized by decreased cell size and metabolic 
activity characteristic of unstimulated, mature peripheral lymphocytes.  While quiescence 
was previously considered a default state for lymphocytes in the absence of activating 
stimuli, it is now clear that active process of gene regulation are involved in the 
maintenance of the resting state characteristic of peripheral lymphocytes.  The gene 
program regulating quiescence operates through constitutive activity of specific 
transcription factors that maintain survival while preventing unwarranted cellular 
activation.  Similarly, the induction of clonal anergy restricts T cells to a state of 
quiescence in the absence of specific signals.  Moreover, inhibition or loss of T cell-
expressed quiescence factors results in immune activation and lymphoproliferation.  
Thus, quiescence factors are key regulators of gene programs controlling peripheral self-
tolerance and autoimmunity, and are potential candidates for therapeutic manipulation. 
Lung Kruppel-like factor (Lklf) is a zinc-finger transcription factor(376) that 
regulates T cell quiescence and survival(377).  The Lklf gene is composed of three exons 
and is predominantly regulated by a single upstream promoter element (-138/-111bp) that 
does not correspond to known transcription factor consensus sequences(378).  Lklf 
expression is high in naïve T cells, reportedly down-regulated upon antigen stimulation, 
and re-expressed in memory T cells as a result of IL-7 stimulation(379) where its 
expression correlates with long-term survival(380).  Lklf expression in naïve T cells is 
IL-7 independent and is upregulated by ERK5 activation of  MEF2 transcription 
factors(381).  Lklf is upregulated two to three fold in Jurkat cells when SHIP-1 is 
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overexpressed, and correlates with significant growth inhibition(382).  Recently, 
numerous factors critical for Lklf expression have been identified including GRp-78, 
hnRNP-U and –D, CBF, PCAF, CREB, and SWI/SNF(383).  However, the mechanism 
and signaling pathways responsible for Lklf regulation in lymphocytes remain 
incompletely understood. 
The Lklf protein contains a transactivation domain and an autoinhibitory domain 
that mediates negative regulation of Lklf transactivation upon binding the E3 ubiquitin 
ligase, WWP1(384).   Lklf-deficiency is embryonic lethal and results in widespread 
growth and developmental defects in numerous tissues(385). Moreover, Lklf 
overexpression in certain transformed cell lines is sufficient for the induction of a 
quiescent phenotype characterized by decreased proliferation, reduced cellular 
metabolism and cell size, and reduced expression of activation markers on the cell 
surface(386).  Lklf is reported to maintain cellular quiescence by negatively regulating 
expression of the proto-oncogene, c-myc, and a dominant negative form of c-myc 
recapitulates many of the phenotypic changes that result from Lklf deficiency(386).  Lklf 
negatively regulates expression of the proto-oncogene Vav in some tissues, a critical 
determinant of T cell activation and membrane proximal signaling in antigen receptor 
stimulated T cells(387).  Lklf is also reported to reciprocally regulate genes involved in 
cellular division (p21WAF1/CIP1)(388)and apoptosis (WEE1)(389)  Despite its central 
role in the maintenance of T cell quiescence, little is known about the role Lklf plays 
during T cell activation.   
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 Ctla-4 functions to prevent T cell activation to self-antigen in the periphery, and 
preserves the quiescent phenotype of naïve T cells.  Thus, we proposed that Ctla-4 
operated to maintain peripheral self-tolerance by regulating the expression of quiescence 
factors.  An initial screen for genes differentially regulated by Ctla-4 ligation in actively 
dividing cells identified Lklf as positively regulated by Ctla-4 engagement (Figure 5.1).  
Inspection of Lklf expression within the context of a kinetic study of global expression 
profiles in antigen-stimulated TCR-tg T cells under varying conditions of costimulation 
indicated a central role for CD28 and Ctla-4 signals in the regulation of Lklf expression 
(Figure 5.2).  Moreover, numerous genes regulated by antigen receptor stimulation were 
coordinately regulated with Lklf upon costimulation, suggesting that integration of 
costimulatory signals originating with CD28 and Ctla-4 may operate via Lklf to regulate 
distal events in T cell activation.  Thus, we sought to define Lklf-regulated genes as a 
means of better understanding the genetic programs that result from TCR, CD28, and 
Ctla-4 ligation. 
 
Expression pattern of Lklf resulting from CD28 and Ctla-4 costimulation 
 The observed expression of Lklf in our kinetic analysis of genomic expression 
profiles in activated T cells is internally controlled, ensuring that relative measurements 
and the trends that result are reliable.  However, appropriate data normalization is 
dependent on certain assumptions that may be invalidated by the high percentage of 
genes being regulated in activated or dividing lymphocytes.  In order to more precisely 
determine the expression of Lklf in stimulated cells sorted for activation status under 
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Figure 5.1:  Ctla-4 ligation maintains high Lklf expression in dividing CD4+ T cells 
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6: TCR+CD28+Ctla-4 stimulated cells, undivided at 60 hours 
7: TCR+CD28+Ctla-4 stimulated cells, dividing at 60 hours 
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Figure 5.1:  Ctla-4 ligation during activation influences Lklf expression in dividing 
5C.C7 TCR-tg CD4+ T cells stimulated with TCR and CD28 ligands. 5C.C7 CD4+ 
lymphocytes were activated in vitro by coculture with engineered APCs expressing 
varying combinations of ligands for the TCR, CD28 and Ctla-4.  60 hours after 
stimulation, naïve and dividing lymphocytes were purified by FACS based on dilution of 
the cytoplasmic dye CFSE.  Unstimulated, naïve, peripheral CD4+ 5C.C7 lymphocytes 
were purified ex vivo.  Previously activated cells were obtained by stimulating 5C.C7 
CD4+ T cells in the presence of engineered APCs expressing TCR and CD28 ligands.  10 
U/ml of IL-2 was added at day 3 after stimulation, and resting previously activated cells 
were harvested at day 7 after stimulation.  RNA was isolated from all samples and RT-
PCR was performed to provide semi-quantitative measurement of Lklf and tubulin gene 
expression.  Lklk is highly expressed in naïve peripheral CD4+ lymphocytes, its 
expression is maintained in non-dividing cells culture in stimulating conditions, and it is 
downregulated during T cell activation following TCR and CD28 stimulation.  Cells 
activated in the presence of Ctla-4 ligands, in addition to TCR and CD28 stimulation, 
maintain Lklf expression despite entry into cell-cycle (Panel A).  4-fold serial dilutions 
indicate that Lklf is maintained at levels nearly 16-fold greater in dividing cells following 
stimulation in the presence of Ctla-4 ligands relative to TCR and CD28 stimulation 
(Panel B).  Panel B samples were normalized to tubulin expression as seen in panel A. 
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Figure 5.2: Ctla-4 ligation reverses CD28-mediated Lklf downregulation 
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Figure 5.2: Ctla-4 ligation reverses CD28-mediated Lklf downregulation over the critical 
period of costimulatory signal integration in activated CD69+ CD4+ T cells.  5C.C7 
CD4+ lymphocytes were stimulated with engineered APCs presenting MCC in the 
context of I-Ek in the presence or absence of Ctla-4 ligands in conjunction with CD28 
costimulation.  Populations purified for the positive expression of CD69 allowed for 
subsequent microarray analysis of the transcriptome and identification of gene regulation 
occurring over time in activated lymphocyte populations.  Biological duplicates were 
obtained and average gene expression at each time interval normalized to expression in 
naïve, unstimulated, peripheral CD4+ 5C.C7 lymphocytes.  Measurements represent the 
average of two experiments per condition, per timepoint.  As indicated, costimulatory 
signals delivered by CD28 and Ctla-4 ligation in this sytem are integrated over a period 
of 12-16 hours.  Lklf expression remains steady in TCR monostimulated cells despite 
expression of the early activation marker CD69 and commitment to cell-cycle entry as 
previously shown.  CD28 costimulation results in rapid down regulation of Lklf more 
than 44-fold by 20 hours.  T cell activation in the presence of Ctla-4 ligands prevents 
CD28-mediated Lklf downregulation and maintains Lklf expression at levels comparable 
with cells activated by TCR monostimulation. 
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varying condition of costimulation, we performed real-time RT-PCR on the same 
samples analyzed by microarray. 
 Lklf primers were designed and tested in our lab.  Biological replicates were 
processed in triplicate, and repeated (Figure 5.3).  The observed expression pattern was 
consistent with the general trend observed by microarray analysis, but indicated that 
levels of Lklf gene expression detected by microarray were artificially suppressed to an 
increasing degree beyond 24 hours (data not shown).  The divergence of the two datasets 
over time reflects both the difficulty involved in normalizing microarray data from 
dramatically different biological samples, and may also reflect a dilution of stably 
expressed transcripts leading to underestimation of expression and decreased signal 
intensity and significance.  
 
Genomic Expression Patterns Resulting from Overexpression of Lklf in NFC cells 
 As a first approach towards understanding the role of Lklf in activated 
lymphocytes we sought to identify genes regulated by Lklf using microarray analysis.  A 
retroviral expression construct was constructed that included a MSCV promoter, the 
protein coding region of Lklf, an internal ribosomal entry site (IRES), and the green 
fluorescent protein (GFP) gene.  NFC cells, a double positive thymoma cell line capable 
of undergoing differentiation, were cocultured with the Phoenix cell packaging line 
transfected with the Lklf-MSCV or control construct for several days and purified for 
positive GFP expression by FACS.  RNA was isolated from purified Lklf-MSCV- and 
control MSCV-infected GFP+ populations for microarray analysis.  Lklf overexpression 
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was confirmed in Lklf-MSCV transfected cells by RT-PCR ( Data not shown).  RNA 
from FACS-purified Lklf-transfected and control samples was labeled for microarray 
analysis using 5-8ug of total RNA in a single-step amplification and labeling protocol.  
Labeled samples were subsequently processed for, and analyzed on, Affymetrix 
MgU74Av2 microarrays.  Three independent experiments were performed starting with 
transfection of the Phoenix cell packaging line yielding triplicate RNA samples for 
microarray analysis.  Biological replicates were processed for microarray hybridization 
and scanning at separate times and data analysis was performed using the Genespring 
expression analysis software. 
 To allow for the identification of Lklf target genes, the microarray data was 
normalized as follows.  Data transformation was performed such that signal values below 
0.01 were set to 0.01.  Per chip normalization was accomplished by dividing each 
measurement by the 50.0th percentile of all measurements in that sample.  Specific 
samples were normalized to one another: values obtained in Lklf transfected samples 
were normalized to MSCV control samples. Each measurement for each gene in Lklf 
transfected samples was divided by the median of that gene's measurements in the 
corresponding MSCV control samples. 
 Screens to identify differentially expressed genes were performed as follows.  An 
initial analysis was applied to identify genes whose expresseion was altered 2-fold 
following Lklf overexpression using a Student’s T test with p-value cutoff of  0.05 and 
utilizing the Benjamini and Hochberg multiple testing correction.  766 genes were 
identified in this initial screen.  Genes with detectable expression in at least 3 samples for 
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Figure 5.3:  Real-time quantitative PCR of Lklf in sorted population. 
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Figure 5.3:  Quantitative real-time PCR verifies inhibition of CD28-mediated Lklf 
downregulation by Ctla-4.  5C.C7 CD4+ lymphocytes were stimulated with engineered 
APCs presenting MCC in the context of I-Ek in the presence or absence of Ctla-4 ligands 
in conjunction with CD28 costimulation.  Activated lymphocyte populations were 
purified based on expression of CD69 at early times after stimulation and dilution of the 
cytoplasmic dye CFSE at late timepoints (>32 hours post-activation). Biological 
duplicates were obtained for all conditions prior to 24 hours.  Real-time PCR reactions 
specific for Lklf were performed in triplicate on all samples used in the kinetic 
microarray analysis of expression patterns in activated TCR-tg CD4+ T cells.  The results 
indicate that Ctla-4 ligation provides long-term modification of CD28-induced changes in 
gene expression despite similarities in activation marker expression, commitment to cell-
cycle entry, and division status.  Moreover, the stability of Lklf expression detected in 
TCR monostimulated and Ctla-4 costimulated populations beyond 24 hours exceeds that 
seen by microarray analysis, suggesting that data normalization at late time-points is 
inadequate as a result of large-scale alterations in the global expression profile.  
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both MSCV control and Lklf-transfected samples were screened for fold-changes greater 
than 3 with p values <0.05 assuming equal variance, and ranked by the magnitude of 
observed regulation. 176 genes were identified in this screen.  Genes detectable in at least 
three samples in either condition of MSCV control or Lklf-transfected samples but not in 
the alternate condition were considered present to absent calls and ranked by the 
magnitude of expression in the condition with detectable expression.  An additional 151 
genes with significant expression in one condition only were detected in this manner.  
Thus 766 genes displayed statistically significant (p<0.05) regulation resulting in 2-fold 
or greater differences in expression.  Moreover 327 genes were regulated at least 3-fold 
by Lklf expression or displayed consistent mixed calls (present to absent, or vice versa) 
between MSCV control and Lklf-transfected samples. 
 
  Discussion 
Lklf is essential for the maintenance of peripheral T cell quiescence in vivo, and 
Lklf deficiency result in a predominantly activated phenotype in peripheral T cells.  
Moreover, Lklf is dramatically downregulated during T cell activation, suggesting that it 
may serve to restrict or prevent cellular processes leading to cell-cycle entry and gain of 
effector function.  However, a precise understanding of Lklf function is still lacking.  Our 
data suggests that Lklf is differentially regulated by engagement of the TCR or CD28, 
and may potentially be regulated by Ctla-4.  Thus, Lklf expression and subsequent 
transcriptional regulation of target genes may initiate gene programs resulting in unique 
phenotypes depending on the specific combination of stimulatory signals received.   
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A single report has been published describing microarray analysis of Lklf –
regulated genes detected in Jurkat cells expressing a tetracycline inducible form of 
LKLF(386, 390).  Induction of LKLF in Jurkat cells generates a quiescent phenotype 
resembling memory CD4+ T lympohcytes.  Approximately 200 transcripts were 
reportedly altered more than 1.5 fold by LKLF induction with nearly equivalent numbers 
up and down regulated.  Based on a perceived over-representation of cell-surface 
molecules involved in the initiation or propagation of signaling cascades, the authors 
conclude that LKLF expression primes quiescent cells for responses to specific 
extracellular stimuli.  However, in our kinetic study of genomic expression patterns in 
CD4+ T cells undergoing primary activation, the majority of published Lklf target genes 
identified in Jurkat cells were not significantly regulated, and none of the identified genes 
showed significant coregulation with Lklf (Data not shown).  Thus, it seems likely that 
genes regulated by Lklf in Jurkat cells may not correlate with Lklf-mediated gene 
regulation in primary CD4+ T cells.  To characterize Lklf-mediated gene regulation, we 
identified genes differentially regulated in NFC cells, a cell line that may be more 
physiologically relevant to primary CD4+ T cells than Jurkat cells.  In general, the results 
we obtained upon over-expressing Lklf in NFC cells do not correlate with those 
published by Buckley et.al(386).  Moreover, the amplitude and scope of transcriptional 
regulation by Lklf detected in NFC cells is significantly greater than those reported to 
occur in Jurkat cells.  Lklf regulates transcription of genes involved in diverse cellular 
process and is critical for development of numerous tissues.  Thus Lklf transcriptional 
regulation is likely to depend on the concomitant action of numerous other factors 
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enabling coordinated gene programs in a context-dependent manner.  It is possible that 
the undifferentiated state of NFC cells is more permissive for Lklf activity than 
transformed leukemic cells derived from mature peripheral lymphocytes.  Consequently, 
the relevance of Lklf target genes identified in cell lines is best assessed by inspection of 
their regulation in primary cells following antigen receptor mediated stimulation. 
  Microarray analysis of Lklf regulated genes was performed in triplicate and 
measures of sample similarity show consistent segregation of MSCV and Lklf-MSCV 
when compared across all probesets present or across probesets with significant signal.  
More than six thousand genes had significant signal intensity in 3 of the 6 samples (3 
MSCV control and 3 Lklf-transfected samples) analyzed, which is consistent with our 
earlier results using various cell lines and tissue samples.  We detected 1863, 568, and 
151 genes with fold changes greater than 2, 3, and 5 respectively based on average 
expression values.  A screen for differential expression with p values less than 0.05 
yielded 766, 327, and 111 genes with fold changes of 2, 3, and 5 respectively (Figure 
5.4).  Nearly equivalent numbers of genes were up- and down-regulated by Lklf.   
Lklf-mediated gene transcription is dependent on the cellular context in which it 
operates and genes identified by enforced overexpression may not recapitulate 
physiological expression patterns.  A screen for Lklf target genes regulated during T 
lymphocyte activation revealed a subset of genes that may mediate Lklf function 
following T cell stimulation.  Significant expression during in vitro T cell stimulation was 
defined as detectable expression in 10 of 75 samples processed, and a 3-fold change in 
expression in at least 5 of 48 conditions.  Among the 327 most significantly regulated 
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Figure 5.4:  Identification of gene regulated by Lklf in NFC cells 
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Figure 5.4:  Identification of genes differentially regulated by Lklf expression in NFC 
cells.  A MSCV retroviral construct encoding GFP was used to overexpress Lklf in the 
double-positive thymoma NFC cell line.  RNA was isolated from GFP positive NFC cells 
infected with a control MSCV vector or a Lklf-MSCV vector, and microarray analysis of 
the global expression profiles that resulted was performed.  Triplicate biological samples 
of both control-MSCV and Lklf-MSCV infected NFC cells were obtained.  Data was 
normalized by settting signal values below 0.01 to 0.01 and dividing each measurement 
by the 50.0th percentile of all measurements in that sample.  In some analyses (Panel A), 
gene expression values in Lklf expressing samples were normalized to control samples by 
dividing the measurement for each gene in Lklf-expressing samples by the median of that 
gene's measurements in the MSCV control samples.  Genes whose expression was 
significantly altered by Lklf expression were identified.  A volcano plot (Panel A) shows 
the relative significance (Y-axis p-value) and fold change distribution (X-axis) of genes 
in Lklf-expressing NFC cells when compared to control MSCV-infected samples.  
Individual genes are indicated by dots.  Average fold-change expression (log-base 2) is 
shown on the X-axis.  Genes in red display a minimum two-fold change in expression in 
Lklf-expressing NFC cells with a p-value less than 0.05.  A scatter-plot of these genes 
indicates that Lklf results in widespread positive and negative gene expression changes 
(Panel B).  The average magnitude of signal intensity for specific genes is depicted on a 
log scale in MSCV control (X-axis) and Lklf-expressing (Y-axis) samples.  Indicvidual 
genes are indicated by dots.  The central line indicates equivalent expression.  Inner, 
middle, and outer sets of parallel lines surrounding the line of equivalence indicate 2-, 5-, 
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and 10-fole changes in expression respectively.  Genes displaying less than two-fold 
changes in expression in Lklf expressing samples relative to controls have been excluded 
for clarity.   The greatest number of significant regulation involved enhanced expression 
of genes expressed at low level in MSCV control samples (see line of best fit). 
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genes (>3-fold change in expression, p<0.05, assuming equal variances or consistent 
mixed “present”/”absent” calls) altered by overexpression of Lklf in NFC cells, 92 were 
considered to be relevant to T cell activation in vitro based on signal detection and 
expression pattern.  80 of the 92 genes correspond to unique transcripts, and these are 
listed in bold print in Table 5.1.  Manual editing of genes regulated in both systems, 
revealed 10 Lklf-upregulated target genes with expression patterns consistent with 
regulation by Lklf during primary cell activation (Listed in red).  These included the cell 
cycle regulator Cdkn1c, the pro-apoptotic transcription factor mad4, and cell surface 
signaling molecule Cipp/Patj.  In contrast, six genes displayed expression patterns that 
were inversely correlated with results from Lklf overexpression in NFC cells (Listed in 
blue).  These included the transcription factor BatF, the immunomodulatory surface 
protein Gadd45B/MyD118, and the Bcl2-associated athanogene Bag2.  In addition, 
several genes positively regulated by Lklf in NFC cells were expressed by T cells 
following activation but displayed expression patterns that failed to coregulate with Lklf 
expression. 
Among genes inhibited in NFC cells following enforced Lklf expression, 14 
displayed negative co-regulation with Lklf in activated T cells as expected (Listed in red).  
These include critical regulators of cell signaling, division, and survival including Cyclin 
C, the src-like adaptor SLA, and antiapoptotic genes Bcl2a1a and Bcl2a1b.  15 genes 
showed positive co-regulation with Lklf, in direct contradiction of results in NFC cells 
(Listed in blue).  These include retinoblastoma 1, caspase 8-associated protein 2, 
Map3K3, Map4K2, and the tyrosine kinase Txk.   
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Using microarray analysis we have identified genes regulated by Lklf 
overexpression in the NFC cell line and examined their expression and coregulation with 
Lklf in a kinetic profile of genomic expression patterns in primary CD4+ cell activated in 
vitro.  A relatively small number of genes with known function identified as Lklf target 
genes showed significant regulation during primary CD4+ lymphocyte activation.  
However, the results suggest that a primary mechanism of Lklf maintenance of 
quiescence may involve upregulation of Mad4.  Expression of a dominant-negative 
MadMyc protein recapitulates many of the effects seen in Jurkat cells overexpressing 
Lklf, and overexpression of c-Myc reverses the phenotype that results from Lklf 
overexpression(386).  Member of the Mad family of basic-helix-loop-helix/leucine-
zipper proteins heterodimerize with Max and function as transcriptional repressors.  The 
balance between Myc-Max and Mad-Max complexes is postulated to control cellular 
proliferation and differentiation(391).  Mad4 forms complexes with Max more efficiently 
than other Mad family members or Myc (392) suggesting that Mad4 may have a 
dominant influence on Myc activity.  Moreover, overexpression of Mad4 has been shown 
to induce a replicative senescence-like state in human fibroblasts(393) and Mad4 may 
mediate some effects of TGF-β in multiple tissues (394, 395).  However, to date no 
specific role for Mad4 has been shown in T lymphoyctes.  Our results suggest that Lklf 
may inhibit unwarranted lymphocyte activation in naïve peripheral CD4+ lymphocytes 
by suppressing Myc activity via upregulation of the Max dimerization protein Mad4. 
Lklf also regulates expression of genes involved in cell survival.  Bcl2a1A has 
been shown to regulate apoptosis induction in B cells after antigen receptor engagement 
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(396), promote CD8+ lymphocyte survival following 4-1BB stimulation (397), promote 
thymocyte survival after pre-TCR signaling (398), and is upregulated in CD4+ and CD8+ 
T cells after TCR engagement in a manner independent from cytokine receptor signaling, 
bcl-xL induction, or Bcl-2 upregulation (399).  Upregulation of Bc2a1 in naïve 
lymphocytes treated with retinoid x receptor agonists is also independent of effects on 
Bcl-2 or Bcl-xL and results in decreased apoptosis (400).  A specific role for Bcl2a1 in 
CD4+ lymphocyte activation has not been identified, but our data suggest that Lklf may 
serve to inhibit Bcl2a1 expression in naïve CD4+ T cells and may enhance apoptosis 
following antigen receptor triggering in the absence of sufficient CD28 costimulation.  
Conversely, CD28 costimulation-mediated downregulation of Lklf may result in 
enhanced Bcl2a1 expression, preventing induction of apoptosis in the short term while 
allowing sufficient time for additional survival signals delivered by cytokine receptor 
signaling and subsequent induction of Bcl-2 and Bcl-xL.  Bcl2a1 induction is likely 
cooperative with the CD28-specific downregulation of the apoptosis facilitator Bcl2l11 
(Bcl2-like 11), and TCR-mediated induction of Bcl2a1C, bcl2l1, and Bcl2l2. 
 In order to assess the inclusiveness of our screen for genes regulated by Lklf 
during primary T cell activation, we performed an analysis to identify genes whose 
expression pattern correlated with Lklf in our kinetic study of gene expression profiles.  
Among 505 genes with the greatest negative correlation to Lklf during T cell activation,
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Table5.1.1: Genes upregulated by Lklf 
Category Common Name Fold Change  
    
    
Cell Cycle Regulators Tgf-alpha 8.4 Tranforming growth factor-alpha 
 Cdkn1c 7.5 Cdk inhibitor 
 Ros1 6.0 Protein kinase, proto-oncogene 
 Cxcl12 4.5 Growth factor 
 Cxcl1 4.5 Growth factor 
 Pkd2 3.6 Jak-Stat pathway 
 Fgf5 3.1 Growth factor 
    
Transcriptional Lklf 28.1 DNA-dependent TF 
Regulation Lyl1 11.2 DNA-dependent TF 
 TgfB1i4 10.6 DNA-dependent TF 
 Batf 6.8 DNA-dependent TF 
 Hist1h1c 6.5 Nucleosome organization 
 Klf12 5.6 DNA-dependent TF 
 FoxC1 5.2 DNA-dependent TF 
 Mad4 3.7 Mxd4, Max dimerization protein 4 
 Hist1h2bc 3.6 Nucleosome organization 
 Six5 3.2 DNA-dependent TF 
 Etsrp71 3.0 DNA-dependent TF 
    
Immune Defense Cd2/Ly37 10.1 LFA-3 receptor, Protein kinase, adhesion 
 Prf1 5.7 Perforin 1, Cytolysis, Ca sensitive 
 Klra4 4.2 Heterophilic cell adhesion 
 Litaf 3.7 LPS-induced TNF 
 Gadd45B 3.3 Negative growth-regulatory protein 
MyD118 
 Pik3cd 3.3 PI3K catalytic domain 
    
    
Apoptosis Bag2 4.3 to 3.4 Chaperone, Bcl2-associated athanogene 
Factor Casp4 3.9 Apoptosis induction 
 Mad4 3.7 Mxd4, Max dimerization protein 4 
    
Signaling Molecule Cipp 8.3 INADL, Patj, Protein binding 
 Gnat1 6.1 G-protein signaling 
 Cer1 5.5 Inhibits BMP signaling 
 Rasgrf2 4.7 GEF activity 
 Scn9a 4.6 V-gated ion channel 
 3830613022 4.5 G-protein signaling 
 Map2k1 3.9 Mapk signaling 
 Pkd2 3.6 Jak-stat pathway 
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Table5.1.1: Genes Upregulated by Lklf 
Category Common Name Fold Change  
    
    
Cellular Adhesion Selenbp1 101.6 Selenium binding protein 
And Cytoskeleton Tmsb4x 34.8 Actin Binding 
 Agc1 27.8 Binds hyaluronic acid 
 Mmp8 15.5 Collagen catabolism 
 Gsn 8.4 Gelsolin, Actin binding 
 Capg 6.9 Actin binding 
 Asgr1 5.3 Endocytosis, adhesion 
 Strm 3.9 Striamin 
    
Metabolic/Synthetic Siat7a 11.2 Sialyltransferase 7A, Ganglioside 
biosynthesis 
Processes Fabp4 8.7 Lipid transport 
 Ptgs2 5.1 Prostaglandin synthesis, cyclooxygenase 
2 
 Aldh3a1 5.1 Metabolic pathway 
 Tgm2 5.0 Proteolysis, peptidolysis 
 Nqo1 4.6 NAD(P)H dehydrogenase quinone 1, 
Electron transport 
 Tgm2 5.0 Transglutaminase2  
 Sth2 3.8 soft tissue heal 2,  Steroid Metabloism 
 Txnip 3.7 VDUP1, thioredoxin interacting protein    
 Tcn2 3.6 Transcobalamin 2 
 Smpdl3a 3.1 Sphingomyelin phosphodiesterase 
 
 
 
 
Category Common Name Fold Change  
    
    
Unknown Mkrn3 4.4 Makorin-3, Zfp127 
 Tfpi 3.6 Tissue factor pathway inhibitor 
 Rere 3.4 Atr2, atrophin-2 
 Gkap42 3.1 G kinase anchoring protein 
 Drd3 3.1 EST 
 937302 5.2  
 Eppb9 5.0 endothelial precursor protein B9 
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Table5.1.2: Genes down-regulated by Lklf 
Category Common Name Fold Change  
    
    
Cell Cycle Regulation Bin1 -5.0 Bridging Integrator, Myc box dependent 
interacting protein 1, Sh3p9 
 Ccnc -3.1 Cyclin C 
 Rnf2 -3.3 Chromatin binding 
 Rb1 -3.3 Retinoblasoma-1, Cell-Cycle Inhibitor 
 Cops2 -3.7 Signalosome subunit 
    
Transcriptional Pola1 -3.4 DNA polymerase 
Regulation Pnn -3.4 Pinin, DNA-dependent TF 
 Cnot7 -3.1 to -5.8 DNA-dependent TF 
 NP220 -3.4 Zfml, matrin-like protein, Zinc finger protein 
638, Znf638 
 Rora -3.5 RAR-related orphan receptor alpha    
 Smarca3 -3.6 to -6.0 SNF2/SWI2 family member 
 Cops2 -3.7 COP9 signalosome complex subunit 2, 
Csn2, SGN2, Trip15 
 Gabpa -3.8 GA binding protein alpha chain 
 Tcfap2c -3.9 AP2 TF 
 Zfpn1a2 -5.4 DNA-dependent TF 
 Idb3 -6.0 Id3, inhibits Pol II 
 Hells -6.8 LSH, PASG, lymphoid-cpecific helicase 
 Idb1 -12.5 Id1, inhibits Pol II 
 HIVep1 -12.9 HIV enhancer binding 
    
Immune Defense Rasa1 -3.0 RasGAP, RAS p21 protein activator 
 Cd2ap -3.1 CD2-associated protein 
 Rock1 -3.1 Rho-associated coiled-coil forming kinase 
 CD99 -9.1  
 Ltb -9.4 Lymphotoxin B 
 CD48 -11.7 BCM1, BLAST1, OX-45 
 Ctsw -12.1 Cathepsin W 
 Cst7 -18.8 Leukocystatin 
 Gzma -31.3 Granzyme A 
    
Apoptosis Factors Casp8ap2 -4.6 FLASH, caspase 8 associated protein 2    
 Tnfaip3 -6.7 Tumor necrosis factor, alpha-induced protein 
3, zinc finger protein A20 
 Notch1 -6.7  
 Nr4a1 -7.2 DNA-dependent TF, Caspase inhibitor 
 Bcl2 -7.5  
 Bcl2a1a -15.9 Bfl1 
 Bcl2a1b -31.0 aka Bcl2a1c 
    
Cellular Adhesion Itgb7 -4.0 Integrin-beta 7 
And Cytoskeleton Kif5b -3.9 Kinesin family member 5B 
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Table5.1.2: Genes down-regulated by Lklf 
Category Common Name Fold Change  
    
    
Signaling Molecule Acvrl1 -3.4 Activin receptor-like kinase 1, kinase activity 
 Gem -3.4 RAS-like protein KIR,G-protein signaling 
 Arhgdig -3.4 RHO GDI-gamma 
 Rock1 -3.7 Rho-associated coiled-coil forming kinase 1 
 Map3k3 -3.7 MAPKKK3, Mekk3 
 Sla -4.1 Slap, Src-like adaptor 
 Ptprc -4.7 to -6.8 Protein tyrosine phosphatases receptor 
 Rock2 -4.8 Rho-associated coiled-coil forming kinase 2 
 Ramp2 -4.8 G-protein signaling 
 Map4k2 -5.5 MAPK signaling 
 Sh2d1a -6.1 Sap, Xlp, SLAM-associated protein 
 Gpr65 -10.4 G-protein signalin 
 Txk -17.2 Tyrosine kinase 
    
Metabolic/Synthetic Abcb7 -3.0 ATP-binding cassette transporter 7 
Processes Edem1 -3.1 Mannosidase alpha-like1, ER degradation 
enhancer 
 Slc30a4 -5.2 Zinc transporter 
 Tfrc -5.4 Transferrin receptor 
 Kcna3 -6.0 to -32.8 Potassium channel 
 Man1a -7.6 to -40.5 Mannosidase 1 alpha 
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Table 5.1.2: Down-regulated by Lklf 
Category Common Name Fold Change  
    
    
Unknown Activity Ube2v2 -3.0 Ubiquitin-conjugating enzyme E2 variant 2 
 1110013l07 -3.1 Riken cDNA 
 261010N10 -3.1 Riken cDNA 
 2010300G19 -3.2 Riken cDNA 
 1700065A05 -3.2 Riken cDNA 
 Bat9 -3.2 zinc finger and BTB domain containing 12 
 Rbms1 -3.2 Mssp, RNA binding motif, single stranded 
interacting protein 1 
 Adm -3.2 Adrenomedullin 
 97154_f_at -3.2 EST 
 4921518A06 -3.3 Riken cDNA 
 Siat8d -3.3 Sialyltransferase 8 
 Cspg6 -3.3 Chondroitin sulfate proteoglycan 6 
 Tbc1d15 -3.3 EST 
 Rnf2 -3.3 Ring1B 
 Sema4a -3.4 Receptor 
 Pnpt1 -3.4 polyribonucleotide nucleotidyltransferase 1   
 D3Ertd330e -3.4 94395_at 
 2310005N03 -3.5 Riken cDNA, Hnrpu 
 CD52 -3.5 CAMPATH-1 (Cdw52) 
 Fndc3 -3.8 EST 
 Smarca5 -3.9 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
a, member 5 
 Narg1 -3.9 Nat1, NMDA receptor-regulated gene 1 
 Serpin1 -4.1 serine (or cysteine) proteinase inhibitor 
 Hrb2 -4.1 HIV-1 Rev binding protein 2 
 Matr3 -4.1 matrin 3 
 Lypla1 -4.2 lysophospholipase 1 
 Rcbtb1 -4.4 regulator of chromosome condensation 
(RCC1) and BTB (POZ) domain containing 
protein 1 
 Tm4sf9 -4.5 TM-4 family member 9 
 Crtam -4.6 Surface protein 
 Ptbp2 -4.6 polypyrimidine tract binding protein 2   
 Atp1a1 -4.8 ATPase, Na+/K+ transporting, alpha  1  
 Zfp146 -5.1 OZF, zinc finger protein 146 
 Pscd1 -5.3 Pleckstrin homology, Sec7, coiled-coil 
domains 1 
 Zfpn1a2 -5.4 zinc finger protein, subfamily 1A, 2 (Helios) 
 Spred2 -8.8 sprouty-related, EVH1 domain containing 2 
 Bub1 -12.5 Mitotic checkpoint serine/threonine-protein 
kinase 
 Htatip2 -14.6 HIV-1 tat interactive protein 2, homolog 
 1190002N15 -27.0 Riken cDNA 
 Cd53 -37.6 Ox-44, Tspan25 
 Emb -42.7 EST 
 Itm2a -73 integral membrane protein 2A 
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Table 5.1:  Overexpression of Lklf in NFC cells identifies potential target genes in 
primary CD4+ T cells.  A retroviral vector encoding GFP was used to overexpress Lklf in 
double-positive thymoma NFC cells.  Control-MSCV and Lklf-encoding MSCV vectors 
were used to infect NFC cells.  Infected cells were purified by FACS based on expression 
of GFP.  Triplicate samples were prepared and processed for microarray analysis.  Genes 
differentially regulated upon Lklf overexpression in NFC cells were identified and their 
expression pattern in primary 5C.C7 CD4+ lymphocytes stimulated in vitro under 
varying conditions of TCR, CD28, and Ctla-4 ligation examined.  80 genes identified as 
differentially regulated by Lklf in NFC cells showed significant expression and/or 
regulation in 5C.C7 CD4+ primary cell activated in vitro.  Genes coregulating with Lklf 
during primary CD4+ T cell activation in a manner consistent with their regulation by 
Lklf in NFC cells are listed in red print.  Genes with expression patterns in primary cells 
that reflect an inverse relationship with Lklf relative to that seen in NFC cells are listed in 
blue.  Genes identified as Lklf targets in NFC cells that have variable expression patterns 
without significant co-regulation with Lklf in primary CD4+ T cells stimulated in vitro 
are listed in black. 
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Figure 5.5:  Hierarchical clustering of Lklf target genes based on kinetic 
expression profiles in activated CD4+ T lymphocytes 
 
→Increasing Time→ 
 
 
                        TCR              TCR+CD28        TCR+CD28+Ctla-4 
           CD69-     CD69+  CD69-           CD69+        CD69-            CD69+ 
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Figure 5.5:  Hierarchical clustering of Lklf target genes in kinetic study of genomic 
expression patterns in CD4+ T cells undergoing primary activation in vitro.  5C.C7 CD4+ 
lymphocytes were stimulated in culture by engineered APCs expressing different 
combinations of ligands for the TCR, CD28, and Ctla-4.  Populations of naïve and 
activated lymphocytes were purified by FACS at discrete times between 4 and 60 hours 
and their global expression profiles analyzed by microarray.  Genes with detectable 
expression in at least 10 of 78 samples analyzed were ranked by their degree of positive 
or negative co-regulation with Lklf across all stimulation conditions, states of activation, 
and timepoints based on their Spearman correlation values.  More than 1000 genes 
displaying some measure of co-regulation with Lklf were cross-referenced with Lklf 
target genes identified by retroviral overexpression of Lklf in the NFC cell line.  All 88 
genes represented displayed statistically significant (p<0.05) regulation upon enforced 
Lklf expression in NFC cells analyzed in triplicate on microarrays.  Hierarchical 
clustering based on expression patterns in 5C.C7 CD4+ lymphocytes undergoing primary 
activation in vitro was performed to characterize the temporal and qualitative relationship 
of potential Lklf target genes significantly regulated in primary CD4+ T cells.  Genes 
included in the above diagram are listed in Table 5.2 according to known function and 
degree of regulation following over expression in NFC cells.  These genes had not been 
identified as significantly regulated by Lklf in prior screens that utilized search 
algorithms that biased results based upon the magnitude of regulation resulting from Lklf 
over-expression in NFCs.  Moreover, genes identified by initial screens for co-regulation 
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in primary cells were twice as likely to predict qualitative regulation by Lklf following 
over-expression in NFC cells than analyses performed in the reverse order. 
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Table 5.2 
Categoory Fold 
Change 
Lklf 
Correlation 
Common 
Name 
Description 
     
Cell cycle 2.2 -0.751 Jun Jun oncogenes 
 -3.4 -0.698 Qscn6 Quiescin Q6 
     
Apoptosis  2.4 -0.762 Btg2 B-cell translocation gene 2, anti-proliferative 
     
Transciption 6.7 -0.782 Rere  
 6.5 -0.716 Hist1h1c histone 1, H1c 
 2.3 -0.803 Cebpd CCAAT/enhancer binding protein delta 
 2.1 -0.771 Hdac5 Histone deacetylase 5 
 -2.7 -0.689 Pcaf p300/CBP-associated factor 
     
Translation 2.4 -0.732 Cpeb1 cytoplasmic polyadenylation element-binding protein 
     
Immune Response 6.3 -0.832 Samhd1 SAM domain- and HD domain-containing protein 1 
 4.3 -0.691 G1p2 interferon, alpha-inducible protein 
 3.8 -0.827 Ian1 immune associated nucleotide 1 
 2.8 -0.767 Imap38 immunity-associated protein 
 2.1 -0.774 Ly6c lymphocyte antigen 6 complex, locus C 
 2.1 -0.68 Ctsl Cathepsin L 
 -2.2 -0.686 Ifit2 interferon-induced protein with tetratricopeptide repeats 2 
 -3.2 -0.753 Tap2 transporter 2, ATP-binding cassette, sub-family B 
     
Signaling 4.2 -0.797 Tgtp T-cell specific GTPase 
 3.4 -0.867 Btbd14a BTB (POZ) domain containing 14A 
 2.5 -0.782 Il7r interleukin 7 receptor precursor 
 2.4 -0.696 Gbp2 guanylate nucleotide binding protein 2 
 2.3 -0.898 Il6ra interleukin 6 receptor, alpha 
 2.2 -0.8 Fln29 IFN and LPS inducible, negatively regulates TLR signaling 
 2.1 -0.678 Frat2 frequently rearranged in advanced T-cell lymphomas 2 
 -2.1 -0.895 Tec cytoplasmic tyrosine kinase, Dscr28C related 
 -2.1 -0.682 Sema4d semaphorin 4D 
 -2.2 -0.736 Sh3bp5 SH3-domain binding protein 5 (BTK-associated) 
 -2.3 -0.8 Il27ra interleukin 27 receptor, alpha 
 -2.3 -0.721 Itpr5 inositol trisphosphate receptor type 2 
 -2.4 -0.734 Map3k3 mitogen activated protein kinase kinase kinase 3 
 -2.5 -0.695 Nsg2 neuron specific gene family member 2 
 -3.5 -0.871 Txk TXK tyrosine kinase 
 -3.5 -0.712 Cd3d CD3 antigen, delta polypeptide 
     
Adhesion 23.9 -0.781 Cd9 CD9 antigen 
Cytoskeleton 2.0 -0.848 Map1lc3b microtubule-associated protein 1 light chain 3 beta 
 -2.5 -0.75 Tubb2 tubulin, beta 2 
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Table 5.2 
Categoory Fold 
Change 
Lklf 
Correlation 
Common 
Name 
Description 
     
Metabolism 5.3 -0.88 Dhrs8 dehydrogenase/reductase (SDR family) member 8 
 3.7 -0.917 Dntt deoxynucleotidyltransferase, terminal 
 2.5 -0.92 Dntt Riken cDNA 
 2.1 -0.831 Ctss Cathepsin S 
 2.1 -0.706 Kcnj8 potassium inwardly-rectifying channel J8 
 2.1 -0.878 Cyp2s1 cytochrome P450, family 2, subfamily s, polypeptide 1 
 2.0 -0.733 Cyp4f13  
 2.0 -0.798 Abca1  
 -2.1 -0.736 Hdc histidine decarboxylase 
 
-2.5 -0.719 Elovl6 
ELOVL family member 6, elongation of long chain fatty acids 
(yeast) 
 -4.5 -0.794 Ugcg UDP-glucose ceramide glucosyltransferase 
 -5.5 -0.712 Cnga1 cyclic nucleotide gated channel alpha 1 
     
Miscellaneous 2.3 -0.773 Daf1 decay accelerating factor 1 
 2.3 -0.737 Dnahc8 dynein, axonemal, heavy chain 8 
     
Unknown 
26.0 -0.694 
0610011I04
Rik hepatocellular carcinoma-associated antigen 112 
 
6.2 -0.678 
cDNA 
clone 
IMAGE:100
5369  
 4.7 -0.691 Sntb1 Riken cDNA 
 
2.3 -0.678  
similarity to protein ref:NP_032607.1 (M.musculus)  melanoma 
antigen 
 2.2 -0.685 Itm2c integral membrane protein 2C 
 2.2 -0.685 ud35h06.r1  
 2.2 -0.743 Usp18 ubiquitin specific protease 18 
 2.1 -0.801  EST 
 
2.1 -0.913 
1500005K1
4Rik Riken cDNA 
 
-2.0 -0.894 
5830431A1
0Rik  
 -2.2 -0.776 Osbpl5 EST 
 
-2.2 -0.683 
6330442E1
0Rik Riken cDNA 
 
-2.6 -0.744 
4930422J18
Rik EST 
 -2.6 -0.741 Gbp3 EST 
 -2.7 -0.819 BC052328 EST 
 
-3.1 -0.855 
2810052M0
2Rik Riken cDNA 
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Table 5.2 
Categoory Fold 
Change 
Lklf 
Correlation 
Common Name Description 
     
Cell Cycle 2.6 0.829 Gfi1 growth factor independent 1 
 -3.4 0.814 Arhgdig Rho GDP dissociation inhibitor (GDI) gamma 
     
Transcription -2.0 0.807 Rorc RAR-related orphan receptor gamma 
 -2.2 0.803 Sap30 sin3 associated polypeptide 
 -2.2 0.865 Ddx18 Myc-regulated DEAD-box protein 
 -2.5 0.862 Gtf2h4 general transcription factor II H, polypeptide 4 
 -2.8 0.913 Idb2 inhibitor of DNA binding 2 
     
Signaling 4.3 0.809 Sdc4 syndecan 4 
  -2.1 to -2.7 0.873 Pla2g12a phospholipase A2, group XIIA 
     
Immune  2.7 0.824 Tnfsf11 tumor necrosis factor (ligand) superfamily, member 11 
 -2.8 0.938 Lta lymphotoxin A 
     
Metabolism 2.5 0.9 Alad aminolevulinate, delta-, dehydratase 
 2.2 0.853 Fabp5 fatty acid binding protein 5, epidermal: mal1; Fabpe gene. 
 -2.1 0.806 Slc2a1 
solute carrier family 2 (facilitated glucose transporter), 
member 1 
 -2.3 1 Hk2 hexokinase 2 
 -2.8 0.878 Car12 carbonic anyhydrase 12 
 -2.2 0.856 Tnnt1 troponin T1, skeletal, slow 
     
Unknown -2.2 0.922 AA408556 hypothetical protein LOC107094 
 -2.2 0.811 D3Ertd330e DNA segment, Chr 3, ERATO Doi 330, expressed 
 -2.7 0.87 Dnmt3a vv58e04.r1 Soares_thymus_2NbMT  
 -3.0 0.836 1200007D18Rik hypothetical protein LOC67458 
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Table 5.2:  Identification of potential Lklf target genes in primary CD4+ lymphocytes 
based on initial measures of coregulation.  Microarray analysis was performed to 
characterize the global expression profile of 5C.C7 CD4+ lymphocytes activated in vitro 
by APCs engineered to express varying combinations of ligands for the TCR, CD28 , and 
Ctla-4.  Naïve and activated populations were isolated at discrete times from 4-60 hours 
after initial stimulation based on expression of activation markers and division status.  
Genes with detectable expression in at least 10 of 78 samples analyzed were ranked by 
their degree of coregulation with Lklf across all timepoints, activation states, and 
stimulation conditions.  Genes with the greatest degree of positive or negative co-
regulation with Lklf in primary cells stimulated in vitro were cross referenced with genes 
differentially expressed in NFC cells overexpressing Lklf.  Co-regulation with Lklf in 
primary cells accurately predicted the qualitative nature of Lklf-mediated changes in gene 
expression in NFC cells.  In contrast, the magnitude of Lklf-mediated regulation in NFC 
cells did not accurately predict qualitatitve (positive or negative) co-regulation with Lklf 
in primary cells stimulated in vitro.    Genes initially identified by their coregulation with 
Lklf in primary CD4+ 5C.C7 lymphocytes that had not been previously identified as 
significant Lklf target genes are shown in Table 5.2.  The magnitude of the fold change in 
expression seen with Lklf overexpression in NFC cells is listed.  Correlation values for 
expression profiles detected in primary CD4+ 5C.C7 T cells is shown relative to Lklf.  
Correlation values less than 0 indicate positive coregulation, and correlation values 
greater than 0 indicate negative coregulation in primary cells.  Genes displaying a 
qualitatively consistent relationship with Lklf expression in both NFC and primary CD4+ 
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T cells are shown in red.  Genes displaying inverse relationships in the two systems are 
shown in blue.  
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 27 genes (5.3%) showed statistically significant changes in expression of at least two-
fold upon Lklf overexpression in NFC cells.  22 of the 27 genes (81%) had not been 
previously identified in our analysis as important Lklf targets based on the magnitude of 
their regulation by Lklf in NFC cells.  Similarly, among 503 genes that positively co-
regulated with Lklf during T cell activation in vitro, 80 genes (16%) showed at least 2-
fold changes that were statistically significant (p<0.05) following Lklf overexpression in 
NFC cells.  66 of the 80 genes (83%) had not been previously identified as important Lklf 
target genes as a result of the small fold-changes observed in NFC cells upon Lklf 
overexpression.  These results strongly suggest that for genes undergoing dynamic 
regulation across a variety of conditions and sampled at numerous times, measures of 
correlation based on extended kinetic profiles provides greater predictive value of 
physiologically-relevant gene interaction than the magnitude of resultant gene expression 
changes detected in the context of isolated overxpression. Hierarchical clustering of 
genes regulated more than two fold by Lklf expression in NFCs displaying coregulation 
with Lklf in activated primary CD4+ T cells is shown in Figure 5.5.   
Among genes altered more than two-fold by Lklf expression in NFC cells, the 
magnitude of regulation detected did not correlate with the likelihood of consistent gene 
co-regulation with Lklf in primary T lymphocytes following stimulation.  However, 
measures of co-regulation in a kinetic study of T cell activation reliably predicted the 
qualitative regulation exerted by Lklf over-expression in NFC cells.  Thus, 83% of genes 
evidencing negative co-regulation with Lklf in the kinetic study were depressed in NFC 
 227
cells over-expressing Lklf.  A summary of Lklf regulated genes identified by statistical 
comparison of gene expression profiles in primary CD4+ T cells stimulated in vitro is 
presented in Table 5.2. 
Our data suggest that Lklf expression is not sufficient for the maintenance of a 
naïve phenotype.  Instead, Lklf expression is differentially regulated by costimulatory 
signals triggered by CD28 and Ctla-4 ligation and may mediate unique, long-term 
phenotypic changes as a result.  The lack of overt autoimmunity and pathological disease 
in mice containing Lklf-deficient lymphocytes suggests that mechanisms of peripheral 
tolerance remain intact.  The tendency of Lklf-deficient lymphocytes to display an 
activated phenotype may result from altered expression of only a few genes involved in 
regulating threshold of activation or cell cycle progression, consistent with its down-
regulation by CD28 ligation.  For example, in NFC cells Lklf up-regulates cyclin C while 
down regulating the cyclin-dependent kinase inhibitor Cdkn1c (p57KIP2).  p57Kip2 is 
known to inhibit both cyclin A- and cyclin E-associated cdk2 kinase activities resulting in 
decreased cell proliferation and DNA synthesis(401).  Similarly, cyclin C has been shown 
to act cooperatively with c-myc to induce cdc2 expression and promote G1/S and G2/M 
cell cycle transitions(402).  Additional genes involved in cell cycle regulation (e.g. jun, 
Gfi1), signaling (e.g.Cipp, sla, Gpr65, IL7R, FRAT2, Tgtp, etc), and transcriptional 
regulation (e.g. Pola1, Hells, Cebpd, Hdac5) were identified as Lklf target genes co-
regulating with Lklf in primary T cell activation.  Literature supports the notion that 
altered expression of these genes may predispose lymphocytes to become activated in the 
absence of Lklf. 
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Several genes encoding important T cell signaling molecule that were regulated 
by Lklf in NFC cells possessed contradictory expression patterns in activated primary T 
cells.  Many of these genes, including Tec, Txk, Map3k3, Map4k2, and CD3-delta are 
central to the propagation of antigen-receptor signals.  All of these were downregulated 
by Lklf in NFC cells, and increased expression in Lklf-deficient lymphocytes could lead 
to increased antigen receptor sensitivity in the periphery and inappropriate activation.   
Similarly, Gadd45-beta, was upregulated by Lklf in NFCs but negatively co-regulated 
with Lklf in primary T cells.  Gadd45-beta deficiency predisposes mice to the 
development of spontaneous autoimmune lymphoproliferation(403), and decreased 
expression in the context of Lklf-deficiency may partially explain the Lklf-/--phenotype.  
The positive co-regulation of these genes with Lklf in activated primary T cells 
committed to cell-cycle entry is likely to reflect the influence of dominant mechanisms of 
regulation that result from TCR triggering.   
In summary, we have shown that Lklf is regulated by costimulatory signals 
mediated by CD28 and Ctla-4.  Moreover, we have identified genes significantly 
regulated by Lklf expression in a thymoma cell line and characterized their expression 
pattern in a kinetic study of activated T cells under varying condition of costimulation.  
Our results indicate that a specific subset of dysregulated genes may explain the 
predominantly activated phenotype of Lklf-deficient peripheral T lymphocytes.  
Moreover, we have identified likely targets of Lklf in primary cells that could potentially 
explain observed differences in phenotype that result from varying costimulation 
conditions.  Many of the identified Lklf target genes regulated during primary CD4_ T 
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cell activation, specifically Bcl2a1 and Mad4, have not been well characterized in this 
context.  This work provides the basis for further exploration of mechanisms underlying 
the maintenance of peripheral tolerance, costimulation, and regulation of T cell 
responsiveness. 
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The central importance of costimulatory signals in immune regulation has been 
shown in numerous disease models and is evident in the phenotype of CD28-/- and Ctla-4-
/- mice.  While CD28 signaling pathways have been relatively well defined, attempts to 
define the mechanisms by which Ctla-4 inhibits T cell activation and maintains peripheral 
tolerance have been hampered by the complexities of Ctla-4 expression, ligand binding, 
and signal integration.  Although much has been learned about the proximal events 
associated with CD28 and Ctla-4 ligation, relatively little is known about distal effects of 
costimulatory signal integration that may underlie qualitative aspects of immunity.  While 
CD28 has been shown to reciprocally regulate genes necessary for quiescence and T cell 
activation, a definitive role for Ctla-4 in this process has not been elucidated.  Thus we 
sought to define the transcriptional targets involved in mediating Ctla-4 tolerance 
induction.  
Progressive T cell activation is dependent on changes in gene transcription initiated by 
signals transmitted through the TCR.  CD28 is reported to greatly enhance the TCR-
induced transcriptional response in a primarily quantitative manner.  Ctla-4 reportedly 
counteracts CD28 signaling and mediates a partial inhibition of gene transcription upon T 
cell activation.  We have proposed that Ctla-4 ligation results in the specific regulation of 
genes necessary for the maintenance of a naive phenotype such as quiescence factors and 
that these changes result in altered responsiveness of the T cell to further stimulation.  To 
provide a contextual framework for the identification of potential mediators of Ctla-4 
function, we utilized an in vitro stimulation system capable of differentially signaling 
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through the TCR, CD28, and Ctla-4 to facilitate the generation of an extensive database 
of gene regulations occurring during primary activation of CD4+ T cells experiencing 
varying combinations of antigen receptor stimulation and positive and negative 
costimulation.  Microarray analysis was performed on FACS-purified CD4+ T cells 
stimulated under varying conditions of costimulation and homogenous for activation 
hisotry, expression of activation markers, and division status.  In addition, stringent 
control of activation conditions made possible by the use of engineered APCs and TCR-
tg T cells facilitated further characterization of the temporal parameters of antigen 
receptor and costimulatory signal integration.   The database of gene regulations permits 
extensive data mining and the application of combined bioinformatics approaches. Our 
results are relevant to our understanding of autoimmune disease, peripheral T cell 
tolerance, and T cell differentiation.  Furthermore our results are relevant to numerous 
other model systems, such as those seeking to explain the phenomenon of anergy 
induction in lymphocytes.  Understanding the mechanisms involved in costimulatory 
signal integration, the long term effects of CD28 and Ctla-4 ligation, and the 
intermediates bridging the two, will be essential for the productive manipulation of 
costimulation pathways in clinical applications. 
In general, our results clearly indicate that TCR ligation in the absence of costimulation is 
capable of activating all signaling pathways necessary for commitment to activation and 
cell-cycle entry within 1-2 hours.  TCR signaling induces a dynamic transcriptional 
response characterized by reciprocal regulation of several thousand genes, including key 
determinants of cellular activation and quiescence.   In CD4+ T cell subpopulations 
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purified on the basis of activation marker expression, TCR signaling potently upregulates 
genes necessary for long-term survival and effector function to levels comparable with 
those seen subseqeuent to CD28 costimulation, including interleukin-2, CD25, and Bcl-
xL.  CD28 enhances proximal TCR-signaling events leading to CD4+ T cell activation as 
evidenced by dramatically enhanced responder frequency to a broad range of antigen 
concentrations within 1-2 hours.  In addition, CD28 transmits unique signals that can be 
integrated with sub-mitogenic TCR signals over an extended period of 12-16 hours.  
Thus, CD28 functions to lower the threshold of activation in a manner that allows for 
rapid amplification of T cell responses to antigen receptor stimulation in the presence of 
CD28 ligands, but also allows for prolonged costimulatory signaling that is permissive 
for commitment to activation in CD4+ T cells that have received prior sub-mitogenic 
TCR signals.  Consequently, CD28 signaling prevents the induction of an unresponsive 
phenotype in CD4+ T cells exposed to low levels of antigen receptor stimulation for an 
extended period.  At the transcriptional level, CD28 differentially modifies TCR-
mediated changes in gene expression.  In general, CD28-signaling accelerates the rate of 
transcriptional regulation subsequent to TCR-triggering and results in modest changes in 
the overall scope and magnitude of genomic expression patterns observed during primary 
T cell activation.  Globally, expression patterns of T cells activated by TCR triggering 
with or without CD28 costimulation converge over time and result in relatively few 
stably expressed transcripts displaying differential regulation by CD28 signaling.  These 
data suggest a general overestimation of the role CD28 plays in determining the 
magnitude of gene expression changes in previous reports that failed to use 
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physiologically relevant ligand and did not examine T cell populations homogenous for 
activation status.    Il-2 and bcl-xL, traditionally considered CD28-specific target genes, 
display less than two-fold changes in expression over extended intervals subsequent to 
CD28 costimulation.  The magnitude of differential regulation is consistent with 
increased mRNA stabilization mediated by CD28, and may not require increased 
transcription.  Critically, several genes reportedly expressed in activated T cells in a 
CD28-dependent manner were only marginally increased in expression by CD28 
costimulation relative to TCR monostimulation.  In contrast, numerous genes not 
previously identified as CD28-specific targets were more highly regulated following 
CD28-mediated costimulation, suggesting that novel pathways downstream of CD28 
remain undiscovered.  No genes were reliably regulated by CD28 costimulation in a 
manner reciprocal to that seen following TCR monostimulation.  However, a very small 
number of genes appeared to specifically dependent on CD28 signaling for efficient 
regulation.  The vast majority of genes differentially regulated by CD28(>2-fold average 
difference over a minimum of 12 hours) were associated with metabolic, cytoskeletal, or 
synthetic pathways and may partially explain the observed decrease in time to cell cycle 
entry observed with CD28 costimulation.  A small subset of genes differentially regulated 
by CD28-signaling are transcription factors, and  only one transcription factor, Lklf, 
maintained long-term differential expression subsequent to CD28 ligation suggesting that 
mechanisms underlying regulation of Lklf expression may utilize novel CD28-mediated 
signaling pathways.  
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We have shown that the expression of Ctla-4 ligands on engineered APCs 
providing TCR- and CD28-mediated stimulatory signals to TCR-tg CD4+ T cells 
correlates with changes in gene expression that serve to counteract transcriptional 
regulation by CD28.  .  However, the degree to which Ctla-4 suppressed CD28-mediated 
changes in gene expression was much less than has been reported previously and global 
patterns of expression were largely identical, both quantitatively and qualitatively, by 20 
hours in cells activated under conditions of CD28 ligation with or without concomitant 
Ctla-4 ligation.  A predominant preferential effect of Ctla-4 suppression of transcriptional 
regulation based on molecular function or process was not detected.  However a small 
number of genes remained stably altered by Ctla-4 relative to TCR and CD28 coligation.  
Surpisingly, the most stably altered transcription factor, Lklf, was also the most 
significantly changed by CD28 signaling relative to isolated TCR ligation. 
The central role of CD28 and Ctla-4 in determining the nature and extent of 
immune responses implies that identification of downstream mediators might provide 
useful targets for immunotherapeutic and pharmacological approaches to combating 
immunological disease.  The strength and precision of tolerance induction that can be 
affected by costimulation dependent mechanisms is dramatically revealed in the cell-
extrinsic regulation of Ctla-4 knockout cells in mixed bone marrow chimera.  The stable 
chimerism that results from a 1:1 donor transfusion of Ctla-4-knockout and wild-type 
marrow is dependent on continual Ctla-4-dependent mechanisms of regulation that are 
sufficient for the restoration of normal pathogen-specific immunity, yet maintain 
immunotolerance to self-antigen in otherwise potently self-reactive lymphocyte 
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populations.  Analysis of the genomic expression pattern in these regulated Ctla-4-
deficient CD4+ T cells reveals numerous changes in gene expression that may indicate 
the pathways involved in extrinsic regulation. 
Wild-type cells are capable of reversing the autoreactivity native to Ctla-4-
deficient T cells while maintaining normal responsivness to foreign antigen.  An 
understanding of mechanisms of cell-extrinsic regulation of autoimmune T cells 
operative in the context of mixed Ctla-4-gentoype bone marrow chimerae may lead to the 
development of therapeutic strategies.  Transcriptional mechanisms that might potentially 
mediate the regulatory effect of wild-type cells would be expected to involve regulators 
of lymphocyte signaling pathways operating downstream of the antigen receptor and/or 
CD28.  Expression of the E3 ubiquitin ligase c-Cbl is turned on in Ctla-4 –deficient cells 
and expressed at high levels.  c-Cbl expression and activity also correlates with anergy 
induction and inhibition of peripheral T cell responsiveness, and c-cbl is known to 
regulate proximal signaling molecules downstream of the TCR including Rap1 and 
CrkL(86).  The NFATc2/NFAT1 transcription factor is involved in the regulation of 
numerous processes in lymphocytes including gene regulation during activation and 
cooperative activity with FoxP3 during regulatory T cell development(404) .  In Ctla-4 
deficient cells extrinsically regulated by wild-type cells in mixed bone marrow chimerae, 
NFAT1 is severely upregulated.  Very recently, NFAT1 was clearly identified as a 
critical component of the signaling pathway that results in anergy induction in B cells 
chronically exposed to self-Ag(405).  In contrast, other work has shown that a 
constitutively active form of protein kinase B(PKB) reduced nuclear accumulation of 
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NFAT1 and NF-kappaB when introduced into T cells.  Unexpectedly, the effect of the 
reduced shuttling and nuclear accumulation of NFAT and NF –kappaB was a reduction in 
activation threshold, enhanced cell cycle progression, and increased production of Th1 
and Th2 cytokines similar to what was seen with CD28 costimulation(406)  
Cumulatively, these results suggest that in certain contexts NFAT1 can counteract 
signaling pathways mediated by CD28.   In addition to c-Cbl and NFAT1 upregulation, 
Ctla-4 deficient cells upregulated the atypical protein kinase C, PKC–zeta.  Interestingly, 
T cell:APC interaction via CD40:CD40L results in transient association of c-Cbl with the 
cytoplasmic tail of PI3K resulting in increased PIP3 production.  PIP3 activates 3’ (PI)-
protein kinase 1 that activate PKC-zeta by phosphorylation.  PKC-zeta increases nuclear 
NFAT1 accumulation and phosphorylates the catalytic domain of NFAT1.  Thus a direct 
line of interactions from c-CBL to increased NFAT activity and subsequent inhibition of 
pathways normally regulated by CD28 is enhanced in extrinsically regulated Ctla-4-
deficient T cells.  The lymphoproliferative defect in Ctla-4 deficiency is CD28 
dependent, suggesting that increased nuclear NFAT resulting from a combination of 
increased expression and enhanced upstream activation through c-Cbl and PKC-zeta may 
explain the tolerant phenotype of Ctla-4 deficient T cells in mixed bone marrow 
chimerae.  To date, no other molecular mechanism mediating extrinsic regulation of Ctla-
4 deficiency has been proposed. 
The restoration of appropriate antigen-specific responses in Ctla-deficient T cells 
in the presence of wild-type cells suggests that generalized mechanisms of 
immunosuppression are not operative in this context. Instead, contact dependent 
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mechanisms seem likely to prevail.  Cumulatively, the data available is consistent with a 
model in which Ctla-4 deficient cells are tolerized in a process similar to anergy 
induction by interaction with APCs rendered tolerogenic by interactions with wild-type 
cells.  This model is in accord with numerous findings.  First, Ctla-4 deficiency requires 
antigen receptor triggering and CD28 costimulation to initiate disease(268), suggesting 
that mechanisms of tolerance induction must precede or coincide with antigen 
recognition by the TCR.  The regulation of Ctla-4-deficient cells is dependent on the 
continued presence of either CD4+ or CD8+ wild-type T cells indicating that Ctla-4 
functions on a continuing basis to regulate the knockout T cells.  The ability of Ctla-4 to 
provide extrinsic regulation is only known to occur through a limited number of distinct 
mechanisms.  Ctla-4 can signal through B7 to induce a tolerogenic phenotype in dendritic 
cells characterized by enhanced tryptophan catabolism.  Direct suppression of effector 
cells has also been achieved by T cell-expressed B7-mediated signaling upon binding 
Ctla-4 on regulatory T cells(303).  However, this would represent an antigen non-specific 
mechanism if it did not occur concomitantly with lymphocyte:APC interaction.  
Moroever, PKC-zeta is known to be regulated by CD40/CD40L interaction.  Thus I 
would propose a model in which a three-way interaction occurs between wild-type 
regulatory T cells specific for self-antigen, tolerogenic dendritic cells presenting self-
antigen, and Ctla-4-deficient effector cells capable of responding to self-antigen.  
Tolerogenic dendritic cells provide altered signaling via accessory costimulation 
molecules such as CD40 potentially enabling the upregulation of c-Cbl and blockade of 
CD28-mediated signals by an NFAT1-dependent mechanism.  Confirmation that NFAT1 
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functions as an anergy factor in T cells and is critical for tolerance induction in regulated 
Ctla-4-deficient cells will be an important first step in clarifying the validity of this 
model. 
In contrast to the number and magnitude of changes seen in exrinsically regulated 
Ctla-4 deficient T cells, Ctla-4 deficiency in the context of absent B7 resulted in only 
insignificant changes in expression.  With the exception of Ctla-4 and the melanoma 
antigen, Mela, there were no genes significantly altered more than four fold.   Given the 
absence of pathology in Ctla-4 deficient mice in the presence of inactivating mutations of 
the B7:CD28 signaling pathway, it is likely that the slightly increased sensitivity of Ctla-
4 deficient mice to isolated TCR triggering reflects a partial role for biophysical 
disruption of the immature immunological synapse or altered activity of proximal 
signaling intermediates as a result of Ctla-4 recruitment to the APC:T cell interface.  
Given the recent reemergence of reports suggesting a role for Ctla-4 in thymic 
development, it was important to establish that baseline gene expression is not altered in 
the absence of Ctla-4 prior to activation. 
 Similarities in the the phenotype of Lklf-deficient and Ctla-4-deficient mice 
suggest that they both function to maintain the quiescent phenotype of peripheral 
lymphocytes.  RT-PCR and quantitative real-time PCR confirmed the differential 
regulation by CD28 and Ctla-4.  Lklf is not a Ctla-4-specific target gene.  However, Ctla-
4 ligation abrogated the suppressive effect of CD28 signaling on Lklf expression 
completely, as assessed by quantitative PCR.  Thus, regulation of Lklf transcription may 
represent a critical juncture in the integration of the opposing costimulatory pathways. 
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 Lklf expression is necessary but not sufficient for the maintenance of a quiescent 
phenotype.  Lklf expression is maintained in activated and divided cells stimulated by 
isolated antigen receptor triggering or in the presence of Ctla-4 ligation.  In transformed 
cell lines, Lklf overexpression did not alter growth characteristics (Data not shown).  
Moreover, overexpression of Lklf in primary T cells infected with a retroviral construct 
encoding Lklf showed normal responses to antigen receptor ligation or costimulation 
through CD28 or Ctla-4 (Data not shown).  The ability of forced Lklf expression in Ctla-
4-deficient peripheral T cells to suppress or prevent the development of autoimmune 
disease is being investigated.  The CD28-dependent nature of the lymphoproliferative 
disease in Ctla-4-/- mice suggests that transcriptional regulation mediated by CD28 may 
be important.  Lklf   
 Lklf reproducibly regulates several hundred genes when overexpressed in a 
double positive thymoma cell line.  In contrast, similar experiments with other putative 
immunoregulatory or quiescence factors did not provide reproducible results.  These 
included FoxP3, TSC-22, and Tob.  In an attempt to characterize targets of Lklf relevant 
to primary T cells, a comparison was made between all genes altered more than three fold 
by Lklf overexpression in NFC cells and the observed degree of coregulation with Lklf 
expression in the kinetic profile of T cell activation.  Lklf expression remains unchanged 
in naïve or TCR monostimulated cells, is quickly downregulated by CD28 costimulation, 
and is maintained by Ctla-4 signaling despite concurrent CD28 ligation. As reported, nine 
genes identified as Lklf targets in NFC cells coregulated with Lklf expression in primary 
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cells.  Two of the identified genes, Sh2d1a(SAP/SLAM-associated protein) and Sla(Src-
like adaptore protein), are known to regulate T cell responses.  
 Sla is an adaptor protein containing Src homology 3 (SH3) and SH2 domains 
highly similar to those found in Lck and other Src family members.  Initially 
characterized as an inhibitor of mitogenesis(407), Sla has been shown to inhibit TCR 
signaling by association with a multimolecular signaling complex containing CD3-zeta, 
ZAP-70, VAV, LAT, and SLP-76(408).  Sla mediates downregulation of the TCR in 
thymocytes by targeting TCR-zeta for degradation in a c-cbl-dependent manner(409) and 
interferes wih TCR signaling in peripheral T cells leading to functional downregulation 
of NFAT and NF-kB(410).  Similarly, Sh2d1a/SAP functions to fine-tune immune cell 
activation and disruption of Sh2d1a/SAP function results in X-linked lymphoproliferative 
syndrome (XLP)(411).  XLP is often fatal and is characterized by 
hypogammaglobulinemia, fulminant infectious mononucleosis, and lymphoma.  
Sh2d1a/SAP is required for signaling through CD150/SLAM.  Slam is upregulated on 
naïve T cells during primary activation and is constitutively expressed on memory cells 
where it mediates a positive costimulatory signal capable of enhancing TCR-dependent T 
cell responses independent from CD28.  While most reports have focused on the role 
Sh2d1a/SAP plays in CTL and NKT function, a recent report has shown that memory and 
effector CD4+ T cells from XLP patients are specifically defective in IL-10 
secretion(412).  These observations suggest that Ctla-4 maintenance of Lklf expression 
may result in the direct downregulation of Sla and a consequent increase in TCR signal 
strength.  Enhanced TCR signaling can induce anergy by altering the relative activity of 
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specific transcription factors including NFAT1.  Thus Ctla-4 ligation may operate 
through Lklf to prime cells for anergy induction. 
 
The relationships identified by cross-referencing expression profiles from in vitro 
overexpression data with kinetic expression patterns in primary T cell activation facilitate 
hypothesis-driven experiment design.  Newly available bioinformatics tools allow mass-
incorporation of published observations into statistical analyses defining coordinately 
regulated genes.  Thus the dataset generated by the kinetic profiling of in vitro activated 
primary CD4+ T cells will enable efficient cross-referencing with observations made in 
more focused investigations of gene function.   
The validity of the results presented above is dependent on the the integrity of the 
in vitro stimulation system we have utilized.  The use of TCR-tg T cells and engineered 
APCs capable of differentially signaling through Ctla-4 and CD28 should allow precise 
control of stimulation conditions.  However, apparent instability in the magnitude of 
inhibition mediated by the presence of Ctla-4 ligands raises concerns about the nature of 
the T cell/APC interaction that is occurring.  While surface expression of T cell ligands 
has been matched across cell lines, and is stable over long periods of time, the apparent 
inhibition of T cell activation in the presence of Ctla-4 ligands has intermittently been 
observed to result from undefined variables that are Ctla-4 independent.  Recent work in 
our lab has definitvely shown that the engineered APCs are capable of signaling through 
Ctla-4, and no explanation can be given for the apparent Ctla-4 independent suppression 
of T cell responses that has been observed at various times.  Recent experiments suggest 
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that the CHO APCs maintained in culture for extended periods are more likely to result in 
spurious changes in T cell responsiveness.  The experiments included in the above 
analyses were performed using CHO APCs that had been cultured for relatively shorter 
durations, and thus may have inhibited T cells in a purely Ctla-4 dependent manner.  
Some reassurance is provided by the stability of expression trends seen with the more 
highly expressed genes reportedly influence by costimulatory signals.  However, the 
possibility remains that observed phenotypes may reflect non-specific properties of the 
stimulation system.  Thus all observations and predictions derived from the dataset must 
be validated in independent systems. 
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